The Genetic Landscape of Renal Complications in Type 1 Diabetes

SUPPLEMENTAL INFORMATION

Niina Sandholm, Natalie Van Zuydam, Emma Ahlqvist, Thorhildur Juliusdottir, Harshal A. Deshmukh, N. William Rayner, Barbara Di Camillo, Carol Forsblom, Joao Fadista, Daniel Ziemek, Rany M. Salem, Linda T. Hiraki, Marcus Pezzolesi, David Trégouët, Emma Dahlström, Erkka Valo, Nikolay Oskolkov, Claes Ladenvall, M. Loredana Marcovecchio, Jason Cooper, Francesco Sambo, Alberto Malovini, Marco Manfrini, Amy Jayne McKnight, Maria Lajer, Valma Harjutsalo, Daniel Gordin, Maija Parkkonen, Jaakko Tuomilehto, Valeriya Lyssenko, Paul M. McKeigue, Stephen S. Rich, Mary Julia Brosnan, Eric Fauman, Riccardo Bellazzi, Peter Rossing, Samy Hadjadj, Andrzej Krolewski, Andrew D. Paterson, Jose C. Florez, Joel N. Hirschhorn, Alexander P. Maxwell, David Dunger, The DCCT/EDIC Study Group, GENIE Consortium, The FinnDiane Study Group, Claudio Cobelli, Helen M. Colhoun, Leif Groop, Mark I. McCarthy, Per-Henrik Groop, on behalf of The SUMMIT Consortium

COMPLETE METHODS 4

Subjects with Type 1 diabetes (T1D) 4

Genotypes 7

Statistical methods 9

SUPPLEMENTAL TABLES 14

Supplemental Table 1: Proportion of phenotypic variance explained by the GWAS genotypes in FinnDiane, estimated with GCTA 14

Supplemental Table 2: Information on genotyping, and clinical characteristics of the discovery and replication patients divided based on the seven case – control definitions 15

Supplemental Table 3: Number of subjects included in the analysis in the discovery and *in silico* replication cohorts 16

Supplemental Table 4: Statistical power to detect association with 'combined DKD' with genome-wide significance (p<5×10-8) at the discovery stage. 17

Supplemental Table 5: Association analysis results for the 101 GWAS SNPs selected for *in silico* replication. 18

Supplemental Table 6: Statistical power to detect association with 'Combined DKD' with genome-wide significance ($p<5x10^{-8}$) with the two-stage study design. 19

Supplemental Table 7: Association at the *AFF3* locus with 'ESRD vs. non-ESRD' phenotypic comparison, conditional on the previously reported lead SNP rs7583877 20

Supplemental Table 8: Statistical power to detect association with the 'Late DKD' phenotype for varying odds ratio and risk allele frequency. 21

Supplemental Table 9: Evaluation of previously reported candidate genes or GWAS loci on kidney complications in type 1 and type 2 diabetes, or GWAS on CKD in the general population. 22

Supplemental Table 10: Association between diabetic kidney complications and genetic risk scores of related phenotypes 24

Supplemental Table 11: MAGENTA Gene set enrichment results with FDR<0.05 28

Supplemental Table 12: Characteristics of the patients selected for the whole exome sequencing 30

Supplemental Table 13. Top 20 results of single variant analysis for WES 'ESRD vs. no DKD' using the score test 31

Supplemental Table 14. Top 20 associations for WES 'Late DKD' using the single variant score test 32

Supplemental Table 15: Top 10 associations to WES 'Late DKD' with VT with 4 masks 33

Supplemental Table 16: Top 10 associations to WES 'Late DKD' using SKAT-O with 4 different masks. 34

Supplemental Table 17: Top 10 associations to WES 'Late DKD' using SKAT with 4 masks 35

Supplemental table 18: Top 10 associations to WES 'ESRD vs. no DKD' with VT and 4 masks 36

Supplemental Table 19: Top 10 associations to WES 'ESRD vs. no DKD' with SKAT-O with 4 masks 37

Supplemental Table 20: Top 10 associations to WES 'ESRD vs. no DKD' with SKAT with 4 masks 38

Supplemental Table 21: Gene-sets which showed enrichment in WES association data on the 'Late DKD' phenotype, with permutation (N=100) results 39

Supplemental Table 22: ABACUS association analysis results for the top SNPs from the GWAS discovery 41

Supplemental Table 23: ABACUS association analysis results for the top SNPs from the WES discovery.....43

Supplemental Table 24: DAVID functional clustering of the genes mapped by the SNPs selected by the ABACUS software on GWAS data 44

Supplemental Table 25: DAVID functional clustering of the genes mapped by the SNPs selected by the ABACUS software on WES data 46

Supplemental Table 26: Phenotype definitions. Table A: albuminuria- and eGFR based definitions. Table B: Case – control phenotypes. 48

Supplemental Table 27: Membership of the GENIE Consortium 49

Supplemental Table 28: List of the FinnDiane centers and participating physicians and nurses. 50

Supplemental Table 29: Membership of the SUMMIT Consortium 53

SUPPLEMENTAL FIGURES 61

Supplemental Figure 1: Schematic picture of the study plan. In the GWAS setting, the stage 1 included T1D patients from the FinnDiane, EURODIAB, SDR, and Cambridge studies. Stage 1 GWAS meta-analysis results were used for evaluation of the previously reported loci, analysis of genetic risk scores, LD score regression, and for the pathway analyses. Stage 2 included patients from the UK-ROI, GoKinD US, French-Danish effort, DCCT/EDIC, and Joslin studies. Stage 3 replication consisted of additional T1D FinnDiane patients not part of the FinnDiane GWAS. Whole exome sequencing (WES) included patients from the FinnDiane, SDR, and Steno studies. Finally, the bivariate association analyses were performed in all GWAS stage 1 studies and in WES studies. 61

Supplemental Figure 2: Manhattan and QQ-plots for the seven studied phenotype definitions. 62

Supplemental Figure 3: LocusZoom and Forest plots of the top loci. 65

Supplemental Figure 4: P-value distribution of association at the previously reported loci for DKD or CKD in the general population. 66

Supplemental Figure 5: Association at previously reported loci plotted by the previously reported A) p-values and by B) Z-scores. 67

Supplemental Figure 6: Genome-wide comparison of the association results for the seven DKD traits, evaluated with LD score regression, shows high correlation between the DKD traits. 68

Supplemental Figure 7: KEGG pentose and glucoronate interconversions pathway with the red boxes indicating the genes flagged with MAGENTA enrichment analysis on the DKD phenotype. 69

Supplemental Figure 8: WES QQ-plots of the p-value distribution of associations with 'Late DKD' and 'ESRD vs. no DKD' using the score test. 70

Supplemental Figure 9: WES QQ-plots for 'Late DKD' for different masks using SKAT-O. 71

Supplemental Figure 10: WES QQ-plots for 'ESRD vs. no DKD' for different masks using SKAT-O. 72

Supplemental Figure 11: Top 20 associations for 'Late DKD' for the three gene based tests; VT, SKAT-O and SKAT with the PTV+broad and PTV+missense masks. 73

Supplemental Figure 12: Top 20 associations for 'ESRD vs. no DKD' for the three gene based tests; VT, SKAT-O and SKAT with the PTV+broad and PTV+missense masks. 74

Supplemental Figure 13: Statistical power to detect association at the WES with exome-wide statistical significance ($p<9\times10-8$) for 'Late DKD' setting (panels A and C) and for the 'ESRD vs. no DKD' comparison (panels B and D). 75

REFERENCES 76

COMPLETE METHODS

Subjects with Type 1 diabetes (T1D)

Subjects in the GWAS discovery studies: The GWAS discovery stage included subjects with T1D from four studies: The Finnish Diabetic Nephropathy (FinnDiane) Study[1,2], the EURODIAB Family Study[3], the Scania Diabetes Registry (SDR)[4], and the UK Nephropathy Family Study and Oxford Regional Prospective Study (NFS-ORPS/ Cambridge)[5,6]. All studies were approved by the local ethics committees and conducted according to the principles of the Declaration of Helsinki. Written consent was obtained from the participants in FinnDiane, Eurodiab, SDR and Steno Studies. In the NFS-ORPS study, written consent was obtained from parents, and verbal assent was obtained from children.

The Finnish Diabetic Nephropathy (FinnDiane) Study[1,2]: FinnDiane is a Finnish nationwide prospective multicenter study, with the aim to identify genetic, clinical, biochemical and environmental risk factors for diabetic complications. The study includes patients from all five Finnish University Central Hospitals, all 16 central hospitals, and 56 regional hospitals and health care centers. The study protocol and patient recruitment criteria have been previously described [1]. In short, patients with type 1 diabetes (T1D) were recruited at their own health care center by their attending physician, who completes the main questionnaire. Blood and urine samples are sent to the central laboratory of the FinnDiane Study. The patients have been followed up in prospective follow-up visits roughly 5-7 years after the baseline visit. In addition, FinnDiane Study includes patients with type 1 diabetes recruited by the Finnish National Institute of Health and Welfare across Finland. Retrospective data has been retrieved from medical records. Furthermore, information on major clinical events, such as the onset of ESRD, can be retrieved from the Finnish Hospital Discharge Registry (HILMO).

The EURODIAB Family Study[3]: The Eurodiab Insulin Dependent Diabetes (IDDM) Complications Study was a cross-sectional investigation of a stratified random sample of IDDM patients attending 31 clinics in 16 European countries that were carried out in 1989/91. These subjects were then followed up around 6-8 years later in the EURODIAB Prospective Complications Study. T1D was defined as diabetes onset <35 years with insulin within one year of diagnosis. This collection was supplemented by additional T1D cases with nephropathy at those EURODIAB

participating centres even if the patient hadn't participated in the original EURODIAB IDDM Complications study. We also recruited several additional centres (UK, Austria & Poland) to focus specifically on late stage and dialysis patients. The current GWAS study comprised cases with micro- or macroalbuminuria, ESRD, or elevated serum creatinine (>200 µmol/lit) consistent with ESRD. Cases were captured from several sources (EURODIAB at baseline, EURODIAB at follow up, additional cases from these centres not in the original cohort study and renal failure cases from several new non-EURODIAB centres). Non-DKD controls were only recruited from the original Eurodiab IDDM Complications Study cohort. They had at least 15 years of T1D duration and remained normoalbuminuric for the follow-up period. In addition to local MICRAL strip testing, the controls had normoalbuminuria confirmed by the central EURODIAB on two overnight collections at follow up and on one collection at baseline.

Scania Diabetes Registry (SDR)[4]: Patients in SDR were randomly collected from the Department of Endocrinology, Malmö Sweden and surrounding clinics in Skåne (Scania) Sweden. Patients of known non-Scandinavian origin were excluded from the analysis. Diabetes classification was done based on presence of GAD antibodies and low c-peptide levels, or in case of incomplete information, based on the diagnosis given by the treating physician. All patients with T1D were diagnosed before 35 years of age.

The UK Nephropathy Family Study and Oxford Regional Prospective Study (NFS-ORPS/ Cambridge)[5,6]: ORPS is a population-based inception cohort of childhood-onset T1D, established between 1986 and 1997, with the aim of assessing the natural history of microalbuminuria [5]. Children diagnosed with T1D under the age of 16 years, in the defined geographic region of the Oxford Health Authority, were recruited within 3 months of diagnosis of Type 1 diabetes to receive annual assessments. Ninety-one percent of eligible children were recruited at a mean age of 8.8 years and were followed annually thereafter. The overall dropout rate for the ORPS cohort has been 9.6%.

The NFS is a prospective study started in the year 2000 with the aim of assessing factors influencing changes in albumin excretion during adolescence in young people with T1D [6]. Between 2000 and 2005, adolescents (aged 10–18 years), diagnosed with T1D before the age of 16 years, were recruited throughout England. Cases of secondary diabetes treated with insulin or maturity-onset diabetes of the young were identified by clinical histories and

examination of case records, and were excluded. Similarly, children with chronic renal disease or other chronic diseases likely to affect renal function were excluded.

Both cohorts were monitored with annual centralized assessments of ACR, based on three consecutive early morning urine samples.

The studies received ethical approval from district ethics committees. Written consent was obtained from parents, and verbal assent was obtained from children.

Phenotype definitions: All subjects had T1D as diagnosed by their attending physician. In addition, subjects were limited to those with the age at diabetes onset ≤40 years and insulin treatment initiated within one year of diagnosis. The kidney status was classified based on the urinary albumin excretion rate (AER) and on the estimated glomerular filtration rate (eGFR). The subjects were classified as normal AER, microalbuminuria or macroalbuminuria based on two out of three consecutive urine samples surpassing the required threshold (Supplemental Table 26). Patients receiving dialysis treatment, with a kidney transplant, or with an eGFR ≤15 ml/min/1.73m^2 were defined to have ESRD. eGFR was calculated either with the MDRD4 [7] or the CKD-EPI [8] formula depending on the study. In addition, subjects were classified to CKD classes: No CKD was defined as eGFR ≥60ml/min/1.73m^2 (i.e. CKD classes 1 and 2), and CKD as eGFR <60 ml/min/1.73m^2 (i.e. CKD classes 3-5). Based on these definitions, we analysed seven different case – control phenotypes: i) cases with DKD (microalbuminuria or worse) versus controls with normal AER; ii) cases with macroalbuminuria or ESRD versus normal AER; iii) cases with ESRD versus controls with normal AER; iv) cases with ESRD versus everyone else; v) cases with microalbuminuria versus controls with normal AER; vi) cases with CKD versus controls without CKD; vii) cases with severe CKD (eGFR ≤45 ml/min/1.73m^2) and microalbuminuria or worse versus controls with normal AER and no CKD. The number of subjects in the four discovery studies is specified for the different phenotype definitions in Supplemental Table 3.

Patient selection for WES: WES included subjects from FinnDiane, SDR, and Steno Diabetes Center (Supplemental Table 12). Whilst we adopted broadly similar schemes for ascertaining the extremes in each of three contributing

studies, there were some differences. Patients were selected from the extreme ends of the liability distribution of DKD from each participating study (FinnDiane, SDR, and Steno). Cases were defined as subjects with rapid onset of macroalbuminuria (within 20/25 years of diabetes onset in FinnDiane and Steno, respectively; no threshold in SDR) or ESRD (onset within 25 years of diabetes onset in FinnDiane and Steno). Controls were subjects with normal AER despite prolonged duration of T1D (≥ 32, 30, or 27 years in FinnDiane, Steno, and SDR, respectively). In addition, the FinnDiane controls were enriched for higher HbA_{1c} values (excluding subjects with HbA_{1c} < 6.5 %), and a half of the controls were selected to have proliferative diabetic retinopathy or retinal laser treatment.

Genotypes

Genome-wide genotyping and imputation of the discovery cohorts: The genome-wide genotyping of the subjects in the SDR, NFS-ORPS, and EURODIAB (a sub-study of the EURODIAB PCS) was performed within the SUMMIT project with the Illumina OmniExpress assays (Illumina, San Diego, CA, USA). Samples with a call rate <98% or gender discrepancy were removed in the first step of quality control. Subsequently, common single nucleotide polymorphisms (SNPs; i.e. minor allele frequency (MAF) ≥0.05) with low genotyping rate (<95%) or not in Hardy-Weinberg equilibrium (HWE; p-value≤5.7×10^{-7}) were removed. For non-common SNPs (MAF 0.01 – 0.05), the thresholds were 99% and p-value <10^{-4}, respectively. Samples with extremely high or low heterozygosity or excess of estimated relatedness were removed due to suspected sample contamination or issues in the sample processing, based on study specific distributions. In the FinnDiane Study, genotyping was performed with the Illumina 610Quad assay and the quality control was similar to the other studies, as described previously in detail [2]. Principal component analysis was performed in all cohorts with the Eigenstrat software (Eigensoft v. 3.0, [9]).

After the quality control, the SNP positions were converted to human genome build 37, and genome-wide imputation was performed with IMPUTE2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html [10]) using 1,092 samples from the 1000 Genomes project (http://www.1000genomes.org, phase 1 v.3, released March 2012) as the imputation reference panel [11]. The pre-phasing and imputation were performed with the default parameters and the effective

sample size of 20,000 as suggested in the IMPUTE2 tutorial. Variants were filtered post-imputation to those with MAF ≥ 0.01, minor allele count ≥10 in both cases and controls, and SNPtest INFO estimate of imputation quality ≥0.4.

Whole exome sequencing and variant calling: Samples were sequenced at two centres. The samples were prepared using the Illumina TruSeq™ DNA LT Sample Prep Kit, pooled into multiplexes of five and were captured using the Illumina TruSeq™ Exome Enrichment Kit. The concentration of each library was determined by real-time qPCR using Agilent qPCR Library Quantification Kit and a MX3005P instrument (Agilent). Sequencing was performed on an Illumina HiSeq2000, using 100bp paired end reads and with an anticipated minimum yield of 30 Gb per lane. Five exomes of 63Mb were run per lane (single lane for most), aiming for approximately 100x read depth. We required an average 20x target capture above 80% coverage, otherwise additional DNA was requested to 'top up' the sample. This resulted in mean sequencing depth of 54.97 (FinnDiane) and 42.23 (SDR and Steno) bases per position. After additional sequencing 497 samples were included from FinnDiane and 500 from SDR and Steno.

Samples were mapped with Burrows-Wheeler aligner v7.4 (BWA), refined by removing duplicates and realigning around known insertions and deletions (INDELs), and recalibrated using genome analysis toolkit v2.1 (GATK). GATK's UnifiedGenotyper was applied to call variants, followed by recalibration of SNVs using VQSR and hard filtering of INDELs.

Polymorphic variants (MAF>0) with a mapping quality < 250, HWE *p*-value >1×10^{-10} and call rate ≥75% were retained in the analysis. Samples with ≥10% missingness or heterozygosity rate greater or less than 3 standard deviations from the sample mean were excluded. Population outliers (based on visual inspection of the four first principal components), duplicates and related samples were removed. Variants were annotated using CHAos (http://www.well.ox.ac.uk/~kgaulton/chaos.shtml), snpEff (http://snpeff.sourceforge.net/ [12]) and VEP (http://www.ensembl.org/info/docs/tools/vep/ [13]) for functional class and transcript.

With 530,565 variants (491,553 SNPs and 39,012 indels) across 479 controls and 481 cases after the quality control, each individual carried a mean of 7,566 synonymous, 6,452 missense and 103 protein truncating variants. The lower number of total variant sites compared to other, more outbred populations [14] is in line with fewer variable sites seen in founder populations such as the Finns [15].

Statistical methods

Heritability estimates: The narrow-sense heritability of the kidney phenotypes was estimated as the proportion of the phenotypic variance explained by the additive effects of the genotyped SNPs based on the FinnDiane GWAS data using the GCTA v. 0.93.9, excluding samples with estimated relatedness ≥ 0.025 [16]. The observed variance explained was transformed to the underlying population scale based on rough prevalence estimates as given in Supplemental Table 1. The heritability was estimated without covariates, and adjusting for sex, duration of T1D and age at T1D onset.

GWAS analysis: The genome-wide association analysis was performed with two methods in parallel. To obtain stable effect size estimates, we performed additive test for association using SNPtest with the score method and adjusted for sex, diabetes duration and age at diabetes onset [17], and the two first principal components calculated with the Eigenstrat software (Eigensoft v. 3.0, [9]). Close relatives were not included in the analysis. *P*-values were obtained with a variance component based mixed model method, EMMAX, which accounts for the sample structure, allowing to include close relatives in the analysis [18]. Models were adjusted for sex, diabetes duration and age at diabetes onset and the kinship matrix was calculated with EMMAX. EMMAX algorithm was implemented with the EPACTS software (www.sph.umich.edu/csg/kang/epacts/).

Meta-analyses of the effect sizes were performed with the fixed-effect inverse variance method implemented in GWAMA [19]). *P*-values were combined with METAL software based on the study-wise *p*-values, sample sizes and effect directions [20]. Meta-analysis results were further filtered to those with valid results from at least two studies. P-values below 5×10^{-8} were considered genome-wide significant, not correcting for multiple testing due to seven phenotypic comparisons, as the case and control groups were overlapping and the traits were correlated with each other.

Power calculations were performed with the genetic power calculator (pngu.mgh.harvard.edu/~purcell/gpc/) for simple case-control setting,[21] and with Power Calculator for Two Stage Association Studies (CaTS; http://csg.sph.umich.edu//abecasis/cats/).[22]

***In silico* Replication:** Independent variants with a *p*-value < 5×10^{-6} were selected for *in silico* replication. Variants were defined independent if they were at least 100 kilo base pair (kbp) away from each other. The selection was performed separately for each phenotype, and therefore, multiple variants were selected for some loci with different lead variants for different phenotypes. Replication consisted of six additional studies: the All Ireland – Warren 3 – Genetics of Kidneys in Diabetes UK collection (UK-ROI) [2] and the Genetics of Kidneys in Diabetes US Study (GoKinD US) [2] from the GENIE Consortium, the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study [23,24], 1,073 subjects from the Joslin Diabetes Center T1D nephropathy collection, and the French, Belgian and Danish subjects (the Steno Diabetes Center) from the French-Danish Effort [25]. The number of subjects in each study is given in Supplemental Table 3. Association testing was performed with PLINK or SNPtest depending on the study, using the same covariates as in the discovery stage.

***De novo* replication and genotyping:** After *in silico* replication, variants replicated with a $p<0.05$ or a combined *p*-value < 1×10^{-7} after meta-analysis were selected for *de novo* replication. A total of 1,095 additional FinnDiane patients, not part of the GWAS, were genotyped for stage 3 analysis with TaqMan (Supplemental Table 2). Additionally, subjects with T1D from the Diabetes in Region of Vaasa (DIREVA) study, a follow-up study from Finland with >5,000 subjects with diabetes, were genotyped together with DIREVA subjects with T2D using either Taqman (rs72809865) or Sequenom (the rest). rs1989248 was not successfully genotyped in either *de novo* replication study. Additionally, genotyping of rs72809865 was unsuccessful in DIREVA, and only four cases with T1D and ESRD were identified in DIREVA after removing subjects that were included in the FinnDiane discovery study. Thus, no SNPs remained for analysis from DIREVA. Association analysis was performed in the FinnDiane replication cohort similarly to *in silico* replication using logistic regression and adjusted for sex, duration of diabetes, and age at diabetes onset. As one of the lead SNPs, rs61277444 was imputed with only moderate quality, that SNP was *de novo* genotyped also in 2,913 FinnDiane subjects from the discovery study. Concordant to the imputation quality INFO score of 0.83 in FinnDiane, the *de novo* genotyping agreed with the imputed genotypes (converted to most likely genotypes with genotype likelihood threshold of 0.9) for 73% of the samples.

Genetic risk score analysis: SNPs associated with Waist-Hip-ratio (adjusted for BMI, N_{SNPs}=54)[26], BMI (untransformed, N_{SNPs}=96 [27] and z-transformed, N_{SNPs}=24 [28]), systolic blood pressure (SBP, N_{SNPs}=22)[29], low-density lipoprotein cholesterol (LDL-C, N_{SNPs}=24), triglycerides (TRIG, N_{SNPs}=20), high-density lipoprotein cholesterol (HDL-C, N_{SNPs}=26)[30], T1D (N_{SNPs}=51) [31], T2D [32] (including all SNPs (N_{SNPs}=70), and without any other effects other than on T2D or lipids (N_{SNPs}=56)[30] and T2D or glycemic traits (N_{SNPs}=62)[33,34]), 2-hr glucose (adjusted for BMI, N_{SNPs}=15)[35], fasting glucose (FG, adjusted for BMI, N_{SNPs}=21) [34], glycated haemoglobin (HbA1c, N_{SNPs}=15)[36], fasting insulin (natural log transformed and adjusted for BMI, N_{SNPs}=13)[34], fasting pro-insulin (adjusted for BMI and FG, N_{SNPs}=10)[37], HOMA-B (N_{SNPs}=15), HOMA-IR (N_{SNPs}=15)[38] and insulin resistance [39] at genome-wide significance were included in a genetic risk score (GRS) for each trait respectively. The GRS was weighted by the allelic effect of each variant on the DKD risk factor and associated with the DKD phenotypes using meta-analysis data [29]. The lipid GRS were restricted to variants that predicted that specific trait and removed those that had effects on other lipid traits. We did not include a GRS for smoking behaviours as there were too few genome-wide significant associations to form a sufficient instrument.

LD score regression to estimate genetic correlation: Genetic correlation was estimated between the GWAS stage 1 meta-analysis results of the seven binary DKD phenotypes, and related traits. We assembled the summary statistics from all the studies used to calculate genetic risk scores except for systolic blood pressure and T1D as the full summary statistics were not available. We restricted the GRS and LD score regression analyses to reports from full genome-wide SNP data as LDScore regression takes the effect of all SNPs into account. We additionally computed genetic correlation with smoking behaviour phenotypes (cigarettes per day, smoking addiction, smoking cessation and age at smoking onset).[40]

Gene set enrichment analyses: MAGENTA gene set enrichment analysis was performed in the GWAS stage 1 meta-analysis results with the MAGENTA (vs.2) software, [41] applied on 10,992 partially overlapping gene sets from GO, PANTHER, INGENUITY, KEGG, REACTOME, and BIOCARTA data bases; 3,126 gene sets with ≥10 genes were analysed. Gene boundaries used for mapping SNPs onto genes were 110kb upstream to most extreme gene transcript start position, and 40kb downstream to most extreme gene transcript end position. The 95 percentile cut-off for the gene scores was employed to define the significant results.

Correction for multiple testing: The significance threshold for the results of the evaluation of previous loci, GRS, LD score regression, and pathway enrichment analyses were Bonferroni corrected for multiple testing with α=0.05 significance level, accounting for the number of performed tests. The results were not corrected for the seven phenotypic comparisons due to a considerable overlap of the case and control groups.

WES single variant analysis: Single variants were tested for association with DKD (N cases=481, N controls=479) and ESRD (N cases=168, N controls=479) using the logistic score test [42] implemented in Epacts, with sex and two principal components as covariates. Related individuals, monomorphic SNPs and those with standard error greater than 10 were excluded from the analysis. While the study setting provided low statistical power to detect rare variants with exome-wide significance ($p<9\times10^{-8}$ to correct for 530,776 tested variants) in line with previous reports on the statistical power to detect rare variants [43], we had sufficient power (80%) to detect a low frequency variant (MAF=0.05) with a large OR of 5.65 (Supplemental Figure 13).

WES gene-based analysis: We applied three series of gene based tests: a burden test (VT) [44] that assumes the direction of effect of grouped variants is the same, a dispersion test (SKAT) [45] that performs well when the direction of variant effect differs, and a hybrid (SKAT-O) [46] that uses multiple methods in a single test. Only unrelated individuals were included in the analysis and sex and principal components were used as covariates to adjust for population structure. For all three tests we grouped variants into four categories using the same procedure as described in Mahajan *et al.* [47], were variants were categorized as either protein truncating (PTV; e.g. nonsense, frameshift, essential splice site), deleterious protein altering variants (e.g. missense, in-frame indel, and non-essential splice-site variants predicted to be deleterious, further sub-divided into "strict" and "broad" grouping if predicted deleterious by all five/ at least one annotation algorithm (Polyphen2-HumDiv, PolyPhen2-HumVar, LRT, MutationTaster and SIFT), respectively, as described by Purcell *et al.* [48], and any protein altering variants (e.g. missense, in-frame indel, non-essential splice-site) if predicted to be so by at least one of three annotation algorithms (snpEff, CHAos and VEP). These four groups are referred to as 1) PTV-only, 2) PTV+strict, 3) PTV+broad, and 4) PTV+missense, from the strictest to the most permissive class. A MAF threshold of 1% was applied to the more permissive masks PTV+missense and PTV+broad to exclude common variants from the WES analysis.

WES gene set enrichment analysis: We were interested in seeing whether we could find any signals in common with GWAS and WES association data, as well as detect enrichment for specific gene-sets. A total of 43 gene sets were created, based on top findings from the GWAS analyses, kidney-related functional terms in public databases, text mining approaches and kidney gene expression. These gene sets were analysed for enrichment in WES association results (obtained with SKAT-O using the four different masks described above) using the GSEA method with SKAT-O's p-value as the ranking statistic[49]. We applied permutations to the enriched gene sets to verify whether this enrichment was greater than expected by chance, by randomly assigning case/control status to the samples prior to re-analysing them with SKAT-O (using the same parameter settings as applied to the real data). This was repeated 100 times for each of the enriched gene sets, noting the number of times the top finding in the permuted data had a better enrichment score than the candidate geneset in the real data. Since both of the enriched gene sets were derived from GWAS data, which included some of the WES samples, we removed overlapping samples and re-created the gene-sets and repeated the GSEA analysis.

Bivariate analysis of GWAS and WES data: We applied ABACUS[50] to the individual GWAS discovery cohorts (FinnDiane, EURODIAB, SDR, NFS-ORPS) on each of the seven different case-control phenotypes. In addition, ABACUS was applied to the WES cohorts (FinnDiane, Steno and SDR) on the 'Late DKD' and 'ESRD vs. no DKD' phenotypic comparisons as in the main WES analysis. For the SNP-sets definition we used REACTOME, KEGG and GO Biological Process, as defined in MSigDB database (sets c2 and c5) after mapping SNPs to genes according to the Illumina HumanOmniExpress.12v1_J gene annotation file. In order to analyse non-annotated SNPs/genes, we also defined SNP-sets of continuous 3,000 SNPs within each chromosome. Functional clustering of the ABACUS results was performed with DAVID software[51,52].

SUPPLEMENTAL TABLES

Supplemental Table 1: Proportion of phenotypic variance explained by the GWAS genotypes in FinnDiane, estimated with GCTA

Phenotype	Prevalence	N	Adj	V(G)/V(p)	SE V(G)/V(p)	V(G)/V(p_L)	SE V(G)/V(p_L)	P
Combined DKD	0.3	2,843	no	0.24	0.10	0.35	0.15	6.4E-03
Combined DKD	0.3	2,843	yes	0.34	0.10	0.50	0.15	2.5E-04
Late DKD	0.2	2,495	no	0.32	0.11	0.43	0.15	1.3E-03
Late DKD	0.2	2,495	yes	0.51	0.12	0.67	0.15	2.0E-06
ESRD vs. no DKD	0.1	1,985	no	0.38	0.14	0.47	0.18	3.4E-03
ESRD vs. no DKD	0.1	1,985	yes	0.54	0.15	0.68	0.18	7.5E-05
ESRD vs. non-ESRD	0.1	2,843	no	0.31	0.10	0.51	0.17	1.2E-03
ESRD vs. non-ESRD	0.1	2,843	yes	0.34	0.10	0.57	0.17	4.7E-04
CKD	0.3	2,595	no	0.28	0.11	0.47	0.18	4.2E-03
CKD	0.3	2,595	yes	0.39	0.11	0.65	0.19	1.5E-04
CKD+DN	0.2	1,949	no	0.42	0.14	0.59	0.20	1.1E-03
CKD+DN	0.2	1,949	yes	0.59	0.15	0.84	0.20	9.8E-06
Early DKD	0.1	1,820	no	0.02	0.16	0.02	0.24	0.46
Early DKD	0.1	1,820	yes	0.03	0.16	0.04	0.24	0.43

Prevalence: Estimated prevalence of the cases in the T1D, employed for transforming the results for the underlying T1D population. Adj: no, model unadjusted; yes: model adjusted for sex, diabetes duration, and age at diabetes onset. V(G)/V(p) proportion of phenotypic variance explained by the genotypes, i.e. heritability, as observed in the study population. SE: standard error. V(G)/V(p_L): proportion of phenotypic variance explained by the genotypes, i.e. heritability, transformed for the underlying population scale.

Prevalences were estimated as a combination of the following data:

Microalbuminuria or worse: Cumulative incidence of persistent micro-albuminuria was 33,6% (95% confidence interval 27.2% to 40.0%; median follow-up 18-years) in Hovind P. *et al*., *BMJ* 2004 [53]

Macroalbuminuria or worse: Cumulative incidence of persistent macroalbuminuria was 14.6% (8.9% to 20.3%; Median follow-up 18 years) in Hovind P. *et al*., *BMJ* 2004 [53]

ESRD: 40-year Cumulative risk of ESRD was 23.0% in Harjutsalo V. *et al., Diabetologia* 2011 [54]

CKD (eGFR≤60 ml/min/1.73m^2): The 16-year cumulative incidence of CKD was 31.7 percent in Shankar A et al., *Exp Clin Endocrinol Diabetes* 2007 [55]

CKDDN: All patients with ESRD, plus patients with macroalbuminuria and eGFR<45 ml/min/1.73m^2.

Supplemental Table 2: Information on genotyping, and clinical characteristics of the discovery and replication patients divided based on the seven case – control definitions

Supplemental Table 2 can be found on the Supplemental Excel sheet.

Supplemental Table 3: Number of subjects included in the analysis in the discovery and *in silico* replication cohorts

Phenotype criteria	Cohort	Stage 1: Discovery GWAS					Stage 2: *In silico* replication						Total Stages 1+2
		FinnDiane	EURODIAB	SDR	NFS-ORPS	Total	UK-ROI	GoKinD US	French/Danish	DCCT/EDIC	Joslin	Total	
	N total	3,415	789	556	396	5,156	1,726	1,595	1,415	1,271	1,073	7,095	12,251
Combined DKD	**total**	3,415	789	556	396	5,156	1,726	1,595	1,430	1,271	1,073	7,095	12,251
miA/maA/ESRD	**case**	1,802	298	266	197	2,563	823	774	691	551	349	3,188	5,751
noA	**control**	1,613	491	290	199	2,593	903	821	739	720	724	3,907	6,500
Early DKD	**total**	2,076	586	382	349	3,393	–	–	931	1,130	–	2,061	5,454
miA	**case**	463	95	92	150	800	–	–	192	410	–	602	1,402
noA	**control**	1,613	491	290	199	2,593	–	–	739	720	–	1,459	4,052
Late DKD	**total**	2,952	694	458	246	4,350	1,726	1,595	1,188	861	1,073	6,443	6,878
maA/ESRD	**case**	1,339	203	168	47	1,757	823	774	449	141	349	2,536	4,293
noA	**control**	1,613	491	290	199	2,593	903	821	739	720	724	3,907	6,500
ESRD vs. no DKD	**total**	2,267	575	365	–	3,207	1,149	1,329	811	–	862	4,151	7,358
ESRD	**case**	654	84	75	–	813	246	508	72	–	138	964	1,777
noA	**control**	1,613	491	290	–	2,394	903	821	739	–	724	3,187	5,581
ESRD vs. non-ESRD	**total**	3,415	789	604	–	4,808	1,687	1,595	1,415	–	1,073	5,770	5,385
ESRD	**case**	654	84	75	–	813	246	508	72	–	138	964	1,777
noA/miA/maA	**control**	2,761	705	529	–	3,995	1,441	1,087	1,343	–	935	4,806	8,801
CKD	**total**	3,056	580	528	–	4,164	1,274	1,586	1,421	1,266	1,048	6,595	10,759
eGFR<60	**case**	979	113	163	–	1,255	668	710	391	79	198	2,046	3,301
eGFR>60	**control**	2,077	467	365	–	2,909	606	876	1,030	1,187	850	4,549	7,458
CKD+DKD	**total**	2,211	567	357	–	3,135	839	1,419	836	–	827	3,921	7,056
eGFR<45 AND miA/maA/ESRD	**case**	789	210	118	–	1,117	316	635	162	–	153	1,266	2,383
eGFR>60 AND noA	**control**	1,422	357	239	–	2,018	523	784	674	–	674	2,655	4,673

miA: microalbuminuria. maA: Macroalbuminuria. noA: normal albuminuria.

Supplemental Table 4: Statistical power to detect association with 'combined DKD' with genome-wide significance (p<5×10-8) at the discovery stage.

			Risk Allele frequency				
OR	**RR (Aa)**	**RR (AA)**	**0.01**	**0.05**	**0.10**	**0.20**	**0.50**
1.10	1.07	1.14	0.00	0.00	0.00	0.00	0.00
1.2	1.13	1.28	0.00	0.00	0.00	0.04	0.16
1.3	1.19	1.42	0.00	0.00	0.00	0.04	0.16
1.4	1.25	1.56	0.00	0.05	0.39	0.90	1.00
1.5	1.30	1.70	0.00	0.17	0.76	1.00	1.00
1.55	1.33	1.77	0.00	0.30	0.90	1.00	1.00
1.6	1.36	1.84	0.00	0.46	0.97	1.00	1.00
2.0	1.54	2.37	0.03	0.99	1.00	1.00	1.00

RR: Relative Risk, calculated as RR = OR/((1-prev)+(prev x OR)), where prev is the incidence in non-carrier group, assumed to be 30% for the Combined DKD phenotype. RR (AA) was calculated as RR(Aa)^2

Supplemental Table 5: Association analysis results for the 101 GWAS SNPs selected for *in silico* replication.
Supplemental Table 5 can be found on the Supplemental Excel sheet.

Supplemental Table 6: Statistical power to detect association with 'Combined DKD' with genome-wide significance ($p<5x10^{-8}$) with the two-stage study design.

			Risk allele frequency						
OR	**RR (Aa)**	**RR (AA)**	**0.01**	**0.05**	**0.10**	**0.20**	**0.30**	**0.40**	**0.50**
1.10	1.07	1.14	0	0	0	0	0	0.01	0.01
1.2	1.13	1.28	0	0	0.01	0.09	0.19	0.25	0.25
1.3	1.19	1.42	0	0.02	0.17	0.57	0.78	0.84	0.83
1.4	1.25	1.56	0	0.13	0.57	0.95	0.99	0.99	0.99
1.47	1.29	1.66			**0.80**				
1.5	1.30	1.70	0	0.33	0.87	1	1	1	1
2	1.54	2.37	0.09	1	1	1	1	1	1

RR: Relative Risk, calculated as RR = OR/((1-prev)+(prev x OR)), where prev is the incidence in non-carrier group, assumed to be 30% for the Combined DKD phenotype.

RR (AA) was calculated as $RR(Aa)^2$

Power calculations were performed with Power Calculator for Two Stage Association Studies (CaTS; http://csg.sph.umich.edu//abecasis/cats/)

Parameters used in the calculations:

N= 5,751 cases, 6,500 controls; 42% of samples genotyped in stage 1

11/ 8,578,867 = 0.000128% of markers genotyped at stage 2

Significance level: $p=5\times10^{-8}$

Prevalence: 30%

Additive genetic model

Supplemental Table 7: Association at the *AFF3* locus with 'ESRD vs. non-ESRD' phenotypic comparison, conditional on the previously reported lead SNP rs7583877

					Raw results			Conditional on the other SNP		
Chr	**SNP**	**bp**	**refA**	**freq**	**Beta**	**se**	**p**	**Beta**	**se**	**p**
2	rs7583877	100460654	T	0.71	-0.26	-0.06	8.71E-05	0.01	0.04	0.78
2	rs7562121	100384354	G	0.77	-0.38	-0.07	8.92E-08	-0.16	0.04	1.97E-04

Supplemental Table 8: Statistical power to detect association with the 'Late DKD' phenotype for varying odds ratio and risk allele frequency.

Power to detect association with p<0.05

			Risk allele Frequency			
OR	**RR (Aa)**	**RR (AA)**	**0.05**	**0.10**	**0.20**	**0.50**
1.10	1.08	1.16	0.17	0.27	0.42	0.56
1.2	1.15	1.33	0.45	0.71	0.91	0.98
1.25	1.19	1.42	0.63	0.88	0.99	1.00
1.3	1.23	1.50	0.79	0.96	1.00	1.00
1.4	1.30	1.68	0.95	1.00	1.00	1.00
1.5	1.36	1.86	0.99	1.00	1.00	1.00
2	1.67	2.78	1.00	1.00	1.00	1.00
2.5	1.92	3.70	1.00	1.00	1.00	1.00

Power to detect association with $p<1.1\times10^{-3}$ (correction for multiple testing)

			Risk allele Frequency			
OR	**RR (Aa)**	**RR (AA)**	**0.05**	**0.10**	**0.20**	**0.50**
1.10	1.08	1.16	0.01	0.03	0.07	0.13
1.2	1.15	1.33	0.08	0.23	0.53	0.79
1.3	1.23	1.50	0.31	0.69	0.95	0.99
1.4	1.30	1.68	0.62	0.94	1.00	1.00
1.5	1.36	1.86	0.84	0.99	1.00	1.00
2	1.67	2.78	1.00	1.00	1.00	1.00
2.5	1.92	3.70	1.00	1.00	1.00	1.00

RR: Relative Risk, calculated as RR = OR/((1-prev)+(prev × OR)), where prev is the incidence in non-carrier group, assumed to be 20% for the Late DKD phenotype. RR(AA) was calculated as $RR(Aa)^2$.

Supplemental Table 9: Evaluation of previously reported candidate genes or GWAS loci on kidney complications in type 1 and type 2 diabetes, or GWAS on CKD in the general population.

						DKD			Early DKD			Late DKD			ESRD vs. no DKD			ESRD vs. non-ESR			CKD			CKD+DKD			
SNP	GENE	Source	Type	EA	NEA	EAF	P	OR	EAF	P	OR	EAF	P	OR	EAF	P	OR	EAF	P	OR	EAF	P	OR	EAF	P	OR	Direction
rs2838302	*SIK1*	Sambo 2014	GWAS, T1D-ESRD	G	A	0.08	0.81	1.04	0.08	0.25	0.9	0.08	0.32	1.09	0.08	0.0017	1.39	0.08	4.10E-05	1.56	0.08	0.0019	1.35	0.09	0.03	1.24	Same
rs7583877	*AFF3*	Sandholm 2012	GWAS, T1D-ESRD	T	C	0.71	0.85	0.99	0.71	0.06	1.13	0.7	0.21	0.94	0.7	0.0044	0.81	0.71	8.70E-05	0.77	0.71	0.02	0.88	0.7	0.01	0.85	same
rs17709344	*RGMA-MCTP2*	Sambo 2014	GWAS, T1D-ESRD	A	G	0.03	0.01	1.39	0.02	0.1	1.4	0.03	0.004	1.56	NA	NA	NA	NA	NA	NA	0.02	0.01	1.56	0.03	8.20E-04	1.73	Same
rs12437854	*RGMA–MCTP2*	Sandholm 2012	GWAS, T1D-ESRD	G	T	0.06	0.03	1.2	0.05	0.31	1.14	0.06	0.03	1.22	NA	NA	NA	NA	NA	NA	0.06	0.01	1.33	0.06	0.0013	1.43	same
rs12137135	*WNT4-ZBTB40*	Sambo 2014	GWAS, T1D-ESRD	G	A	0.16	0.95	1	0.16	0.39	0.94	0.16	0.72	1.02	0.16	0.05	1.21	0.16	0.01	1.28	0.16	0.04	1.18	0.16	0.23	1.08	Same
rs1801282	*PPARG*	Mooyaart 2011	CGM, T1D/T2D	G	C	0.15	0.13	1.08	0.14	0.95	0.98	0.15	0.07	1.12	0.15	0.05	1.16	0.16	0.02	1.18	0.15	0.01	1.18	0.15	0.05	1.16	Opposite, NS
rs12917114	*SEMA6D-SLC24A5*	Sambo 2014	GWAS, T1D-ESRD	T	C	0.13	0.39	0.97	0.12	0.15	0.9	0.13	0.81	1.01	0.13	0.15	1.18	0.13	0.01	1.27	0.13	0.07	1.18	0.13	0.24	1.12	same
rs699	*AGT*	Mooyaart 2011	CGM, T1D/T2D	G	A	0.43	0.14	1.07	0.43	0.01	1.17	0.42	0.67	1.02	0.42	0.49	1.04	0.43	0.74	0.98	0.43	0.59	0.98	0.43	0.98	1.01	Opposite, NS
rs1617640	*EPO*	Tong 2008	CGM, T1D-DN	A	C	0.57	0.03	0.92	0.58	0.45	0.96	0.57	0.02	0.91	0.57	0.49	0.98	0.56	0.71	1	0.56	0.29	0.96	0.57	0.65	0.98	Opposite
rs741301	*ELMO1*	Shimazaki 2005	GWAS, T2D-DN	T	C	0.68	0.54	0.96	0.68	0.69	1.02	0.67	0.34	0.94	0.67	0.04	0.86	0.68	0.02	0.86	0.67	0.3	0.93	0.67	0.31	0.93	Same
rs7588550	*ERBB4*	Sandholm 2012	GWAS, T1D-DN	A	G	0.94	0.05	1.24	0.94	0.66	1.14	0.95	0.02	1.3	NA	NA	NA	NA	NA	NA	0.94	0.05	1.25	0.94	0.03	1.34	same
rs1670754	Chr 4p15.1	Sambo 2014	GWAS, T1D-ESRD	A	G	0.17	0.24	1.07	0.17	0.13	1.13	0.17	0.56	1.04	0.17	0.04	1.21	0.17	0.03	1.2	0.17	0.12	1.11	0.17	0.04	1.16	Same
rs1041466	Chr 13q	Pezzolesi 2009	GWAS, T1D-DN	G	A	0.47	0.54	1.01	0.47	0.86	0.97	0.48	0.38	1.02	0.48	0.09	1.09	0.48	0.03	1.12	0.48	0.14	1.07	0.48	0.64	1.02	same
rs1799987	*CCR5*	Mooyaart 2011	CGM, T1D/T2D	G	A	0.45	0.46	1.04	0.45	0.49	1.05	0.45	0.55	1.04	0.45	0.5	1.07	0.45	0.54	1.06	0.45	0.95	1.01	0.45	0.09	1.11	
rs5186	*AGTR1*	Mooyaart 2011	CGM, T1D/T2D	C	A	0.24	0.11	1.1	0.24	0.57	1.06	0.23	0.21	1.1	0.23	0.93	1.01	0.23	0.82	1	0.23	0.38	0.94	0.24	0.49	1.05	
rs11993333	*PVT1*	Mooyaart 2011	CGM, T1D/T2D	C	T	0.53	0.25	1.05	0.53	0.91	1.02	0.53	0.12	1.07	0.53	0.81	1.02	0.53	0.89	1	0.53	0.83	1.02	0.53	0.37	1.06	
rs833061	*VEGFA*	Mooyaart 2011*	CGM, T1D/T2D	T	C	0.48	0.12	1.07	0.48	0.42	1.05	0.48	0.15	1.07	0.48	0.32	1.07	0.48	0.6	1.04	0.48	0.31	1.05	0.48	0.12	1.1	
rs9298190	*LOC100132891*	Craig 2009	Pooled GWAS on T1D-ESRD	C	T	0.39	0.49	1.03	0.39	0.83	0.99	0.39	0.21	1.06	0.39	0.15	1.09	0.39	0.12	1.09	0.39	0.53	1.04	0.39	0.49	1.04	
rs1564939	*GLRA3*	Sandholm 2014	GWAS, T1D-AER	C	T	0.19	0.26	1.07	0.19	0.61	1.03	0.19	0.27	1.08	0.18	0.37	1.1	0.18	0.47	1.08	0.18	0.24	1.11	0.19	0.13	1.13	
rs2268388	*ACACB*	Mooyaart 2011	CGM, T1D/T2D	A	G	0.15	0.9	1	0.15	0.23	0.92	0.15	0.62	1.04	0.15	0.21	1.11	0.15	0.13	1.12	0.15	0.49	1.05	0.15	0.54	1.05	
rs2070744	*NOS3*	Mooyaart 2011*	CGM, T1D/T2D	T	C	0.62	0.22	1.05	0.61	0.84	1.01	0.62	0.14	1.07	0.62	0.53	1.06	0.63	0.58	1.04	0.62	0.16	1.08	0.61	0.27	1.08	
rs7805747	*PRKGA2*	Köttgen 2010	GWAS CKD	A	G	0.23	0.14	0.94	0.24	0.16	0.91	0.23	0.37	0.97	0.23	0.87	1.02	0.22	0.58	1.04	0.22	0.21	1.07	0.23	0.6	1.03	
rs1749824	*ZMIZ1*	Craig 2009	Pooled GWAS on T1D-ESRD	A	C	0.43	0.31	0.96	0.43	0.29	0.94	0.43	0.44	0.97	0.44	0.47	0.96	0.44	0.83	0.99	0.44	0.14	0.94	0.44	0.42	0.96	
rs10011025	*GLRA3*	Sandholm 2014	GWAS, T1D-AER	G	A	0.18	0.31	1.07	0.18	0.69	1.02	0.18	0.32	1.09	0.18	0.37	1.11	0.18	0.45	1.08	0.18	0.29	1.1	0.18	0.14	1.13	
rs2106294	*LIMK2*	McDonough 2010	GWAS on T2D-DN AA	T	C	0.68	0.46	1.04	0.69	0.27	1.08	0.68	0.61	1.03	0.67	0.84	0.97	0.68	0.14	0.94	0.68	0.34	0.96	0.68	0.83	1.01	
rs6492208	Chr 13q	Pezzolesi 2009	GWAS, T1D-DN	C	T	0.39	0.59	0.99	0.39	0.85	1.01	0.39	0.55	0.99	0.38	0.19	0.94	0.39	0.16	0.94	0.38	0.41	0.97	0.39	0.99	1	
rs1888747	*FRMD3*	Pezzolesi 2009	GWAS, T1D-DN	G	C	0.7	0.78	1	0.7	0.95	1	0.7	0.6	1.02	0.7	0.17	1.11	0.7	0.34	1.07	0.71	0.96	1	0.7	0.49	1.04	
rs1129456	*GREM1*	Mooyaart 2011*	CGM, T1D/T2D	T	A	0.12	0.38	1.06	0.12	0.47	0.95	0.13	0.18	1.1	0.12	0.55	1.04	0.13	0.86	0.99	0.13	0.86	1.01	0.13	0.89	1.01	
rs7989848	Chr 13q	Pezzolesi 2009	GWAS T1D-DN	A	G	0.56	0.62	1.01	0.56	0.97	0.99	0.56	0.51	1.02	0.56	0.22	1.06	0.56	0.19	1.06	0.56	0.36	1.04	0.56	0.58	1.03	
rs10868025	*FRMD3*	Pezzolesi 2009	GWAS T1D-DN	G	A	0.36	0.62	0.98	0.37	0.91	1	0.36	0.38	0.96	0.36	0.2	0.92	0.36	0.34	0.94	0.36	0.75	0.99	0.36	0.29	0.94	
rs16864170	*SOX11*	Köttgen 2010	GWAS CKD	C	T	0.04	0.89	1.03	0.04	0.22	0.82	0.05	0.31	1.12	0.04	0.6	1.07	0.04	0.53	1.09	0.04	0.94	0.99	0.04	0.69	0.95	
rs13293564	*UNC13B*	Mooyaart 2011*	CGM, T1D/T2D	T	G	0.44	0.76	1.01	0.43	0.25	0.94	0.45	0.33	1.04	0.45	0.33	1.05	0.45	0.51	1.03	0.45	0.66	1.02	0.44	0.73	0.96	
rs1411766	*NA*	Pezzolesi 2009	GWAS T1D-DN	A	G	0.36	0.27	0.95	0.37	0.26	0.92	0.37	0.46	0.96	0.37	0.7	1.02	0.36	0.32	1.06	0.37	0.78	1.02	0.37	0.93	1	
rs39075	*CPVL/CHN2*	Pezzolesi 2009	GWAS T1D-DN	A	G	0.39	0.34	0.96	0.39	0.27	0.94	0.39	0.59	0.97	0.4	0.83	0.99	0.39	0.76	1.02	0.39	0.65	1.02	0.4	0.76	1.01	
rs9521445	Chr 13q	Pezzolesi 2009	GWAS T1D-DN	A	C	0.51	0.39	1.03	0.52	0.32	1.06	0.51	0.65	1.02	0.51	0.72	1.01	0.51	0.94	0.99	0.51	0.86	1	0.51	0.96	1	
rs739401	*CARS*	Pezzolesi 2009	GWAS T1D-DN	T	C	0.43	0.34	1.05	0.44	0.43	1.06	0.43	0.54	1.03	0.42	0.76	1.03	0.42	0.94	1.01	0.43	0.66	0.98	0.43	0.64	1.03	
rs451041	*CARS*	Pezzolesi 2009	GWAS T1D-DN	G	A	0.43	0.38	1.05	0.44	0.51	1.05	0.43	0.53	1.03	0.42	0.98	1.01	0.42	0.82	1	0.43	0.57	0.97	0.43	0.72	1.02	
rs17300539	*ADIPOQ*	Mooyaart 2011,	CGM, T1D/T2D	A	G	0.05	0.67	1.06	0.06	0.45	1.09	0.05	0.96	1.02	0.05	0.57	1.11	0.05	0.5	1.11	0.05	0.43	1.08	0.06	0.75	1.05	
rs2410601	*PSD3-SH2D4A*	Sandholm 2014	GWAS T1D-AER	C	G	0.57	0.87	0.98	0.56	0.44	0.93	0.57	0.86	1	0.57	0.9	1	0.57	0.7	1.02	0.57	0.64	1.02	0.57	0.45	0.95	

rs6930576	*SASH1*	McDonough 2010	GWAS T2D-DN AA	A	G	0.34	0.59	1.04	0.34	0.72	1.04	0.34	0.91	1.02	0.33	0.67	1	0.33	0.47	0.97	0.33	0.56	0.98	0.34	0.74	0.98	
rs3767140	*HSPG2*	Mooyaart 2011*	CGM, T1D/T2D	A	C	0.23	0.81	1.02	0.22	0.74	1.03	0.23	0.81	1	0.23	0.79	1.02	0.23	0.88	1	0.22	0.47	1.04	0.22	0.84	0.99	
rs39059	*CPVL/CHN2*	Pezzolesi 2009	GWAS T1D-DN	G	A	0.36	0.48	0.96	0.36	0.66	0.97	0.36	0.52	0.96	0.36	0.67	0.99	0.36	0.92	1	0.36	1	1	0.37	0.96	0.99	
rs12917707	*UMOD*	Köttgen 2010	GWAS CKD	T	G	0.22	0.71	0.99	0.22	0.74	1.02	0.22	0.64	0.98	0.22	0.85	1.01	0.22	0.97	1.02	0.22	0.57	0.97	0.22	0.59	0.96	
rs2358944	*MSRB3-HMGA2*	McDonough 2010	GWAS T2D-DN AA	A	G	0.84	0.66	0.98	0.84	0.82	0.98	0.84	0.66	0.97	0.84	0.8	0.98	0.84	0.92	0.99	0.84	0.8	0.99	0.84	0.75	0.99	
rs7769051	*RPS12*	McDonough 2010	GWAS T2D-DN AA	A	C	0.14	0.89	1	0.14	0.86	0.98	0.14	0.77	0.99	0.14	0.68	0.98	0.14	0.89	1	0.14	0.89	1	0.15	0.94	1.01	
rs841853	*GLUT1*	Mooyaart 2011*	CGM, T1D/T2D	C	A	0.69	0.74	1.01	0.68	0.93	0.99	0.69	0.72	1.01	0.68	0.93	0.99	0.69	0.71	0.97	0.68	0.8	1	0.67	0.75	0.97	
Results excluding the FinnDiane patients for SNPs were the source publication includes FinnDiane patients																										
SNP	**GENE**	**Source**	**Type**	**EA**	**NEA**	**EAF**	**OR**	**P**	**EAF**	**OR**	**P**	**EAF**	**OR**	**P**	**EAF**	**OR**	**P**	**EAF**	**OR**	**P**	**EAF**	**OR**	**P**	**EAF**	**OR**	**P**	**Direction**
rs13293564	*UNC13B*	Mooyaart 2011*	CGM, T1D/T2D	T	G	0.41	0.83	0.03	0.42	0.80	0.02	0.42	0.83	0.11	0.43	0.93	0.87	0.42	1.00	0.78	0.42	0.88	0.31	0.42	0.77	0.02	Opposite
rs2838302	*SIK1*	Sambo 2014	GWAS, T1D-ESRD	G	A	0.09	1.23	0.22	0.08	1.20	0.55	0.09	1.27	0.14	0.08	1.52	0.04	0.09	1.39	0.09	0.09	1.22	0.28	0.09	1.19	0.33	same
rs12137135	*WNT4-ZBTB40*	Sambo 2014	GWAS, T1D-ESRD	G	A	0.15	0.81	0.04	0.16	0.89	0.29	0.16	0.76	0.04	0.17	0.81	0.11	0.16	0.91	0.32	0.15	0.97	0.62	0.15	0.77	0.08	Opposite
rs699	*AGT*	Mooyaart 2011	CGM, T1D/T2D	G	A	0.43	1.09	0.33	0.43	1.24	0.05	0.42	0.98	0.79	0.43	1.08	0.59	0.43	1.08	0.67	0.43	0.98	0.65	0.43	1.00	0.74	
rs7583877	*AFF3*	Sandholm 2012	GWAS, T1D-ESRD	T	C	0.66	1.12	0.19	0.66	1.21	0.07	0.66	1.08	0.72	0.66	1.07	0.49	0.66	1.03	0.89	0.67	1.03	0.98	0.66	1.03	0.83	
rs5186	*AGTR1*	Mooyaart 2011	CGM, T1D/T2D	C	A	0.30	1.17	0.10	0.29	1.08	0.71	0.30	1.21	0.11	0.28	1.10	0.86	0.29	1.07	0.96	0.30	0.94	0.78	0.30	1.17	0.08	
rs1801282	*PPARG*	Mooyaart 2011	CGM, T1D/T2D	G	C	0.11	1.18	0.10	0.11	1.20	0.20	0.11	1.18	0.18	0.11	1.31	0.11	0.12	1.18	0.24	0.12	1.12	0.23	0.12	1.08	0.47	
rs7588550	*ERBB4*	Sandholm 2012	GWAS, T1D-DN	A	G	0.96	0.92	0.57	0.96	0.71	0.10	0.96	1.00	0.95	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
rs1799987	*CCR5*	Mooyaart 2011	CGM, T1D/T2D	G	A	0.45	1.09	0.65	0.46	1.21	0.11	0.45	1.03	0.74	0.44	1.02	0.63	0.45	0.97	0.36	0.44	0.99	0.56	0.45	1.17	0.22	
rs12917114	*SEMA6D-SLC24A5*	Sambo 2014	GWAS, T1D-ESRD	T	C	0.08	0.86	0.13	0.08	0.87	0.27	0.08	0.86	0.24	0.07	0.94	0.68	0.07	1.05	0.94	0.07	1.08	0.98	0.07	0.94	0.74	
rs1564939	*GLRA3*	Sandholm 2014	GWAS, T1D-AER	C	T	0.22	0.92	0.34	0.22	0.94	0.82	0.22	0.90	0.27	0.21	0.82	0.13	0.21	0.84	0.19	0.20	1.02	0.79	0.20	0.92	0.39	
rs10011025	*GLRA3*	sandholm 2014	GWAS, T1D-AER	G	A	0.21	0.92	0.32	0.21	0.92	0.69	0.21	0.91	0.27	0.20	0.83	0.14	0.20	0.85	0.21	0.20	0.98	0.61	0.19	0.91	0.33	
rs12437854	*RGMA–MCTP2*	Sandholm 2012	GWAS, T1D-ESRD	G	T	0.06	1.03	0.73	0.06	1.15	0.47	0.06	0.95	0.99	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.06	1.29	0.19	
rs2410601	*PSD3-SH2D4A*	Sandholm 2014	GWAS T1D-AER	C	G	0.53	1.05	0.41	0.53	0.95	0.92	0.54	1.10	0.31	0.54	1.03	0.83	0.54	1.02	0.86	0.54	0.98	0.96	0.54	0.89	0.25	
rs1670754	*Chr 4p15.1*	Sambo 2014	GWAS, T1D-ESRD	A	G	0.20	0.96	0.82	0.21	1.09	0.46	0.20	0.89	0.32	0.20	1.00	0.90	0.20	0.98	0.76	0.20	0.97	0.93	0.20	1.13	0.25	
N subjects						**Case**	**Ctrl**	**Total**	**Case**	**Ctrl**	**Total**	**Case**	**Ctrl**	**Total**	**Case**	**Ctrl**	**Total**	**Case**	**Ctrl**	**Total**	**Case**	**Ctrl**	**Total**	**Case**	**Ctrl**	**Total**	
SDR + Eurodiab + Cambridge						761	980	1,741	337	980	1,317	418	980	1,398	159	781	940	159	1,234	1,393	276	832	1,108	328	596	924	

Direction: Direction of effect compared between this and the original study; Opposite, NS: Association was non-significant in the previous meta-analysis, trending in the opposite direction. CGM: meta-analysis of candidate gene studies. P-value required for statistical significance after adjustment for multiple testing is 0.0011 (significance level α=0.05, 46 loci), highlighted with green background and bold text. *Variant was significant in the literature-based meta-analysis [56]. Source: Sambo 2014 [57]; Sandholm 2012 [2]; Mooyaart 2011 [56]; Tong 2008 [58]; shimazaki 2005 [59]; Pezzolesi 2009 [60]; Craig 2009 [61]; Sandholm 2014 [62]; Köttgen 2010 [63]; McDonough 2010 [64].

Supplemental Table 10: Association between diabetic kidney complications and genetic risk scores of related phenotypes

DKD phenotype	trait	OR	95% CI	P-value
Late DKD	Body mass index (z transformed)	2.51	1.64 - 3.84	***2.20E-05***
Late DKD	Body mass index (BMI)	2.06	1.37 - 3.07	***4.50E-04***
ESRD vs. no DKD	Body mass index (BMI)	2.52	1.49 - 4.26	***5.40E-04***
Combined DKD	Type 2 diabetes (inclu. lipid SNPs)	1.28	1.11 - 1.47	***6.10E-04***
Combined DKD	Body mass index (z transformed)	1.92	1.32 - 2.78	***6.30E-04***
CKD	Body mass index (BMI)	2.04	1.33 - 3.13	***1.00E-03***
CKD	Body mass index (z transformed)	2.04	1.33 - 3.14	***1.10E-03***
Late DKD	Type 2 diabetes (inclu. lipid SNPs)	1.28	1.1 - 1.5	***1.90E-03***
Combined DKD	Type 2 diabetes	1.19	1.07 - 1.32	***1.90E-03***
ESRD vs. no ESRD	Body mass index (BMI)	2.1	1.3 - 3.39	***2.50E-03***
Late DKD	Type 2 diabetes	1.21	1.07 - 1.36	2.80E-03
Combined DKD	Type 2 diabetes (inclu. glycaemic SNPs)	1.18	1.05 - 1.32	5.60E-03
Late DKD	Fasting proinsulin (BMI+FG adj.)	2.78	1.35 - 5.72	5.70E-03
CKD and DKD	Body mass index (BMI)	1.92	1.2 - 3.09	6.90E-03
ESRD vs. no DKD	Body mass index (z transformed)	2.03	1.2 - 3.44	8.30E-03
ESRD vs. no DKD	Type 2 diabetes (inclu. lipid SNPs)	1.32	1.07 - 1.63	8.30E-03
CKD and DKD	Low-density lipoprotein C	1.79	1.15 - 2.79	9.70E-03
Late DKD	Type 2 diabetes (inclu. glycaemic SNPs)	1.18	1.04 - 1.34	1.30E-02
CKD and DKD	Type 2 diabetes	1.19	1.03 - 1.37	1.70E-02
Late DKD	Waist-Hip Ratio (BMI adj.)	1.76	1.1 - 2.79	1.80E-02
CKD and DKD	Body mass index (z transformed)	1.77	1.09 - 2.86	2.00E-02
Combined DKD	Body mass index (BMI)	1.52	1.06 - 2.17	2.10E-02
Combined DKD	Fasting proinsulin (BMI+FG adj.)	2.13	1.11 - 4.09	2.20E-02
CKD and DKD	Type 2 diabetes (inclu. glycaemic SNPs)	1.19	1.02 - 1.38	2.70E-02
CKD and DKD	Type 2 diabetes (inclu. lipid SNPs)	1.21	1.01 - 1.46	4.00E-02
Late DKD	Insulin resistance	13.96	1.12 - 174.72	4.10E-02
Early DKD	Type 2 diabetes (inclu. glycaemic SNPs)	1.18	1 - 1.39	4.50E-02
Early DKD	Type 2 diabetes (inclu. lipid SNPs)	1.22	1 - 1.49	4.70E-02
CKD	Waist-Hip Ratio (BMI adj.)	1.65	1.01 - 2.71	4.80E-02
Early DKD	Type 2 diabetes	1.16	1 - 1.36	5.30E-02
Combined DKD	Insulin resistance	9.11	0.95 - 87.3	5.50E-02
ESRD vs. no ESRD	Type 2 diabetes (inclu. lipid SNPs)	1.2	0.99 - 1.45	6.30E-02
CKD	Fasting proinsulin (BMI+FG adj.)	2.07	0.95 - 4.5	6.60E-02
ESRD vs. no DKD	Type 2 diabetes	1.16	0.99 - 1.36	7.10E-02
Early DKD	Fasting glucose (BMI adj.)	4.71	0.86 - 25.96	7.50E-02
ESRD vs. no DKD	Low-density lipoprotein C	1.58	0.95 - 2.61	7.70E-02
Late DKD	ln(Fasting insulin) BMI adj.	5.53	0.83 - 37.02	7.80E-02
ESRD vs. no DKD	High-density lipoprotein C	1.95	0.91 - 4.15	8.40E-02
Early DKD	Insulin resistance	15.17	0.61 - 376.25	9.70E-02
ESRD vs. no DKD	Type 2 diabetes (inclu. glycaemic SNPs)	1.15	0.97 - 1.36	1.00E-01
ESRD vs. no ESRD	Low-density lipoprotein C	1.49	0.92 - 2.4	1.00E-01
Combined DKD	ln(Fasting insulin) BMI adj.	4.07	0.74 - 22.36	1.10E-01
Early DKD	Low-density lipoprotein C	1.51	0.91 - 2.5	1.10E-01
ESRD vs. no DKD	Systolic blood pressure	0.45	0.17 - 1.19	1.10E-01

DKD phenotype	trait	OR	95% CI	P-value
CKD and DKD	Waist-Hip Ratio (BMI adj.)	1.56	0.9 - 2.71	1.10E-01
CKD and DKD	Fasting proinsulin (BMI+FG adj.)	1.96	0.85 - 4.5	1.10E-01
CKD	Systolic blood pressure	0.53	0.23 - 1.19	1.20E-01
CKD	Type 2 diabetes (inclu. glycaemic SNPs)	1.11	0.97 - 1.28	1.30E-01
Early DKD	ln(Fasting insulin) BMI adj.	6.39	0.57 - 72.23	1.30E-01
ESRD vs. no ESRD	Body mass index (z transformed)	1.43	0.89 - 2.29	1.40E-01
Combined DKD	Fasting glucose (BMI adj.)	2.45	0.75 - 8	1.40E-01
Combined DKD	Waist-Hip Ratio (BMI adj.)	1.37	0.9 - 2.06	1.40E-01
ESRD vs. no ESRD	High-density lipoprotein C	1.69	0.84 - 3.38	1.40E-01
CKD	Type 2 diabetes (inclu. lipid SNPs)	1.13	0.96 - 1.34	1.40E-01
Late DKD	High-density lipoprotein C	1.52	0.86 - 2.7	1.50E-01
ESRD vs. no DKD	Fasting proinsulin (BMI+FG adj.)	1.94	0.76 - 4.94	1.60E-01
ESRD vs. no ESRD	HbA1c	0.28	0.04 - 1.8	1.80E-01
Late DKD	2hr-Glucose (BMI adj.)	0.75	0.49 - 1.15	1.90E-01
CKD and DKD	ln(Fasting insulin) BMI adj.	4.32	0.46 - 40.29	2.00E-01
CKD and DKD	Insulin resistance	6.99	0.36 - 135.72	2.00E-01
CKD and DKD	Systolic blood pressure	0.56	0.23 - 1.38	2.10E-01
ESRD vs. no DKD	HbA1c	0.29	0.04 - 2.14	2.30E-01
Combined DKD	High-density lipoprotein C	1.36	0.82 - 2.26	2.30E-01
CKD and DKD	Fasting glucose (BMI adj.)	2.65	0.53 - 13.22	2.40E-01
CKD	Type 2 diabetes	1.08	0.95 - 1.23	2.40E-01
ESRD vs. no DKD	Waist-Hip Ratio (BMI adj.)	1.43	0.77 - 2.67	2.60E-01
ESRD vs. no DKD	2hr-Glucose (BMI adj.)	0.74	0.43 - 1.26	2.70E-01
CKD and DKD	Triglycerides	0.67	0.32 - 1.37	2.70E-01
ESRD vs. no DKD	ln(Fasting insulin) BMI adj.	3.84	0.34 - 42.91	2.80E-01
Late DKD	Systolic blood pressure	0.66	0.31 - 1.4	2.80E-01
Early DKD	Body mass index (BMI)	0.76	0.46 - 1.27	3.00E-01
CKD and DKD	High-density lipoprotein C	1.42	0.72 - 2.77	3.10E-01
Combined DKD	Low-density lipoprotein C	1.2	0.84 - 1.71	3.20E-01
Late DKD	HbA1c	0.46	0.1 - 2.21	3.30E-01
ESRD vs. no ESRD	2hr-Glucose (BMI adj.)	0.8	0.48 - 1.31	3.70E-01
ESRD vs. no ESRD	Type 2 diabetes (inclu. glycaemic SNPs)	1.07	0.92 - 1.26	3.80E-01
ESRD vs. no ESRD	Systolic blood pressure	0.67	0.27 - 1.67	3.90E-01
Late DKD	Triglycerides	0.77	0.42 - 1.41	4.00E-01
CKD	Fasting glucose (BMI adj.)	0.54	0.13 - 2.26	4.00E-01
CKD	HOMA-B	0.57	0.15 - 2.17	4.10E-01
CKD	Low-density lipoprotein C	1.19	0.78 - 1.82	4.10E-01
Late DKD	Fasting glucose (BMI adj.)	1.73	0.46 - 6.47	4.10E-01
CKD and DKD	HOMA-IR	3.01	0.2 - 44.97	4.30E-01
Combined DKD	2hr-Glucose (BMI adj.)	0.86	0.58 - 1.26	4.40E-01
Early DKD	Fasting proinsulin (BMI+FG adj.)	1.43	0.56 - 3.65	4.50E-01
ESRD vs. no ESRD	Type 2 diabetes	1.06	0.91 - 1.22	4.60E-01
CKD	High-density lipoprotein C	1.26	0.68 - 2.34	4.60E-01
ESRD vs. no DKD	Insulin resistance	3.4	0.13 - 90.6	4.60E-01
Late DKD	HOMA-IR	2.32	0.24 - 22.65	4.70E-01
CKD	2hr-Glucose (BMI adj.)	1.18	0.74 - 1.86	4.90E-01

DKD phenotype	trait	OR	95% CI	P-value
CKD	HOMA-IR	0.46	0.04 - 4.77	5.10E-01
ESRD vs. no ESRD	Insulin resistance	0.38	0.02 - 8.04	5.30E-01
ESRD vs. no DKD	Triglycerides	0.78	0.35 - 1.74	5.50E-01
ESRD vs. no ESRD	Triglycerides	0.8	0.38 - 1.69	5.60E-01
Early DKD	HOMA-B	0.63	0.13 - 3.03	5.60E-01
Early DKD	HbA1c	1.83	0.22 - 15.06	5.70E-01
CKD and DKD	Type 1 diabetes	0.98	0.93 - 1.04	5.80E-01
ESRD vs. no ESRD	Fasting proinsulin (BMI+FG adj.)	1.28	0.54 - 3.02	5.80E-01
Combined DKD	Systolic blood pressure	0.83	0.42 - 1.63	5.90E-01
ESRD vs. no ESRD	Waist-Hip Ratio (BMI adj.)	1.17	0.65 - 2.09	6.00E-01
ESRD vs. no ESRD	HOMA-IR	0.51	0.04 - 6.97	6.20E-01
Combined DKD	HOMA-IR	1.68	0.22 - 12.67	6.20E-01
Early DKD	Systolic blood pressure	0.79	0.3 - 2.04	6.20E-01
ESRD vs. no ESRD	HOMA-B	1.44	0.33 - 6.25	6.30E-01
CKD	Type 1 diabetes	0.99	0.94 - 1.04	6.80E-01
Early DKD	Body mass index (z transformed)	1.11	0.66 - 1.86	6.90E-01
Combined DKD	HbA1c	0.75	0.18 - 3.14	7.00E-01
Early DKD	High-density lipoprotein C	1.15	0.57 - 2.33	7.00E-01
ESRD vs. no DKD	HOMA-B	1.35	0.28 - 6.59	7.10E-01
ESRD vs. no DKD	Type 1 diabetes	0.99	0.94 - 1.05	7.30E-01
CKD	ln(Fasting insulin) BMI adj.	0.72	0.1 - 5.39	7.50E-01
CKD	HbA1c	1.31	0.23 - 7.44	7.60E-01
CKD	Triglycerides	0.9	0.46 - 1.76	7.60E-01
ESRD vs. no ESRD	Fasting glucose (BMI adj.)	0.78	0.15 - 4.13	7.80E-01
CKD and DKD	HOMA-B	0.81	0.19 - 3.49	7.80E-01
CKD and DKD	2hr-Glucose (BMI adj.)	0.93	0.57 - 1.54	7.90E-01
Early DKD	Waist-Hip Ratio (BMI adj.)	1.08	0.6 - 1.95	7.90E-01
Late DKD	HOMA-B	1.17	0.34 - 3.98	8.00E-01
ESRD vs. no ESRD	ln(Fasting insulin) BMI adj.	1.31	0.14 - 12.29	8.10E-01
ESRD vs. no DKD	Fasting glucose (BMI adj.)	1.24	0.21 - 7.41	8.10E-01
Early DKD	2hr-Glucose (BMI adj.)	1.06	0.61 - 1.86	8.30E-01
ESRD vs. no ESRD	Type 1 diabetes	1	0.94 - 1.05	8.70E-01
Late DKD	Type 1 diabetes	1	0.95 - 1.04	8.70E-01
Combined DKD	Type 1 diabetes	1	0.96 - 1.04	8.70E-01
Early DKD	Type 1 diabetes	1	0.95 - 1.06	8.80E-01
Combined DKD	HOMA-B	0.92	0.31 - 2.76	8.80E-01
Combined DKD	Triglycerides	0.96	0.56 - 1.65	8.80E-01
CKD	Insulin resistance	0.84	0.06 - 12.46	9.00E-01
Early DKD	Triglycerides	1.02	0.47 - 2.19	9.70E-01
ESRD vs. no DKD	HOMA-IR	0.96	0.05 - 17.34	9.80E-01
Late DKD	Low-density lipoprotein C	1	0.67 - 1.5	9.80E-01
Early DKD	HOMA-IR	0.99	0.06 - 17.58	1.00E+00
CKD and DKD	HbA1c	1	0.16 - 6.4	1.00E+00

Significant *p*-values ($p<2.6\times10^{-3}$, α=0.05 Bonferroni corrected for the 19 examined traits) are highlighted with ***bold italics***.

References for the SNPs included in the genetic risk scores (GRS): Waist-Hip-ratio (adjusted for body mass index [BMI], N_{SNPs}=54)[26], BMI (untransformed, N_{SNPs}=96 [27] and z-transformed, N_{SNPs}=24 [28]), systolic blood pressure (SBP, N_{SNPs}=22)[29], low-density lipoprotein cholesterol (LDL-C, N_{SNPs}=24), triglycerides (TRIG, N_{SNPs}=20), high-density lipoprotein cholesterol (HDL-C, N_{SNPs}=26)[30], T1D (N_{SNPs}=51) [31], T2D [32] (including all SNPs (N_{SNPs}=70), and without any other effects other than on T2D or lipids (N_{SNPs}=56)[30] and T2D or glycemic traits (N_{SNPs}=62)[33,34]), 2-hr glucose (adjusted for BMI, N_{SNPs}=15)[35], fasting glucose (FG, adjusted for BMI, N_{SNPs}=21) [34], glycated haemoglobin (HbA1c, N_{SNPs}=15)[36], fasting insulin (natural log transformed and adjusted for BMI, N_{SNPs}=13)[34], fasting pro-insulin (adjusted for BMI and FG, N_{SNPs}=10)[37], HOMA-B (N_{SNPs}=15), HOMA-IR (N_{SNPs}=15)[38] and insulin resistance [39].

Supplemental Table 11: MAGENTA Gene set enrichment results with FDR<0.05

pheno	DB	Gene set	EFF GS SIZE	P	FDR	EXP # GENES	OBS # GENES	# GENES FLAGGED	FLAGGED GENE NAMES
CKDDN	BIOCARTA	Shh pathway	16	1.00E-05	0.0001	1	7	16	*DYRK1A, GLI1, GLI2, GLI3, GSK3B, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, PTCH1, SHH, SMO, DYRK1B, SUFU*
Combined DKD	KEGG	ascorbate and aldarate metabolism	17	9.00E-06	0.0001	1	7	22	*ALDH2, ALDH1B1, ALDH9A1, ALDH3A2, ALDH7A1, UGDH, UGT2B4, UGT2B7, UGT2B11, UGT2A1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, MIOX, UGT2A3*
Combined DKD	KEGG	pentose and glucuronate interconversions	20	3.00E-06	0.0002	1	8	24	*AKR1B1, GUSB, RPE, UGDH, UGP2, UGT2B4, UGT2B7, XYLB, UGT2B11, UGT2A1, DHDH, CRYL1, DCXR, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, UGT2A3*
Combined DKD	KEGG	porphyrin and chlorophyll metabolism	31	8.50E-05	0.0020	2	8	38	*ALAD, ALAS1, ALAS2, BLVRA, BLVRB, COX10, COX15, CP, CPOX, EPRS, FECH, FTH1, GUSB, HCCS, HMBS, HMOX1, HMOX2, PPOX, UGT2B4, UGT2B7, UROD, UROS, UGT2B11, UGT2A1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, UGT2A3, FTMT, EARS2, MMAB*
Early DKD	PANTHER BIOLOGICAL PROCESS	Hearing	27	1.00E-04	0.0020	1	8	29	*TIMM8A, DFNA5, COCH, MYO6, MYO7A, MYO7B, P2RX1, P2RX3, P2RX4, P2RX5, P2RX7, TCOF1, WFS1, ZFAND5, P2RX6, KCNQ4, ITM2B, WDR1, P2RX2, DFNB31, TIMM13, TIMM8B, MYO15A, CDHR5, CDH23, ESPN, OTOA, STRC, OC90*
Combined DKD	KEGG	drug metabolism other enzymes	39	3.00E-04	0.0102	2	8	48	*NAT1, NAT2, CDA, CES1, CYP2A6, CYP2A7, CYP3A7, CYP2A13, CYP3A4, CYP3A5, DPYD, DPYS, TYMP, GUSB, HPRT1, IMPDH1, IMPDH2, ITPA, TK1, TK2, TPMT, UGT2B4, UGT2B7, UCK2, UMPS, UPP1, XDH, CES2, GMPS, UGT2B11, UGT2A1, UPB1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, UCKL1, CYP3A43, UGT2A3, UCK1, UPP2, CES5A*
Combined DKD	KEGG	drug metabolism cytochrome p450	49	5.00E-04	0.0107	2	9	68	*ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7, ALDH3A1, ALDH1A3, ALDH3B1, ALDH3B2, AOX1, CYP1A2, CYP2A6, CYP2A7, CYP3A7, CYP2A13, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2C18, CYP2D6, CYP2E1, CYP3A4, CYP3A5, FMO1, FMO2, FMO3, FMO4, FMO5, GSTA1, GSTA2, GSTA3, GSTA4, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTP1, GSTT1, GSTZ1, MAOA, MAOB, MGST1, MGST2, MGST3, UGT2B4, UGT2B7, GSTO1, UGT2B11, UGT2A1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, CYP3A43, UGT2A3, GSTO2, GSTA5, GSTK1*
Combined DKD	KEGG	metabolism of xenobiotics by cytochrome p450	47	5.00E-04	0.0125	2	9	66	*ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7, ALDH3A1, ALDH1A3, ALDH3B1, ALDH3B2, AKR1C4, CYP1A1, CYP1A2, CYP1B1, CYP3A7, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2C18, CYP2E1, CYP2F1, CYP3A4, CYP3A5, AKR1C1, AKR1C2, EPHX1, GSTA1, GSTA2, GSTA3, GSTA4, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTP1, GSTT1, GSTZ1, MGST1, MGST2, MGST3, UGT2B4, UGT2B7, AKR1C3, GSTO1, UGT2B11, UGT2A1, DHDH, CYP2S1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, CYP3A43, UGT2A3, GSTO2, GSTA5, GSTK1*
Combined DKD	KEGG	retinol metabolism	45	1.80E-03	0.0212	2	8	61	*ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7, ALDH1A1, CYP1A1, CYP1A2, CYP2A6, CYP2A7, CYP3A7, CYP2A13, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2C18, CYP3A4, CYP3A5, CYP4A11, CYP26A1, RDH5, RPE65, UGT2B4, UGT2B7, PNPLA4, RDH16, DGAT1, ALDH1A2, LRAT, DHRS3, DHRS9, UGT2B11, DHRS4, UGT2A1, RDH8, RDH11, BCMO1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, RETSAT, CYP26B1, CYP3A43, UGT2A3, DGAT2, RDH12, RDH10, AWAT2, CYP4A22, DHRS4L2, CYP26C1*
Combined DKD	REACTOME	Glucuronidation	13	2.84E-04	0.0238	1	5	16	*UGDH, UGP2, UGT2B4, UGT2B7, UGT2B11, UGT2A1, SLC35D1, UGT2B28, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3*

pheno	DB	Gene set	EFF GS SIZE	P	FDR	EXP # GENES	OBS # GENES	# GENES FLAGGED	FLAGGED GENE NAMES
CKD	Panther	Cholesterol biosynthesis	10	8.00E-04	0.0252	1	4	11	*FDFT1, FDPS, HMGCR, HMGCS1, HMGCS2, IDI1, MVD, MVK, PMVK, PDSS1, IDI2*
Combined DKD	GOTERM	Glucuronosyltransferase activity	15	1.00E-04	0.0304	1	6	20	*EXT1, EXT2, UGT2B4, UGT2B7, UGT2B11, UGT2A1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, CSGALNACT1, UGT2A3, UGT3A1, UGT3A2*
Combined DKD	KEGG	glutathione metabolism	40	3.20E-03	0.0350	2	7	49	*ANPEP, G6PD, GGT1, GGT7, GGT5, GCLC, GCLM, GPX1, GPX2, GPX3, GPX4, GPX5, GPX7, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTP1, GSTT1, GSTZ1, IDH1, IDH2, MGST1, MGST2, MGST3, ODC1, PGD, RRM1, RRM2, SMS, SRM, GSTO1, OPLAH, RRM2B, LAP3, TXNDC12, GGCT, GSTO2, GGT6, GSTA5, GPX6, GSTK1*
CKD+DKD	BIOCARTA	Cystic Fibrosis Transmembrane Conductance Regulator And Beta 2 Adrenergic Receptor Pathway	12	2.50E-03	0.0366	1	4	12	*ADCY1, ADRB2, CFTR, GNAS, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, EZR, SLC9A3R1*
CKD+DKD	BIOCARTA	Attenuation of GPCR Signaling Pathway	13	3.50E-03	0.0384	1	4	13	*ARRB1, GNAS, GNB1, GNGT1, GRK4, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, PRKCA, PRKCB*
Combined DKD	KEGG	starch and sucrose metabolism	40	4.00E-03	0.0391	2	7	46	*AGL, AMY2A, AMY2B, G6PC, GAA, GANC, GBE1, GCK, GPI, GUSB, GYS1, GYS2, HK1, HK2, HK3, ENPP1, ENPP3, PGM1, PYGB, PYGL, PYGM, SI, UGDH, UGP2, UGT2B4, UGT2B7, MGAM, UGT2B11, UGT2A1, TREH, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, PGM2, GBA3, G6PC2, UGT2A3, UXS1, PGM2L1*
CKD+DKD	BIOCARTA	Repression of Pain Sensation by the Transcriptional Regulator DREAM	14	3.60E-03	0.0394	1	4	14	*CREB1, CREM, FOS, JUN, OPRK1, POLR2A, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, MAPK3, KCNIP3*
CKD+DKD	BIOCARTA	Cytokines and Inflammatory Response	26	1.50E-03	0.0404	1	6	29	*CD4, CSF1, CSF2, CSF3, HLA-DRA, HLA-DRB1, IFNA1, IFNB1, IFNG, IL1A, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL10, IL11, IL12A, IL12B, IL13, IL15, LTA, PDGFA, TGFB1, TGFB2, TGFB3, TNF*
CKD+DKD	REACTOME	Cell extracellular matrix interactions	14	5.00E-04	0.0417	1	5	16	*ACTN1, FLNA, FLNC, ILK, ITGB1, LIMS1, PXN, RSU1, TESK1, VASP, ARHGEF6, FERMT2, PARVB, FBLIM1, LIMS2, PARVA*
Combined DKD	Panther	FAS signaling pathway	22	1.10E-03	0.0424	1	6	22	*PARP1, PARP4, CAPG, CASP6, CASP7, CASP8, CASP10, CYC1, DFFB, GSN, LMNA, LMNB1, CFLAR, PARP2, PARP3, NOD1, FAF1, NLRP1, LMNB2, SCIN, IFLTD1, NLRP10*
CKD+DKD	BIOCARTA	Phospholipase C-epsilon pathway	12	2.10E-03	0.0426	1	4	12	*ADCY1, ADRB2, GNAS, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, PTGER1, RAP2B, PLCE1*
Combined DKD	KEGG	steroid hormone biosynthesis	41	4.70E-03	0.0480	2	7	52	*STS, AKR1C4, COMT, CYP1A1, CYP1B1, CYP3A7, CYP3A4, CYP3A5, CYP7A1, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP21A2, AKR1C1, AKR1C2, HSD3B1, HSD3B2, HSD11B1, HSD11B2, HSD17B1, HSD17B3, HSD17B2, SRD5A1, SRD5A2, AKR1D1, SULT1E1, SULT2B1, UGT2B4, UGT2B7, HSD17B8, HSD17B6, AKR1C3, CYP7B1, UGT2B11, UGT2A1, HSD17B12, HSD17B7, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, CYP3A43, SRD5A3, UGT2A3*

Supplemental Table 12: Characteristics of the patients selected for the whole exome sequencing

	FinnDiane				Steno				SDR	
Group	**Controls (no DKD)**		**Cases (Late DKD)**		**Controls (no DKD)**		**Cases (Late DKD)**		**Controls (no DKD)**	**Cases (Late DKD)**
Subgroup	**no RT**	**RT**	**maA**	**ESRD**	**no RT**	**RT**	**maA**	**ESRD**	*****	**maA**
N (Male%)	125 (26)	125 (50)	125 (51)	125 (56)	46 (54)	74 (42)	139 (57)	49 (78)	130 (49)	62 (61)
Age ± sd (yr)	57±9	56±9	46±10	45±9	53±12 (30-80)	55±10 (31-78)	39±9 (22-70)	38±8 (20-59)	55±13 (33-84)	52±12 (29-84)
Age at Onset ± sd (yr)	13±7	13±7	13±7	15±7	15±10 (0-32)	16±9 (1-35)	13±8 (1-33)	15±8 (0-31)	15±9 (0-35)	14±8 (1-35)
Duration ± sd (yr)	43 ± 7 (32-66)	43 ± 6 (33-56)	34 ± 7 -	30 ± 7 -	38±8 (30-63)	39±6 (30-53)	- -	- -	40±10 (27-74)	38±11 (13-66)
Time to maA ± sd (yr)	-	-	16 ± 3	-	-	-	18±3	-	-	29±11
(range)	-	-	(8-20)	-	-		(12-25)	-	-	(11-64)
Time to ESRD ± sd (yr)	-	-	-	20 ± 3	-	-	-	26±5	-	-
(range)	-	-	-	(15-27)	-		-	(18-24)	-	-
Time to RT/ laser ± sd (yr)	-	26 ± 8	17 ± 5	16 ± 5	-	28±7	19±5	16±4	-	-
(range)	-	(12-47)	(8-33)	(2-33)	-	(12-41)	(8-35)	(6-27)	-	-
HbA1c ± sd (%)	8.4 ± 1.0	8.4 ± 0.9	8.5 ± 1.5	8.9 ± 1.5	8.4±1.0	8.7±1.2	9.5±1.4	9.8±1.5	7.0±0.9	8.1±1.2
Further definitions							all cases had proliferative RT		no record of proliferative retinopathy was available for patients who did not have DN	61/62 cases had proliferative RT

RT: diabetic retinopathy, based on either a clinical diagnosis or laser treatment

Supplemental Table 13. Top 20 results of single variant analysis for WES 'ESRD vs. no DKD' using the score test

Chr:pos	Id	Maf	Pval	Ref/alt	Ctrlcnt	Casecnt	Gene	type
1:224492543	rs188427269	0.0023184	3.3046e-07	G/T	482/0/0	166/3/0	*NVL*	INTRON
2:212243703	rs13003941	0.3524	3.5931e-06	G/T	182/229/71	92/67/10	*ERBB4*	UTR_3_PRIME
9:37729786	rs1359590	0.20015	4.8522e-06	C/T	277/189/16	132/35/2	*FRMPD1*	NON_SYNONYMOUS_CODING
21:34697316	rs112371220	0.0054687	5.4552e-06	C/T	474/1/0	164/4/1	*IFNAR1*	UTR_5_PRIME
19:1782842	rs146522765	0.003864	7.4797e-06	G/T	482/0/0	164/5/0	*ATP8B3*	EXON
7:27168590	rs1801085	0.10974	1.2659e-05	A/G	402/77/3	113/52/4	*HOXA4*	UPSTREAM
7:27159136	rs6969780	0.11283	1.4914e-05	G/C	399/80/3	113/51/5	*HOXA3*	INTRON
2:43518932	2:43518932	0.0092736	1.7014e-05	AC/A	479/3/0	160/9/0	*THADA*	INTRON
2:43804334	rs149038509	0.0092736	1.7014e-05	C/T	479/3/0	160/9/0	*THADA*	EXON
19:4502778	19:4502778	0.0030912	1.7702e-05	G/A	482/0/0	165/4/0	*PLIN4*	DOWNSTREAM
2:212251864	rs3748962	0.3408	2.0785e-05	T/C	192/222/68	94/65/10	*ERBB4*	SYNONYMOUS_CODING
5:157078632	rs13181859	0.0015528	2.9199e-05	G/A	479/0/0	167/2/0	*SOX30*	NON_SYNONYMOUS_CODING
1:64015722	rs41285382	0.0092736	2.9641e-05	T/C	480/2/0	159/10/0	*DLEU2L*	EXON
12:62996508	12:62996508	0.0015576	3.1046e-05	G/A	477/0/0	167/2/0	*C12orf61*	UPSTREAM
5:132086671	rs111822821	0.0015456	3.2297e-05	G/A	482/0/0	167/2/0	*SEPT8*	SYNONYMOUS_CODING
12:53468971	rs142430651	0.0015456	3.2926e-05	G/C	482/0/0	167/2/0	*SPRYD3*	SYNONYMOUS_CODING
8:107531123	8:107531123	0.0015456	3.5069e-05	G/T	482/0/0	167/2/0	*OXR1*	INTRON
X:12908121	rs192357402	0.0015456	3.5163e-05	C/T	482/0/0	167/2/0	.	.
3:188595287	rs182465976	0.0015456	3.7313e-05	A/G	482/0/0	167/2/0	*LPP*	UTR_3_PRIME
7:27146202	rs61384251	0.12133	3.8108e-05	A/G	390/88/4	111/54/4	*HOXA3*	UPSTREAM

Supplemental Table 14. Top 20 associations for WES 'Late DKD' using the single variant score test

Chr:pos	Id	Maf	Pval	Ref/alt	Casecnt	Ctrlcnt	Gene	type
15:75762082	rs117245151	0.011992	4.0048e-05	G/A	458/21/0	478/2/0	*PTPN9*	INTRON
7:27168590	rs1801085	0.1147	5.3839e-05	A/G	400/76/3	352/118/10	*HOXA4*	UPSTREAM
1:35562965	rs2971408	0.10323	6.0045e-05	G/A	2/70/407	5/114/361	*ZMYM1*	NON_SYNONYMOUS_CODING
7:27159136	rs6969780	0.11731	7.3659e-05	G/C	397/79/3	351/118/11	*HOXA3*	INTRON
1:1222958	rs111819661	0.015328	7.7877e-05	C/T	450/25/0	467/4/0	*SCNN1D*	DOWNSTREAM
6:126334041	rs2206941	0.29406	8.2189e-05	G/A	28/187/264	57/207/216	*TRMT11*	INTRON
7:137561465	rs77218976	0.03806	9.2539e-05	G/A	427/52/0	459/21/0	*CREB3L2*	UTR_3_PRIME
1:1195690	rs11260568	0.013034	0.0001173	G/C	457/22/0	477/3/0	*LOC100128842*	INTRON
1:1196374	rs72894077	0.013034	0.0001173	C/T	457/22/0	477/3/0	*LOC100128842*	INTRON
6:126299264	rs9388464	0.29249	0.00013887	A/T	28/187/264	57/204/219	*HINT3*	UTR_3_PRIME
6:126288023	rs3757212	0.29041	0.00013905	T/C	26/189/264	57/202/221	*HINT3*	INTRON
11:10650350	rs190761149	0.0067779	0.00014425	G/A	466/13/0	480/0/0	*MRVI1*	SYNONYMOUS_CODING
6:126300270	rs6909664	0.29145	0.0001443	G/A	27/188/264	57/203/220	*HINT3*	UTR_3_PRIME
19:4945974	rs2250978	0.039749	0.00015331	T/C	2/50/426	0/22/456	*UHRF1*	SYNONYMOUS_CODING
12:70914045	rs5798988	0.028676	0.00015412	A/AAAGT	438/41/0	466/14/0	*PTPRB*	UTR_3_PRIME
15:37109504	rs17417429	0.10949	0.00015916	G/C	358/110/11	409/64/7	*CSNK1A1P*	INTRON
6:126299984	rs10659948	0.29197	0.00016327	A/ACT	27/189/263	56/205/219	*HINT3*	UTR_3_PRIME
2:223783841	rs13000358	0.051616	0.00016344	G/A	414/60/5	453/25/2	*ACSL3*	SYNONYMOUS_CODING
2:212243703	rs13003941	0.34619	0.00017464	G/T	180/228/71	229/208/43	*ERBB4*	UTR_3_PRIME
2:71413771	rs357781	0.20177	0.0001777	G/C	330/136/13	278/179/23	*PAIP2B*	UTR_3_PRIME

Supplemental Table 15: Top 10 associations to WES 'Late DKD' with VT with 4 masks

Position	n.pass.v	P-value	Gene
PTV+missense			
11:68673615-68707139	17	4.9e-05	*IGHMBP2*
13:53035097-53049198	8	0.00012	*CKAP2*
20:57415627-57430300	13	0.00012	*GNAS*
3:123213786-123286612	3	0.00014	*PTPLB*
14:24837601-24846073	12	0.00025	*NFATC4*
10:45798933-45803264	5	0.00036	*OR13A1*
20:1099459-1146882	9	0.00049	*PSMF1*
19:36509815-36518135	5	0.0005	*CLIP3*
11:35454383-35515695	14	0.00056	*PAMR1*
15:59750819-59813476	8	0.00063	*FAM81A*
PTV+broad			
22:38013000-38028693	5	3.1e-05	*GGA1*
11:68673615-68707139	9	0.00012	*IGHMBP2*
19:12954416-12984677	7	0.00028	*MAST1*
11:102094424-102101456	2	0.00029	*YAP1*
20:1099459-1146882	8	0.00049	*PSMF1*
13:28794420-28866586	6	0.00059	*PAN3*
17:38933291-38938348	5	0.00062	*KRT27*
14:24837601-24846073	9	0.00063	*NFATC4*
5:110835655-110835762	2	0.00066	*STARD4*
18:77891038-77896253	6	0.00067	*ADNP2*
PTV+strict			
19:6743822-6744853	2	0.00021	*TRIP10*
10:49931476-50018711	2	0.0006	*WDFY4*
19:19166642-19168396	2	0.00062	*ARMC6*
5:133686100-133702055	3	0.00072	*CDKL3*
11:128781680-128781799	2	0.00087	*KCNJ5*
19:33370070-33450911	4	0.00089	*CCDC123*
2:163124596-163144807	7	0.00103	*IFIH1*
11:76157998-76170978	2	0.00113	*C11orf30*
1:151734628-151734961	2	0.0012	*MRPL9*
3:54952509-54952627	2	0.0012	*LRTM1*
PTV+only			
11:67815031-67818400	2	0.00088	*TCIRG1*
3:54952509-54952627	2	0.00113	*LRTM1*
10:49931476-50018711	2	0.0012	*WDFY4*
2:163124596-163144807	7	0.0015	*IFIH1*
17:8701157-8701167	2	0.0016	*MFSD6L*
2:43458439-43804337	3	0.0022	*THADA*
19:15233517-15235879	2	0.0025	*ILVBL*
6:101079090-101248282	2	0.0027	*ASCC3*
5:149676827-149677481	2	0.0028	*ARSI*
14:50117073-50141063	2	0.003	*POLE2*

N.pass.v = number of variants passing the mask definitions

Supplemental Table 16: Top 10 associations to WES 'Late DKD' using SKAT-O with 4 different masks.

Position	n.pass.v	n.sing.v	P-value	Gene
PTV+missense				
13:53035097-53049198	8	4	0.00012156	*CKAP2*
10:45798933-45803264	5	4	0.00048573	*OR13A1*
3:54952509-54959089	5	2	0.00063959	*LRTM1*
1:151139478-151140817	6	3	0.0006738	*SCNM1*
20:57415627-57430300	13	9	0.00086146	*GNAS*
7:18066456-18067243	5	3	0.0012014	*PRPS1L1*
19:6730150-6736607	19	8	0.0012488	*GPR108*
17:38933291-38938348	6	2	0.0012682	*KRT27*
19:42392130-42410847	17	8	0.0013578	*ARHGEF1*
3:122103120-122128670	3	1	0.0015433	*FAM162A*
PTV+broad				
11:68673615-68707139	9	6	0.00024156	*IGHMBP2*
13:53035097-53049198	7	4	0.0004632	*CKAP2*
7:18066456-18067059	4	3	0.00054833	*PRPS1L1*
3:54952509-54952627	2	0	0.00064301	*LRTM1*
10:45799065-45799733	2	1	0.00076937	*OR13A1*
18:77891038-77896253	6	3	0.0011557	*ADNP2*
13:28794420-28866586	6	3	0.0011976	*PAN3*
17:38933291-38938348	5	2	0.0013916	*KRT27*
5:37815803-37816112	3	1	0.0014264	*GDNF*
3:122103120-122128670	3	1	0.0015433	*FAM162A*
PTV+strict				
3:54952509-54952627	2	0	0.00064301	*LRTM1*
3:150384657-150421396	4	2	0.00066435	*FAM194A*
3:39228815-39229781	3	2	0.0035418	*XIRP1*
6:45909349-45916999	2	0	0.0035639	*CLIC5*
9:75774283-75777764	2	1	0.0072129	*ANXA1*
1:151773808-151774922	4	2	0.0076929	*LINGO4*
17:8701157-8701167	2	1	0.0088381	*MFSD6L*
17:40933276-40948304	4	3	0.0089785	*WNK4*
1:46016829-46034879	3	1	0.0094446	*AKR1A1*
3:38307398-38318485	2	1	0.0094456	*SLC22A13*
PTV+only				
3:54952509-54952627	2	0	0.00064301	*LRTM1*
19:15233517-15235879	2	1	0.0016954	*ILVBL*
17:8701157-8701167	2	1	0.0088381	*MFSD6L*
3:38307398-38318485	2	1	0.0094456	*SLC22A13*
2:43458439-43804337	3	2	0.010444	*THADA*
16:334920-336888	5	1	0.010482	*PDIA2*
17:5486023-5487821	2	1	0.01087	*NLRP1*
22:41257273-41257834	3	2	0.01437	*DNAJB7*
22:19189003-19220052	2	1	0.017846	*CLTCL1*
5:111500816-111519735	2	1	0.018258	*EPB41L4A*

N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants

Supplemental Table 17: Top 10 associations to WES 'Late DKD' using SKAT with 4 masks

Position	n.pass.v	n.sing.v	P-value	Gene
PTV+missense				
13:53035097-53049198	8	4	0.00041305	*CKAP2*
3:54952509-54959089	5	2	0.00060623	*LRTM1*
10:45798933-45803264	5	4	0.00072656	*OR13A1*
7:18066456-18067243	5	3	0.00091793	*PRPS1L1*
1:151139478-151140817	6	3	0.0011152	*SCNM1*
5:37815803-37816112	5	3	0.0013631	*GDNF*
8:70585265-70744856	14	6	0.0018813	*SLCO5A1*
14:75321989-75330435	10	4	0.0022685	*PROX2*
7:1855776-2269648	13	9	0.0026609	*MAD1L1*
18:42260994-42643270	16	12	0.0028434	*SETBP1*
PTV+broad				
13:53035097-53049198	7	4	0.00056746	*CKAP2*
3:54952509-54952627	2	0	0.00059024	*LRTM1*
10:45799065-45799733	2	1	0.00072803	*OR13A1*
7:18066456-18067059	4	3	0.0010284	*PRPS1L1*
5:37815803-37816112	3	1	0.0013592	*GDNF*
18:42281357-42618578	13	10	0.0023793	*SETBP1*
7:1937887-2269648	11	8	0.0024099	*MAD1L1*
6:45882076-45922972	7	2	0.0029219	*CLIC5*
1:186862169-186946869	3	2	0.0030571	*PLA2G4A*
3:150377770-150421666	10	6	0.0031755	*FAM194A*
PTV+strict				
3:150384657-150421396	4	2	0.00057312	*FAM194A*
3:54952509-54952627	2	0	0.00059024	*LRTM1*
6:45909349-45916999	2	0	0.0025361	*CLIC5*
1:46016829-46034879	3	1	0.0062285	*AKR1A1*
9:75774283-75777764	2	1	0.0062769	*ANXA1*
17:40933276-40948304	4	3	0.0069954	*WNK4*
17:34861135-34881073	3	2	0.0076076	*MYO19*
3:121491422-121544920	5	3	0.0081831	*IQCB1*
3:39228815-39229781	3	2	0.0098747	*XIRP1*
19:15233517-15235879	4	1	0.010502	*ILVBL*
PTV+only				
3:54952509-54952627	2	0	0.00059024	*LRTM1*
19:15233517-15235879	2	1	0.0024413	*ILVBL*
16:334920-336888	5	1	0.0067681	*PDIA2*
3:38307398-38318485	2	1	0.013673	*SLC22A13*
17:8701157-8701167	2	1	0.015528	*MFSD6L*
17:5486023-5487821	2	1	0.018495	*NLRP1*
17:72363857-72366663	2	1	0.021549	*GPR142*
14:24566139-24569423	5	4	0.024283	*PCK2*
22:19189003-19220052	2	1	0.024653	*CLTCL1*
3:149238595-149245675	1	0	0.024785	*WWTR1*

N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants

Supplemental table 18: Top 10 associations to WES 'ESRD vs. no DKD' with VT and 4 masks

Position	n.pass.v	P-value	Gene
PTV+missense			
12:518580-550003	7	2.1e-05	*CCDC77*
16:28877711-28884952	7	3.1e-05	*SH2B1*
12:102108407-102120196	4	8.6e-05	*CHPT1*
14:23846482-23848306	3	0.00012	*CMTM5*
11:5775980-5776749	5	0.00019	*OR52N4*
12:100685365-100732822	8	0.00032	*SCYL2*
15:44065537-44068996	7	0.00035	*ELL3*
9:130494915-130496639	6	0.00037	*TOR2A*
20:61907925-61919795	12	0.00053	*ARFGAP1*
1:156182876-156209351	6	0.0006	*PMF1*
PTV+broad			
12:102113935-102120196	3	3.4e-05	*CHPT1*
6:31525437-31526261	3	0.000124	*NFKBIL1*
14:23846482-23848306	3	0.00015	*CMTM5*
13:28794420-28866586	6	0.00018	*PAN3*
16:28877939-28884858	5	0.00029	*SH2B1*
6:160543080-160577058	9	0.00054	*SLC22A1*
1:229730547-229738417	4	0.00073	*TAF5L*
1:228612639-228612822	3	0.00077	*HIST3H3*
14:52472205-52534758	18	0.0008	*NID2*
11:5775984-5776749	4	0.00104	*OR52N4*
PTV+strict			
8:22884744-22885843	2	0.00019	*TNFRSF10B*
17:77100210-77102746	2	0.0006	*HRNBP3*
8:133083602-133090167	2	0.00083	*HHLA1*
6:136560616-136560647	2	0.00114	*FAM54A*
4:38798235-38800282	5	0.0012	*TLR1*
19:8138170-8203184	3	0.0016	*FBN3*
17:72954475-72960618	2	0.0017	*C17orf28*
18:21752415-21957382	3	0.0018	*OSBPL1A*
6:34003851-34100981	4	0.0018	*GRM4*
8:38834236-38845519	3	0.0025	*HTRA4*
PTV-only			
8:22884744-22885843	2	0.00017	*TNFRSF10B*
8:133083602-133090167	2	0.00072	*HHLA1*
19:8138170-8203184	3	0.0012	*FBN3*
3:4355014-4355131	2	0.0025	*SETMAR*
11:121008192-121058691	3	0.0035	*TECTA*
4:47538723-47574170	2	0.0035	*ATP10D*
10:75184515-75187483	2	0.0041	*ZMYND17*
3:9960192-9974543	3	0.0049	*IL17RC*
2:169727989-169728004	2	0.0056	*SPC25*
22:42473722-42473986	3	0.0061	*FAM109B*

N.pass.v = number of variants passing the mask definitions

Supplemental Table 19: Top 10 associations to WES 'ESRD vs. no DKD' with SKAT-O with 4 masks

Position	n.pass.v	n.sing.v	P-value	Gene
PTV+missense				
11:5775980-5776749	4	3	2.8913e-05	*OR52N4*
12:102108407-102120196	3	1	4.3482e-05	*CHPT1*
14:23846482-23848306	2	2	8.5563e-05	*CMTM5*
12:100685365-100732822	6	2	8.6197e-05	*SCYL2*
12:518580-550003	7	4	9.0216e-05	*CCDC77*
2:43458176-43819161	21	12	0.00015065	*THADA*
11:62575105-62598496	5	3	0.00016229	*STX5*
15:44065537-44068996	3	2	0.00016763	*ELL3*
20:61907925-61919795	9	4	0.00027894	*ARFGAP1*
13:28794420-28866586	7	5	0.00030024	*PAN3*
PTV+broad				
12:102113935-102120196	2	0	1.8982e-05	*CHPT1*
13:28794420-28866586	5	3	2.0813e-05	*PAN3*
6:31525437-31526261	2	2	8.4194e-05	*NFKBIL1*
14:23846482-23848306	2	2	8.5563e-05	*CMTM5*
11:5775984-5776749	3	2	0.00017668	*OR52N4*
11:62592777-62598496	3	1	0.00021827	*STX5*
20:44047493-44054249	8	7	0.0002694	*PIGT*
5:39376125-39394413	3	1	0.00029884	*DAB2*
17:7094043-7107367	5	4	0.00049654	*DLG4*
19:49407625-49424482	8	6	0.00054261	*NUCB1*
PTV+strict				
8:22884744-22885843	2	2	9.8064e-05	*TNFRSF10B*
4:38798235-38800282	4	3	0.00046089	*TLR1*
17:77100210-77102746	1	0	0.00062522	*HRNBP3*
19:10738409-10748401	3	2	0.0010388	*SLC44A2*
16:61687916-61689548	1	0	0.0012592	*CDH8*
4:186111299-186111306	2	1	0.0013119	*KIAA1430*
8:133083602-133090167	2	2	0.0013399	*HHLA1*
8:38834236-38845519	2	1	0.0013474	*HTRA4*
16:89985750-89986215	2	1	0.0014125	*MC1R*
17:41004777-41006634	2	1	0.0014339	*AOC3*
PTV+only				
8:22884744-22885843	2	2	9.8064e-05	*TNFRSF10B*
8:133083602-133090167	2	2	0.0013399	*HHLA1*
16:89985750-89986215	2	1	0.0014125	*MC1R*
11:67786064-67789293	2	0	0.0020716	*ALDH3B1*
3:4355014-4355131	2	2	0.0020738	*SETMAR*
19:8138170-8203184	1	1	0.0028026	*FBN3*
4:47538723-47574170	1	1	0.0032767	*ATP10D*
22:41257273-41257834	3	2	0.0033414	*DNAJB7*
11:121008192-121058691	2	2	0.0033577	*TECTA*
1:151493123-151508777	1	1	0.0037668	*CGN*

N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants

Supplemental Table 20: Top 10 associations to WES 'ESRD vs. no DKD' with SKAT with 4 masks

Position	n.pass.v	n.sing.v	P-value	Gene
PTV+missense				
2:43458176-43819161	21	12	8.3459e-05	*THADA*
5:39376125-39394413	8	2	0.00018914	*DAB2*
17:34071959-34079805	9	5	0.00020671	*GAS2L2*
12:102108407-102120196	3	1	0.00021871	*CHPT1*
14:23846482-23848306	2	2	0.00026538	*CMTM5*
11:62575105-62598496	5	3	0.00038847	*STX5*
12:57345928-57351029	3	2	0.00055704	*RDH16*
5:63986481-64013795	5	3	0.00066429	*FAM159B*
5:157053392-157078632	7	5	0.00088391	*SOX30*
4:186111299-186112220	4	3	0.0010538	*KIAA1430*
PTV+broad				
12:102113935-102120196	2	0	0.00021073	*CHPT1*
5:39376125-39394413	3	1	0.00022996	*DAB2*
6:31525437-31526261	2	2	0.00025304	*NFKBIL1*
14:23846482-23848306	2	2	0.00026538	*CMTM5*
11:62592777-62598496	3	1	0.00049172	*STX5*
5:63986481-63991426	4	2	0.00061686	*FAM159B*
17:7094043-7107367	5	4	0.00086232	*DLG4*
5:157053392-157078632	7	5	0.00088391	*SOX30*
17:77100210-77111580	2	1	0.0010418	*HRNBP3*
22:21235389-21242054	1	0	0.0010726	*SNAP29*
PTV+strict				
8:22884744-22885843	2	2	0.0002888	*TNFRSF10B*
17:77100210-77102746	1	0	0.00062522	*HRNBP3*
19:10738409-10748401	3	2	0.00089608	*SLC44A2*
16:89985750-89986215	2	1	0.001117	*MC1R*
17:41004777-41006634	2	1	0.0011256	*AOC3*
4:186111299-186111306	2	1	0.0012193	*KIAA1430*
11:67786064-67789293	2	0	0.001238	*ALDH3B1*
16:61687916-61689548	1	0	0.0012592	*CDH8*
1:104116940-104117921	2	0	0.0022375	*AMY2B*
19:8138170-8203184	1	1	0.0028026	*FBN3*
PTV+only				
8:22884744-22885843	2	2	0.0002888	*TNFRSF10B*
16:89985750-89986215	2	1	0.001117	*MC1R*
11:67786064-67789293	2	0	0.001238	*ALDH3B1*
19:8138170-8203184	1	1	0.0028026	*FBN3*
4:47538723-47574170	1	1	0.0032767	*ATP10D*
12:55863064-55863661	3	1	0.0034269	*OR6C70*
1:151493123-151508777	1	1	0.0037668	*CGN*
2:169727989-169728004	1	1	0.0037668	*SPC25*
13:40235019-40261900	1	1	0.0042598	*COG6*
16:10837724-10846536	1	1	0.0042598	*NUBP1*

N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants

Supplemental Table 21: Gene-sets which showed enrichment in WES association data on the 'Late DKD' phenotype, with permutation (N=100) results

				Real data				Random data (# of times a better finding is observed in the random data)/100				
Gene set	**Genes**	**SNPs**	**SKATO mask**	***NES***	***Pval*****	***FDR***	***FWER***	***NES***	***Pval***	***FDR***	***FWER***	***NES & FDR***
FUNC_meta_T1D-ESRDvsNonESRD_emmax_FD-SDR-ED1	16	120	Ptv.miss.0.01	2.12	0.0022	0.0396	0.044	0.04	0.1	0.08	0.09	0.03
TOP_meta_T1D-macro-ESRD_emmax_FD-SDR-Cam-ED1	43	147	Ptv.strict.broad.0.01	2.3	0.000*	0.012	0.013	0	0	0.02	0.02	0

Non-significant, tested gene sets

Gene set	Genes
Orpha.kidney	466
GWAS.kidney	65
GO.BP.kidney	357
MGI.kidney	836
expression.kidney	1597
LitMS.kidney	1349
overexpressed.in.isolated.mouse.podocytes	756
mouse.K.O.has.abnormal.podocyte	39
causes.rare.human.glomerular.disease	45
TOP_meta_T1D-CKD_emmax_FD-SDR-ED1	67
TOP_meta_T1D-CKDDN_emmax_FD-SDR-ED1	69
TOP_meta_T1D-ESRD_emmax_FD-SDR-ED1	243
TOP_meta_T1D-ESRDvsNonESRD_emmax_FD-SDR-ED1	56
TOP_meta_T1D-micro_emmax_FD-SDR-Cam-ED1	22
TOP_Meta_T1D-T2D_CKDDN_min_emmax_131202	93
TOP_Meta_T1D-T2D_ESRDvsALL_min_emmax	289
TOP_Meta_T1D-T2D_ESRDvsCONTROL_min_emmax_131101	449
TOP_Meta_T1D-T2D_MACROESRD_min_emmax_131101	181
TOP_Meta_T1D-T2D_MICRO_min_emmax_131101	35
TOP_Meta_T2D_CKD_min_emmax_131202	4
TOP_Meta_T2D_DN_min_emmax_131101	6

TOP_Meta_T2D_eGFR_min_emmax_131128	26
TOP_Meta_T2D_ESRDvsALL_min_emmax_131128	186
FUNC_meta_T1D-CKD_emmax_FD-SDR-ED1	13
FUNC_meta_T1D-CKDDN_emmax_FD-SDR-ED1	6
FUNC_meta_T1D-DN_emmax_FD-SDR-Cam-ED1	1
FUNC_meta_T1D-ESRD_emmax_FD-SDR-ED1	30
FUNC_meta_T1D-macro-ESRD_emmax_FD-SDR-Cam-ED1	4
FUNC_Meta_T1D-T2D_CKD_min_emmax_131202	3
FUNC_Meta_T1D-T2D_CKDDN_min_emmax_131202	12
FUNC_Meta_T1D-T2D_MACROESRD_min_emmax_131101	23
FUNC_Meta_T2D_eGFR_min_emmax_131128	14
FUNC_Meta_T2D_MACROESRD_min_emmax_131101	6
FUNC_Meta_T2D_MICRO_min_emmax_131101	2
Podo_Axonal Guidance Signaling	159
Podo_Signaling by Rho Family GTPases	97
Podo_Epithelial Adherens Junction Signaling	66
Podo_ILK Signaling	79
Podo_RhoA Signaling	57
Podo_Integrin Signaling	79
Podo_Germ Cell-Sertoli Cell Junction Signaling	65

*NES= Normalised Enrichment Score

**In the GSEA report, a p value of zero (0.0) indicates an actual p value of less than 1/number-of-permutations. For example, if the analysis performed 100 permutations, a reported p value of 0.0 indicates an actual p value of less than 0.001. For a more accurate p-value, increase the number of permutations performed by the analysis.

Supplemental Table 22: ABACUS association analysis results for the top SNPs from the GWAS discovery

Pheno	Cohort	SNP	CHR	P value	Gene
CKD	FINNDIANE	rs1622208	1	4.80E-06	*MAST2*
CKD	FINNDIANE	rs6682683	1	4.51E-06	*MAST2*
ESRD vs. NO DKD	FINNDIANE	rs17024167	1	7.97E-07	*PHGDH*
CKD	EURODIAB	rs13384229	2	3.16E-06	*ALS2*
CKD+ DKD	EURODIAB	rs11898503	2	4.31E-06	*KLHL29*
DKD & Late DKD	EURODIAB	rs906651	2	4.51E-06	*LRP1B*
CKD+DKD	FINNDIANE	rs7577925	2	7.97E-07	*NCKAP5*
Late DKD	FINNDIANE	rs3773786	3	3.77E-07	*IQCJ-SCHIP1*
Late DKD & CKD+DKD	FINNDIANE	rs6785153	3	3.77E-07	*IQCJ-SCHIP1*
Combined DKD	FINNDIANE	rs1061860	3	7.97E-07	*MB21D2*
Combined DKD	FINNDIANE	rs2986	3	7.97E-07	*MB21D2*
Late DKD	FINNDIANE	rs1434546	4	4.03E-06	*BMPR1B*
Late DKD	FINNDIANE	rs1545326	4	4.27E-06	*BMPR1B*
Late DKD	FINNDIANE	rs17022885	4	4.31E-06	*BMPR1B*
CKD	FINNDIANE	rs4352548	4	6.35E-07	*BTC*
CKD	FINNDIANE	rs3796588	4	6.34E-07	*GUCY1A3*
Late DKD	FINNDIANE	rs10037055	5	1.73E-06	*NSD1*
Late DKD	FINNDIANE	rs2244012	5	4.00E-06	*RAD50*
Early DKD	SDR	rs1970549	6	4.77E-06	*KCNQ5*
Early DKD	EURODIAB	rs1019046	7	1.64E-06	*GLI3*
CKD	SDR	rs7778308	7	3.65E-06	*GRM8*
ESRD vs. NO DKD	FINNDIANE	rs6983307	8	1.09E-06	*ST18*
Late DKD & CKD+DKD & ESRD vs. NO DKD	FINNDIANE	rs10121901	9	1.89E-06	*ABCA1*
Late DKD & CKD+DKD & ESRD vs. NO DKD	FINNDIANE	rs2066720	9	1.96E-06	*ABCA1*
CKD	FINNDIANE	rs2855171	9	4.37E-06	*ABL1*
Late DKD	SDR	rs10794197	10	4.66E-06	*CTBP2*
Early DKD	NFS-ORPS	rs2236418	10	1.73E-06	*GAD2*
Early DKD	NFS-ORPS	rs10508715	10	1.73E-06	*MYO3A*
Early DKD	NFS-ORPS	rs994502	10	1.73E-06	*MYO3A*
CKD	FINNDIANE	rs1784175	11	4.39E-06	*OPCML*
Late DKD & Combined DKD	FINNDIANE	rs3059	11	1.73E-06	*POLR2L*

Pheno	Cohort	SNP	CHR	P value	Gene
Late DKD	FINNDIANE	rs3741935	12	1.80E-06	*PRMT8*
Combined DKD	EURODIAB	rs9540711	13	4.03E-06	*PCDH9*
Late DKD	FINNDIANE	rs2278709	15	2.15E-06	*ARNT2*
Early DKD	SDR	rs678892	15	3.53E-06	*PIGB*
Late DKD	FINNDIANE	rs173839	16	3.65E-06	*CDH13*
ESRD vs. NO DKD	EURODIAB	rs4782574	16	2.89E-06	*OSGIN1*
Late DKD	FINNDIANE	rs8075035	17	2.15E-06	*AIPL1*
CKD+DKD	SDR	rs1972933	17	1.28E-06	*MAP2K6*
Early DKD	NFS-ORPS	rs7234763	18	7.18E-07	*PTPRM*
Late DKD	FINNDIANE	rs2544795	19	3.20E-06	*SULT2B1*
Late DKD	FINNDIANE	rs2665579	19	2.74E-06	*SULT2B1*
ESRD vs. NO DKD	EURODIAB	rs17420378	20	6.34E-07	*STK4*
ESRD vs. NO DKD	EURODIAB	rs6073622	20	6.34E-07	*STK4*
ESRD vs. NO DKD	EURODIAB	rs7266289	20	6.34E-07	*STK4*
ESRD vs. NO DKD	EURODIAB	rs7271519	20	6.34E-07	*STK4*

Supplemental Table 23: ABACUS association analysis results for the top SNPs from the WES discovery

Pheno	Cohort	SNP	CHR	P value	Gene
ESRD vs. no DKD	FINNDIANE	rs2297955_G_A	1	1.66E-06	*ACTN2*
ESRD vs. no DKD	FINNDIANE	rs41293273_C_T	1	1.14E-07	*NSUN4*
ESRD vs. no DKD	FINNDIANE	rs41293275_T_A	1	3.41E-07	*NSUN4*
Late DKD	STENO	rs2289239_A_G	2	4.09E-06	*POLR1A*
Late DKD	SDR	rs6775309_T_C	3	2.15E-06	*GPD1L*
Late DKD	SDR	rs6788436_C_T	3	2.15E-06	*GPD1L*
Late DKD	SDR	rs6799559_G_A	3	2.15E-06	*GPD1L*
Late DKD	SDR	rs6799728_T_A	3	2.15E-06	*GPD1L*
Late DKD	SDR	rs2813_C_T	3	3.08E-06	*GPD1L*
ESRD vs. no DKD	STENO	rs55642964_C_T	4	1.82E-06	*SH3TC1*
ESRD vs. no DKD	STENO	rs2136662_G_T	16	9.10E-07	*OSGIN1*
ESRD vs. no DKD	STENO	rs3087852_A_G	17	8.89E-07	*PSMD3*
ESRD vs. no DKD	STENO	rs12102_A_G	18	2.05E-06	*SERPINB2*
ESRD vs. no DKD	STENO	rs3217292_G_GTGAGA	18	2.05E-06	*SERPINB2*
ESRD vs. no DKD	STENO	rs6093_T_C	18	2.05E-06	*SERPINB2*
ESRD vs. no DKD	STENO	rs6095_G_C	18	2.05E-06	*SERPINB2*
ESRD vs. no DKD	STENO	rs6098_G_A	18	2.05E-06	*SERPINB2*
ESRD vs. no DKD	STENO	var_chr18_61569819_T_TTTAAGTTTCTGGGGC	18	2.05E-06	*SERPINB2*
ESRD vs. no DKD	FINNDIANE	rs2295490_G_A	20	4.64E-06	*TRIB3*
Late DKD	FINNDIANE	rs2073278_A_G	22	2.65E-06	*SBF1*

Supplemental Table 24: DAVID functional clustering of the genes mapped by the SNPs selected by the ABACUS software on GWAS data

Key Terms	Genes	Score
macromolecular complex subunit organization, protein oligomerization	*AGTR1,APC,CCDC88C,COLEC12,GTF3C4,H3F3B,HELLS,KCNQ5,NCK2,NDUFS4 ,PFKP,PPARGC1A,PRKAA2,SYT1,TRIM27,YWHAB*	3.16
kidney & urogenital system development, positive regulation of developmental process	*AGTR1,APC,GLI3,GNAS,HELLS,IL7R,NTN1,ROBO1,SART1,SLIT2,TGFBR2*	2.76
adenyl nucleotide binding, ATP binding, Serine/threonine protein kinase	*ABL1,AOX1,CARM1,CDC7,CELF2,CHST11,CTBP2,GNAS,GTF3C4,HELLS,KARS, KIF13B,KRAS,MAP2K6,MGAT5,MYH6,MYH9,MYO3A,NDUFS4,NUAK2,OPA1, PAK7,PAPOLA,PDE10A,PFKP,PGM1,PIGB,PPARGC1A,PRKAA2,PRKAG2,PTPR M,PTPRN2,STK4,SULT2B1,TEC,TGFBR2,TRIM27,WEE1*	2.15
hemopoietic or lymphoid organ development, leukocyte/lymphocyte activation & differentiation	*APC,BLNK,BRCA2,CD40LG,HELLS,IL7R,KIF13B,MYH9,NCK2,TGFBR2,TLR1,TLR 3*	2.09
positive regulation of kinase activity, positive regulation of transferase activity	*ABL1,AGTR1,ALS2,APC,CASP9,CCDC88C,FSHR,GAP43,GNAS,KRAS,MAP2K6, NCK2,NDUFS4,PRKAG2,RPS3,TGFBR2,TLR3,YWHAB*	2.06
cellular response to stress, regulation of apoptosis	*ABL1,APC,BIRC5,BRCA2,CASP9,CD40LG,CHST11,FOXN3,GLI3,HELLS,KRAS,M AP2K6,NUAK2,PAK7,RPA3,RPS3,SART1,SCAP,STK4,TNFRSF8,YWHAB*	1.91
actin cytoskeleton organization	*ABL1,APC,ATG4A,BIRC5,BRCA2,CNTROB,DIAPH2,KRAS,LIMA1,MYH6,MYH9, MYO3A,NCK2,NUAK2*	1.77
lipid moiety-binding region:S-palmitoyl cysteine, lipoprotein, palmitate	*ABL1,AGTR1,GAD2,GAP43,GNAS,KRAS,LRP1B,RGS7,SYT1*	1.70
glycoprotein, glycosylation site:N-linked (GlcNAc...)	*ABL1,AGTR1,APBB1IP,APC,ARSF,BLNK,CACNA2D1,CBL,CD40LG,CHST11,COL EC12,CTBP2,FSHR,GABRA2,GAD2,GAP43,GNAS,GRB10,GRIK4,GRM8, HLA-E, IGSF21,IL7R,KAL1,KCNK2,KCNQ5,KRAS,LIMA1,LPHN3,LRMP, LRP1B,MGAT5,MYH6,MYH9,NTN1,PCDH9,PIGB,PPARGC1A,PRELP,PTPRM,P TPRN2,RGS7,ROBO1,RPS3,SCAP,SLC34A3,SLC8A1,SLIT2,STAB2,SYT1,TF,TGF BR2,TLR1,TLR3,TLR8,TNFRSF8,TRIM27*	1.62
inflammatory response, Toll-Interleukin receptor, positive regulation of cytokine biosynthetic process	*ALS2,AOX1,BLNK,CD40LG,COLEC12,FSHR,PRELP,SLIT2,STAB2,TF,TLR1,TLR3, TLR8,TNFRSF8*	1.60
leukocyte proliferation/activation, lymphocyte proliferation, mononuclear cell proliferation	*APC,BLNK,CD40LG,HELLS,IL7R,KIF13B,MYH9,NCK2*	1.54
SH2 domain	*ABL1,BLNK,CBL,GRB10,NCK2,TEC*	1.54
axon guidance, axonogenesis, cell morphogenesis involved in differentiation, cell motion	*ABL1,ALS2,APC,CBL,GAD2,GAP43,GLI3,GRIK4,IL7R,KAL1,KRAS,LIMA1,MYH6 ,MYH9,NCK2,NTN1,OPA1,PAK7,PPARGC1A,PTPRM,ROBO1,SLIT2,STK4*	1.52
regulation of myeloid leukocyte differentiation, regulation of osteoclast differentiation	*APC,GNAS,TLR3*	1.43
insulin signalling pathway, regulation of cellular ketone metabolic process,regulation of fatty acid metabolic	*AGTR1,CBL,KRAS,PPARGC1A,PRKAA2,PRKAG2,RAPGEF1,SCAP*	1.38

Key Terms	Genes	Score
process		
apoptosis	*BIRC5,CASP9,EGLN3,KRAS,NTN1,NUAK2,OPA1,RPS3,STK4,YWHAB*	1.37
positive regulation of cellular component organization	*APC,CBL,NCK2,NTN1,PPARGC1A,ROBO1,SLIT2*	1.35
actin-dependent ATPase activity, calmodulin-binding, microfilament motor activity, myosin	*GAP43,KIF13B,MYH6,MYH9,MYO3A,SLC8A1,SYT1*	1.32
angiogenesis, blood vessel endothelial cell migration	*MYH9,ROBO1,SLIT2,STAB2,TGFBR2*	1.32
protein kinase binding	*ALS2,APC,BIRC5,DIAPH2,KIF13B,PRKAG2,RPS3,SUPT5H,TGFBR2,YWHAB*	1.28
positive regulation of leukocyte/lymphocyte activation & differentiation	*IL7R,NCK2,SART1,TGFBR2,TLR3,TLR8*	1.25
low-density lipoprotein binding	*COLEC12,LRP1B,STAB2*	1.24
nuclear lumen, nucleoplasm	*ABL1,BIRC5,BRCA2,CDC7,CTBP2,GLI3,GRHL1,GTF3C4,MYH6,PAPOLA,PPARGC1A,PRKAA2,PRKAG2,PRPF8,RPA3,SUPT5H,TRIM27,WEE1,YWHAB*	1.23
cytokinesis, interphase, tubulin binding	*ABL1,APC,ATG4A,BIRC5,BRCA2,CDC7,CNTROB,DIAPH2,FOXN3,GFI1B,HELLS,MAP2K6,MYH9,SART1,SUPT5H,WEE1*	1.23
cell morphogenesis involved in differentiation, cell motion	*ALS2,APC,GAP43,KAL1,MYH9,NCK2,NTN1,PTPRM,ROBO1,SLIT2*	1.22
cell junction, presynaptic membrane, synaptic vesicle membrane	*ALS2,APBB1IP,APC,CTBP2,GABRA2,GAD2,GAP43,GRIK4,GRM8,KCNQ5,LIMA1,MYH6,MYH9,OPA1,PTPRM,ROBO1,SYT1*	1.21
embryonic development, striated muscle differentiation	*ALS2,BRCA2,GLI3,KRAS,MYH6,MYH9*	1.14
adherens junction, anchoring junction	*APBB1IP,APC,LIMA1,MYH6,MYH9,PTPRM*	1.14
chordate embryonic development	*ALS2,BRCA2,CHST11,GLI3,GNAS,MYH6,MYH9,TGFBR2*	1.10
hypertrophic cardiomyopathy (HCM)	*CACNA2D1,MYH6,PRKAA2,PRKAG2,SLC8A1*	0.97
regulation of lipid metabolic process	*AGTR1,PPARGC1A,PRKAA2,PRKAG2,SCAP*	0.88
Toll-Interleukin receptor, positive regulation of cytokine biosynthetic process	*TLR1,TLR3,TLR8,TNFRSF8*	0.87
domain:EGF-like	*LRP1B,SLIT2,STAB2*	0.86
fatty acid biosynthesis	*ELOVL5,PRKAA2,PRKAG2*	0.84
regulation of system process	*AGTR1,CELF2,GRM8,KRAS,MYH6,SLC8A1,TF*	0.82
negative regulation of cell proliferation	*APC,BRCA2,CTBP2,GLI3,NCK2,PTPRM,TGFBR2,TNFRSF8*	0.80
negative regulation of nucleobase, nucleoside, nucleotide, transcriptional repressor complex	*BRCA2,CTBP2,FOXN3,GFI1B,GLI3,GRM8,HELLS,RPS3,SCAP,SUPT5H,TRIM27,YWHAB*	0.72
metal-binding	*ABL1,ADH1A,AOX1,ARSF,BIRC5,CACNA2D1,CBL,CDC7,COLEC12,CYP4F2,EGLN3,GFI1B,GLI3,KARS,LIMA1,NUAK2,PDE10A,PFKP,PGM1,PRKAA2,STK4,SYT1,TAB3,TEC,TF,TGFBR2,TRIM27,WEE1*	0.70

Supplemental Table 25: DAVID functional clustering of the genes mapped by the SNPs selected by the ABACUS software on WES data

Key Terms	Genes	Score
protein dimerization activity, homodimerization activity	*ACTN2,AMBP,ATF6,AXIN1,BCAT1,CD4,DVL2,FAAH,GCC2,GPD1L,HEXB,IL12B,KYNU,MYO9B,NEUROD1,PCSK9,TAS1R3,TGFB2*	3.90
serpin, serine-type endopeptidase inhibitor activity	*AMBP,CASP3,SERPINA11,SERPINB10,SERPINB2,SERPINF1,TRIAP1,TRIB3*	2.46
lipoprotein, phospholipid metabolic process, phosphotransferase activity	*ACSL3,EPT1,FASN,GGT5,GPD1L,HEXB,LRP1,PCSK9,PIGN,PIGX,PLA2G4D,PRKAB2,SGMS2*	2.26
carboxylic acid, fatty acid metabolic process, pyridoxal phosphate	*ACSL3,ACSL5,BCAT1,EPT1,FAAH,FASN,GGT5,HEXB,KYNU,PIGN,PIGX,PRKAB2,SGMS2,SLC27A6*	2.25
fatty-acid ligase activity, fatty acid metabolic process, long-chain-fatty-acid-CoA ligase activity	*ACSL3,ACSL5,FAAH,FASN,GGT5,PCSK9,PRKAB2,SGMS2,SLC27A6*	1.84
nucleoside and nucleotide biosynthetic process	*AMPD1,ATIC,ATP5A1,BCAT1,KYNU,MYO9B,PPAT,TGFB2*	1.61
transmembrane region	*ABCA4,ABCB11,ACSL3,ACSL5,ALG5,ATF6,ATP5A1,CACNA1D,CD4,CDON,DGKG,EPT1,ERBB4,FAAH,GCC2,GDPD5,GGT5,GLIPR1,GNG4,HLA-DQB1,IL31RA,IMMT,ITPR3,KCNMB2,LRP1,PIGN,PIGX,PLA2G4D,PTGFR,PTPRD,RSAD2,SCN10A,SGMS2,SLC10A6,SLC17A4,SLC27A6,SSR1,ST3GAL1,STOML1,STX2,SYVN1,TAS1R3,TBXA2R,TRPC6*	1.45
glycoprotein, glycosylation site:N-linked (GlcNAc...)	*ABCA4,ABCB11,ALG5,AMBP,ATF6,CACNA1D,CD4,CDON,CGA,DNAH14,ELSPBP1,ERBB4,GDPD5,GGT5,GIP,GLIPR1,HEXB,HLA-DQB1,IL12B,IL31RA,KCNMB2,KLK8,LRP1,PCSK9,PIGN,PIGX,PTGFR,PTPRD,SCN10A,SERPINA11,SERPINB2,SERPINF1,SLC10A6,SLC17A4,SLIT3,SSR1,ST3GAL1,SYVN1,TAS1R3,TBXA2R,TGFB2,TPPP,TRPC6*	1.41
regulation of protein kinase activity	*AXIN1,CASP3,CD4,DGKG,IL31RA,KAT2B,KIF13B,LRP1,MAP2K1,MYO9B,PRKAB2,TGFB2,TRIB3*	1.39
endoplasmic reticulum	*ACSL3,ACSL5,ALG5,ATF6,ATP5A1,CD4,FAAH,IMMT,ITPR3,PCSK9,PIGN,PIGX,RSAD2,SGMS2,SSR1,ST3GAL1,SYVN1*	1.26
carboxylic acid catabolic process	*AMDHD1,BCAT1,FAAH,KYNU*	1.24
cell fraction, insoluble fraction, membrane fraction	*ABCA4,ABCB11,ACSL3,ACSL5,AMBP,CGA,GIP,HEXB,ITPR3,KYNU,LRP1,MAP2K1,MYO9B,PRKCQ,SLC17A4,SLIT3,STX2,TPPP*	1.21
cofactor metabolic process	*AMBP,GGT5,KYNU,NARFL,PPCDC*	1.15
regulation of leukocyte activation, regulation of T cell activation	*CASP3,CD4,IL12B,IL31RA,PRKCQ*	1.11
response to endogenous stimulus, response to hormone stimulus	*ATF6,CASP3,CD4,CGA,ERBB4,GNG4,KAT2B,KYNU,MAP2K1,NEUROD1,PCSK9,PRKCQ,TGFB2*	1.07
adipocytokine signalling pathway	*ACSL3,ACSL5,PRKAB2,PRKCQ*	1.07
regulation of cellular response to stress	*AMBP,AXIN1,KLK8,TGFB2*	1.00
neuron differentiation, positive regulation of cell	*CASP3,CDON,DGKG,ERBB4,KLK8,MAP2K1,NEUROD1,ONECUT2,PCSK9,PRKCQ*	0.99

Key Terms	Genes	Score
migration, positive regulation of cell motion	*,SALL1,SLIT3,TGFB2*	
regulation of protein kinase activity, regulation of transferase activity	*AXIN1,CASP3,CD4,DGKG,DVL2,LRP1,MAP2K1,TGFB2,TRIB3*	0.98
plasma membrane part	*ABCA4,ABCB11,ACTN2,AXIN1,CACNA1D,CD4,ERBB4,GNG4,HLA-DQB1,ITPR3,KCNMB2,LRP1,PCSK9,PLA2G4D,PRKCQ,PTGFR,PTPRD,RSAD2,SCN10A,SGMS2,SLC17A4,STX2,TBXA2R*	0.95
positive regulation of cytokine biosynthetic process, regulation of leukocyte activation, regulation of T cell activation	*ATF6,CASP3,CD4,IL12B,IL31RA,NEUROD1,NPAS2,NR5A2,ONECUT2,PRKCQ,TGFB2*	0.92
ion transport	*ATP5A1,CACNA1D,ITPR3,KCNMB2,SCN10A,SLC10A6,SLC17A4,TRPC6*	0.85
positive regulation of protein modification process	*AXIN1,CD4,IL31RA,PLK1,PSMD3*	0.85
protein kinase C, phorbol ester/diacylglycerol binding	*DGKG,MYO9B,PRKCQ*	0.83
ATP-binding	*ABCA4,ABCB11,ACSL3,ACSL5,ATP5A1,DGKG,DNAH14,ERBB4,KIF13B,MAP2K1,MYLK4,MYO9B,PLK1,PRKCQ*	0.81
calcium channel, Vascular smooth muscle contraction	*ATP5A1,CACNA1D,ITPR3,KCNMB2,MAP2K1,PRKCQ,SCN10A,SLC10A6,SLC17A4,TRPC6*	0.79
negative regulation of growth	*CGA,GNG4,OSGIN1,TGFB2*	0.77
duplication	*ACTN2,AMBP,CD4,DGKG,GIP,PRKCQ*	0.76
cell proliferation	*BCAT1,ERBB4,KLK8,LRP1,MAP2K1,PLK1,SERPINF1,TGFB2*	0.69
negative regulation of response to stimulus, zymogen	*AMBP,CASP3,GGT5,HEXB,KLK8,PCSK9,SERPINF1,TGFB2*	0.54
chemical homeostasis, homeostatic process	*CASP3,ERBB4,HEXB,IL31RA,ITPR3,KCNMB2,NARFL,NEUROD1,NR5A2,PCSK9,TRPC6*	0.52
positive regulation of macromolecule metabolic process	*ATF6,AXIN1,CD4,IL12B,IL31RA,MAP2K1,NEUROD1,NPAS2,NR5A2,ONECUT2,PCSK9,PLK1,PRKCQ,PSMD3,TGFB2*	0.52

Supplemental Table 26: Phenotype definitions. Table A: albuminuria- and eGFR based definitions. Table B: Case – control phenotypes.

Table A:

Class	Definitions
Normoalbuminuria	AER <20 µg/min OR AER <30 mg/24 h OR ACR <2.5 mg/mmol for men ACR <3.5 for women
Microalbuminuria	At least 2 out of 3 consecutive measurements with: AER ≥20 AND <100 µg/min OR AER ≥30 AND <150 mg/24 hr OR ACR ≥2.5 AND <12.5 for men ACR ≥3.5 AND <17.5 for women.
High microalbuminuria	At least one measurement with: AER ≥100 AND <200 µg/min OR AER ≥150 AND <300 mg/24 hr OR ACR ≥12.5 AND <25 for men ACR ≥17.5 AND <35 for women
Macroalbuminuria	At least one measurement* with: AER ≥200 µg/min OR AER ≥300 mg/24 h OR ACR ≥25 mg/mmol for men ACR ≥35 for women *Due to study designs, in some studies at least two out of three consecutive measurements with the given thresholds were required.
ESRD	eGFR ≤15 ml/min/1.73m^2 OR dialysis OR kidney transplantation.
eGFR	eGFR was estimated wither with the MDRD4 [7] or CKD-EPI formula[8], depending of the study. When IDMS-calibrated serum creatinine was used, the MDRD4 formula was multiplied by 175/186 [65].
CKD	eGFR < 60 ml/min/1.73m^2

Table B:

Phenotype name	Cases	Controls
DKD	microalbuminuria OR high microalbuminuria OR macroalbuminuria OR ESRD	normoalbuminuria AND diabetes duration >15 years
Early DKD	microalbuminuria OR high microalbuminuria	normoalbuminuria AND diabetes duration >15 years
Late DKD	macroalbuminuria OR ESRD	normoalbuminuria AND diabetes duration >15 years
ESRD vs. no DKD	ESRD	normoalbuminuria AND diabetes duration >15 years
ESRD vs. non-ESRD	ESRD	patients with no ESRD AND diabetes duration >15 years
CKD	CKD (eGFR<60 ml/min/1.73m^2)	eGFR≥60 ml/min/1.73m^2 AND diabetes duration >15 years
CKD+DKD	(eGFR < 45 ml/min OR ESRD/1.73m^2) AND (High micro OR Macro OR ESRD)	eGFR ≥ 60 ml/min/1.73m^2 AND normo-albuminuria AND diabetes duration >15 years

Supplemental Table 27: Membership of the GENIE Consortium

FinnDiane, Finland:	Niina Sandholm[1,2,3], Carol Forsblom[1,2], Valma Harjutsalo[1,2,4], Ville-Petteri Mäkinen[1,2, 4,6], Aila J Ahola[1,2], Emma Dahlström[1,2], Daniel Gordin[1,2], Outi Heikkilä[1,2], Kustaa Hietala[1,7], Janne Kytö[1,7], Markku Lehto[1,2], Raija Lithovius[1,2], Nicolae Mircea Panduru[1,8], Maija Parkkonen[1,2], Milla Rosengård-Bärlund[1,2], Markku Saraheimo[1,2], Jenny Söderlund[1,2], Aino Soro-Paavonen[1,2], Anna Syreeni[1,2], Lena M Thorn[1,2], Nina Tolonen[1,2], Johan Wadén[1,2], Per-Henrik Groop[1,2,9]
Belfast, UK:	Amy Jayne McKnight[10], Gareth J. McKay[10], Alexander P. Maxwell[10,11]
Boston, MA, USA:	Rany M. Salem[12,13,14], Tamara Isakova[15,16], Cameron Palmer[12,13], Candace Guiducci[12], Andrew Taylor[12,17], Daniel B. Mirel[12], Winfred W. Williams[14,17], Joel N. Hirschhorn[12,13,14], Jose C. Florez[12,14,17]
Dublin, Ireland:	Eoin P. Brennan[18,19], Denise M. Sadlier[18,19], Finian Martin[18,19], Catherine Godson[18,19]
Affiliations:	1. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland 2. Department of Medicine, Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland 3. Department of Biomedical Engineering and Computational Science, Aalto University, Espoo, Finland 4. Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland. 5. Department of Integrative Biology and Physiology, University of California Los Angeles, United States 6. South Australian Health and Medical Research Institute, Adelaide, Australia 7. Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland. 8. Chair of pathophysiology, 2nd clinical Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 9. Baker IDI Heart and Diabetes Institute, Melbourne, Australia. 10. Nephrology Research, Centre for Public Health, Queen's University of Belfast, Belfast, UK. 11. Regional Nephrology Unit, Level 11, Tower Block, Belfast City Hospital, Belfast, UK. 12. Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA. 13. Endocrine Research Unit, Department of Endocrinology, Children's Hospital, Boston, MA, USA. 14. Department of Medicine, Harvard Medical School, Boston, MA, USA. 15. Division of Nephrology and Hypertension, University of Miami, Miami, Florida, USA 16. Center for Translational Metabolism and Health - Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA 17. Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA. 18. Diabetes Research Centre, Conway Institute, School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland. 19. Mater Misericordiae Hospital, Dublin, Ireland.

Supplemental Table 28: List of the FinnDiane centers and participating physicians and nurses.

FinnDiane Study Centers	Physicians and nurses
Anjalankoski Health Center	S. Koivula, T. Uggeldahl
Central Finland Central Hospital, Jyväskylä	T. Forslund, A. Halonen, A. Koistinen, P. Koskiaho, M. Laukkanen, J. Saltevo, M. Tiihonen
Central Hospital of Åland Islands, Mariehamn	M. Forsen, H. Granlund, A-C. Jonsson, B. Nyroos
Central Hospital of Kanta-Häme, Hämeenlinna	P. Kinnunen, A. Orvola, T. Salonen, A. Vähänen
Central Hospital of Länsi-Pohja, Kemi	H. Laukkanen, P. Nyländen, A. Sademies
Central Ostrabothnian Hospital District, Kokkola	S. Anderson, B. Asplund, U. Byskata, M. Kuusela, P. Liedes, T. Virkkala
City of Espoo Health Centre:	
-Espoonlahti	A. Nikkola, E. Ritola
-Samaria	E. Oukko-Ruponen, T. Virtanen
-Tapiola	M. Niska, H. Saarinen
-Viherlaakso	A. Lyytinen
City of Helsinki Health Centre:	
-Puistola	H. Kari, T. Simonen
-Suutarila	A. Kaprio, J. Kärkkäinen, B. Rantaeskola
-Töölö	J. Haaga, P. Kääriäinen, A-L. Pietiläinen
City of Hyvinkää Health Centre	S. Klemetti, T. Nyandoto, E. Rontu, S. Satuli-Autere
City of Vantaa Health Centre:	
-Korso	R. Toivonen, H. Virtanen
-Länsimäki	R. Ahonen, M. Ivaska-Suomela, A. Jauhiainen
-Martinlaakso	M. Laine, T. Pellonpää, R. Puranen
-Myyrmäki	A. Airas, J. Laakso, K. Rautavaara
-Rekola	M. Erola, E. Jatkola
-Tikkurila	R. Lönnblad, A. Malm, J. Mäkelä, E. Rautamo
Heinola Health Centre	P. Hentunen, J. Lagerstam
Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland	M. Feodoroff, C. Forsblom, D. Gordin, PH Groop, V. Harjutsalo, S. Hägg-Holmberg, K. Hietala, M. Kallio, R. Lithovious, M. Parkkonen, M. Rahkonen, M. Rosengård-Bärlund, A.-R. Salonen, L. Salovaara, A. Sandelin, M. Saraheimo, T. Soppela, A. Soro-Paavonen, L. Thorn, N. Tolonen, J. Tuomikangas, J. Wadén,
Ophthalmology, University of Helsinki and Helsinki	P.Summanen

FinnDiane Study Centers	Physicians and nurses
University Hospital, Helsinki, Finland	
Herttoniemi Hospital, Helsinki	V. Sipilä
Hospital of Lounais-Häme, Forssa	T. Kalliomäki, J. Koskelainen, R. Nikkanen, N. Savolainen, H. Sulonen, E. Valtonen
Hyvinkää Hospital	A. Hämäläinen, L. Norvio
Iisalmi Hospital	E. Toivanen
Jokilaakso Hospital, Jämsä	A. Parta, I. Pirttiniemi
Jorvi Hospital, Helsinki University Central Hospital	S. Aranko, S. Ervasti, R. Kauppinen-Mäkelin, A. Kuusisto, T. Leppälä, K. Nikkilä, L. Pekkonen
Jyväskylä Health Centre, Kyllö	K. Nuorva, M. Tiihonen
Kainuu Central Hospital, Kajaani	S. Jokelainen, P. Kemppainen, A-M. Mankinen, M. Sankari
Kerava Health Centre	H. Stuckey, P. Suominen
Kirkkonummi Health Centre	A. Lappalainen, M. Liimatainen, J. Santaholma
Kivelä Hospital, Helsinki	A. Aimolahti, E. Huovinen
Koskela Hospital, Helsinki	V. Ilkka, M. Lehtimäki
Kotka Heath Centre	E. Pälikkö-Kontinen, A. Vanhanen
Kouvola Health Centre	E. Koskinen, T. Siitonen
Kuopio University Hospital	E. Huttunen, R. Ikäheimo, P. Karhapää, P. Kekäläinen, T. Lakka, M. Laakso, E. Lampainen, L. Moilanen, L. Niskanen, U. Tuovinen, I. Vauhkonen, E. Voutilainen
Kuusamo Health Centre	E. Isopoussu, T. Kääriäinen
Kuusankoski Hospital	E. Kilkki, I. Koskinen, L. Riihelä
Laakso Hospital, Helsinki	T. Meriläinen, P. Poukka, R. Savolainen, N. Uhlenius
Lahti City Hospital	A. Mäkelä, M. Tanner
Lapland Central Hospital, Rovaniemi	L. Hyvärinen, S. Severinkangas, T. Tulokas
Lappeenranta Health Centre	P. Linkola, I. Pulli
Lohja Hospital	T. Granlund, M. Saari, T. Salonen
Loimaa Health Centre	P. Eloranta, A. Mäkelä
Länsi-Uusimaa Hospital, Tammisaari	I-M. Jousmaa, J. Rinne
Malmi Hospital, Helsinki	H. Lanki, S. Moilanen, M. Tilly-Kiesi
Mikkeli Central Hospital	A. Gynther, R. Manninen, P. Nironen, M. Salminen, T. Vänttinen
Mänttä Regional Hospital	A-M. Hänninen, I. Pirttiniemi
North Karelian Hospital, Joensuu	U-M. Henttula, P. Kekäläinen, M. Pietarinen, A. Rissanen, M. Voutilainen

FinnDiane Study Centers	Physicians and nurses
Nurmijärvi Health Centre	A. Burgos, K. Urtamo
Oulankangas Hospital, Oulainen	E. Jokelainen, P-L. Jylkkä, E. Kaarlela, J. Vuolaspuro
Oulu Health Centre	L. Hiltunen, R. Häkkinen, S. Keinänen-Kiukaanniemi
Oulu University Hospital	R. Ikäheimo
Päijät-Häme Central Hospital	H. Haapamäki, A. Helanterä, S. Hämäläinen, V. Ilvesmäki, H. Miettinen
Palokka Health Centre	P. Sopanen, L. Welling
Pieksämäki Hospital	V. Javtsenko, M. Tamminen
Pietarsaari Hospital	M-L. Holmbäck, B. Isomaa, L. Sarelin
Pori City Hospital	P. Ahonen, P. Merensalo, K. Sävelä
Porvoo Hospital	M. Kallio, B. Rask, S. Rämö
Raahe Hospital	A. Holma, M. Honkala, A. Tuomivaara, R. Vainionpää
Rauma Hospital	K. Laine, K. Saarinen, T. Salminen
Riihimäki Hospital	P. Aalto, E. Immonen, L. Juurinen
Salo Hospital	A. Alanko, J. Lapinleimu, P. Rautio, M. Virtanen
Satakunta Central Hospital, Pori	M. Asola, M. Juhola, P. Kunelius, M-L. Lahdenmäki, P. Pääkkönen, M. Rautavirta
Savonlinna Central Hospital	E. Korpi-Hyövälti, T. Latvala, E. Leijala
South Karelia Central Hospital, Lappeenranta	T. Ensala, E. Hussi, R. Härkönen, U. Nyholm, J. Toivanen
Tampere Health Centre	P. Alarotu, L. Calonius, S. Gummerus, M. Helin, T. Kaitala, H. Kirkkopelto-Jokinen, E. Kujansuu, T. Niskanen, A. Vaden, T. Vatanen
Tampere University Hospital	I. Ala-Houhala, T. Kuningas, P. Lampinen, M. Määttä, H. Oksala, T. Oksanen, K. Salonen, H. Tauriainen, S. Tulokas
Tiirismaa Health Centre, Hollola	T. Kivelä, L, Petlin, L. Savolainen
Turku Health Centre	I. Hämäläinen, H. Virtamo, M. Vähätalo
Turku University Central Hospital	K. Breitholz, R. Eskola, K. Metsärinne, U. Pietilä, P. Saarinen, R. Tuominen, S. Äyräpää
Vaajakoski Health Centre	K. Mäkinen, P. Sopanen
Vaasa Central Hospital	S. Bergkulla, U. Hautamäki, V-A. Myllyniemi, I. Rusk
Valkeakoski Regional Hospital	T. Immonen, S. Ojanen, M. Rautiainen, E. Valtonen, H. Ylönen
Vammala Regional Hospital	I. Isomäki, R. Kroneld, M. Tapiolinna-Mäkelä

Supplemental Table 29: Membership of the SUMMIT Consortium

Partner	Name	Position
1	**Michael Mark**	**Coordinator, WP6 leader**
Boehringer-Ingelheim	Markus Albertini	Project manager
Ingelheim, Germany	Carine Boustany	Chronic Kidney Disease, Head of Lab
	Alexander Ehlgen	Transmed
	Martin Gerl	Biomarker & Bioanlysis, Groupleader
	Jochen Huber	In vivo Scientist CMDR, Head of Lab
	Corinna Schölch	Biomarker & Bioanlysis, Head of Lab
	Heike Zimdahl-Gelling	Pharmacogenomics, Head of Lab
2	**Leif Groop**	Prof. Endocrinology; Coordinator Managing entity IMI-JU; PI; **WP1 and WP6 leader**
Lund University	Elisabet Agardh	Prof. Ophthalmology
Clinical Research Centre	Emma Ahlqvist	Postdoc
Malmö, Sweden	Tord Ajanki	Communication strategist
	Nibal Al Maghrabi	Research nurse
	Peter Almgren	Biostatistician
	Jan Apelqvist	Diabetologist
	Eva Bengtsson	Assis. Prof. Cardiovascular research
	Lisa Berglund	Postdoc
	Harry Björckbacka	Assis. Prof. Cardiovascular research
	Ulrika Blom-Nilsson	LUDC administrator
	Mattias Borell	Website, server management
	Agneta Burström	Research nurse
	Corrado Cilio	Assoc. Prof. Cellular autoimmunity
	Magnus Cinthio	Assist. Prof. Electrical Measurements, Lund Technical University
	Karl Dreja	Nephrologist
	Pontus Dunér	Postdoc Exp. Cardiovasc. Research
	Daniel Engelbertsen	PhD student Exp. Cardiovasc. Research
	Joao Fadista	Postdoc
	Maria Gomez	Assoc. Prof. Cardiovascular disease, **WP4 co-leader**
	Isabel Goncalves	Assis. Prof. Cardiovascular research
	Bo Hedblad	Prof. Cardiovascular epidemiology
	Anna Hultgårdh	Prof. Vessel Wall Biology
	Martin E. Johansson	Pathologist
	Cecilia Kennbäck	Laboratory Engineer
	Jasmina Kravic	Database manager
	Claes Ladenvall	Genetic statistician
	Åke Lernmark	Prof. Type 1 diabetes and celiac disease
	Eero Lindholm	Physician, Researcher Diabetic Complications
	Charlotte Ling	Assist. Prof. Epigenetics
	Holger Luthman	Prof. Medical genetics

Partner	Name	Position
	Olle Melander	Assoc. Prof. Hypertension and cardiovascular disease
	Malin Neptin	Biomedical analyst
	Jan Nilsson	Prof. Experimental Cardiovascular research, **WP3 leader**
	Peter Nilsson	Prof. Internal medicine
	Tobias Nilsson	PhD student Electrical Measurements, Lund Technical University
	Gunilla Nordin Fredriksson	Prof. Cardiovascular research
	Marju Orho-Melander	Prof. Genetic epidemiology
	Emilia Ottoson-Laakso	PhD student
	Annie Persson	Research nurse
	Margaretha Persson	Laboratory Engineer
	Mats-Åke Persson	Database manager
	Jacqueline Postma	Project manager
	Elisabeth Pranter	Research nurse
	Sara Rattik	PhD student Exp. Cardiovasc. Research
	Gunnar Sterner	Chief physician Internal Medicine Research Unit
	Lilian Tindberg	Research nurse
	Maria Wigren	Postdoc Exp. Cardiovasc. Research
	Anna Zetterqvist	PhD student
	Mikael Åkerlund	Postdoc
	Gerd Östling	Laboratory Engineer
3	**Timo Kanninen**	Technical director; PI
Biocomputing Platforms	Anni Ahonen-Bishopp	Software development manager
(BC Platforms)	Anita Eliasson	Financial and administrative director
Espoo, Finland	Timo Herrala	System (server) specialist
	Päivi Tikka-Kleemola	Service manager
4	**Anders Hamsten**	Prof. Cardiovascular disease; Atherosclerosis Research Unit; PI
Karolinska Institute	Christer Betsholtz	Prof. Vascular biology
Stockholm, Sweden	Ami Björkholm	Administrator
	Ulf de Faire	Professor emeritus Cardiovascular epidemiology
	Fariba Foroogh	Research engineer
	Guillem Genové	Scientist
	Karl Gertow	Research Assist. Prof. Cardiovascular genetics
	Bruna Gigante	Assoc. Professor Cardiovascular epidemiology
	Bing He	Postdoc
	Karin Leander	Assoc. Professor Cardiovascular epidemiology
	Olga McLeod	Postdoc
	Maria Nastase-Mannila	Postdoc
	Jaako Patrakka	Postdoc

Partner	Name	Position
	Angela Silveira	Assoc. Prof. Cardiovascular genetics
	Rona Strawbridge	Postdoc
	Karl Tryggvason	Prof. Medical Chemistry
	Max Vikström	Statistician
	John Öhrvik	Professor
	Anne-May Österholm	Postdoc
5	**Barbara Thorand**	Nutritional scientist, epidemiologist
Helmholtz Centre	Christian Gieger	Statistician
Munich, Germany	Harald Grallert	Biologist
	Tonia Ludwig	Statistician
	Barbara Nitz	Scientist
	Andrea Schneider	Data manager
	Rui Wang-Sattler	Scientist
	Astrid Zierer	Statistician
6	**Giuseppe Remuzzi**	Institute director; PI
Mario Negri Institute for	Ariela Benigni	Head of department Molecular Medicine
Pharmacological Research	Roberta Donadelli	Scientist
	Maria Domenica Lesti	Researcher
Bergamo, Italy	Marina Noris	Head Laboratory Immunology and genetics of transplantation and rare diseases
	Norberto Perico	Senior scientist
	Annalisa Perna	Biostatistician
	Rossella Piras	Postdoc
	Piero Ruggenenti	Head of department Renal medicine, Assist. Prof. Nephrology and dialysis
	Erica Rurali	Postdoc
7	**David Dunger (att: Jane Horsford)**	Prof. Paediatrics; PI
University of Cambridge	Ludo Chassin	Senior Data Manager
UK	Neil Dalton, London	Clinical biochemistry
	John Deanfield, London	Paediatric cardiology
	Jane Horsford	PA to Prof. Dunger
	Clare Rice	Operations manager/financial contact
	James Rudd	Cardiovascular imaging
	Neil Walker	Head Data services
	Karen Whitehead	Technician
	Max Wong	Postdoc
8	**Helen Colhoun**	Prof. Public health and epidemiology; PI; Vice coordinator Managing entity; **WP2 leader**

Partner	Name	Position
	Fiona Adams	
University of Dundee	Tahira Akbar	PA to Helen Colhoun
Scotland	Jill Belch	Prof. Vasucular disease
	Harshal Deshmukh	PhD student
	Fiona Dove	
	Angela Ellingford	NHS Tayside Diabetic Retinopathy Screening Programme manager
	Bassam Farran	Statistician
	Mike Ferguson	Dean of research Biological chemistry and drug discovery
	Gary Henderson	
	Graeme Houston	Consultant radiologist/senior lecturer
	Faisel Khan	Reader, Vascular & Inflammatory Diseases Research Unit
	Graham Leese	Consultant diabetologist/reader
	Yiyuan Liu	PhD student
	Shona Livingstone	Senior statistician
	Helen Looker	Epidemiologist
	Margaret McCann	Project assistant
	Stuart McGurnaghan	Lead data programmer
	Andrew Morris	Prof. Diabetic medicine
	David Newton	
	Colin Palmer	Prof. Pharmacogenomics
	Ewan Pearson	Consultant diabetologist/senior lecturer
	Gillian Reekie	Research Nurse
	Natalie Smith	Research Nurse
9	**Angela Shore**	Prof. Cardiovascular Science, PI
Peninsula Medical School	Kuni Aizawa	Postdoc
Exeter, UK	Claire Ball	Research nurse
	Nick Bellenger	Cardiologist
	Francesco Casanova	Associate Research Fellow Vascular medicine
	Tim Frayling	Prof. Genetics
	Phil Gates	Senior lecturer Cardiovascular science
	Kim Gooding	Postdoc Vascular medicine
	Andrew Hatttersley	Prof. Molecular medicine
	Roland Ling	Consultant opthalmologist
	David Mawson	Research technician
	Robin Shandas	Prof. Bioengineering (Colorado)
	David Strain	Stroke physician, clinical lecturer
	Clare Thorn	Postdoc Vascular medicine
10	**Ulf Smith**	Prof. ; PI
University of	Ann Hammarstedt	Researcher Molecular and clinical medicine

Partner	Name	Position
Gothenburg		
Sweden	Hans Häring	Prof. University of Tübingen
	Oluf Pedersen	Prof. Steno Centre, Copenhagen
	Georgio Sesti	Prof. Universtiy of Catanzaro
11	**Per-Henrik Groop**	Prof. Diabetes genetics; PI
	Emma Fagerholm	PhD student, genetics
Folkhälsan	Carol Forsblom	Clinical coordinator
Helsinki, Finland	Valma Harjutsalo	
	Maikki Parkkonen	Laboratory manager
	Niina Sandholm	DSc(PhD); GWAS and bioinformatics
	Nina Tolonen	MD PhD
	Iiro Toppila	BSc, bioinformatician
	Erkka Valo	MSc, bioinformatician
12	**Veikko Salomaa**	Prof. Epidemiology; PI; **deputy leader WP2**
The National Institute for Health and Welfare	Aki Havulinna	DSc. (tech), statistician
Helsinki, Finland	Kati Kristiansson	Postdoc
	Pia Okamo	THL press officer
	Tomi Peltola	
	Markus Perola	Professor
	Arto Pietilä	Statistician
	Samuli Ripatti	Professor, Statistics
	Marketta Taimi	Research assistant
13	**Seppo Ylä-Herttuala**	Prof.; PI; **WP4 leader**
University of Eastern Finland	Mohan Babu	PhD student
Kuopio, Finland	Marike Dijkstra	PhD student
	Erika Gurzeler	PhD student
	Jenni Huusko	PhD student
	Ivana Kholová	Postdoc
	Markku Laakso	Prof.
	Mari Merentie	PhD student
	Marja Poikolainen	PA Prof Ylä-Herttuala
14	**Mark McCarthy**	Prof. Human type 2 diabetes; Oxford Centre for Diabetes, Endocrinology and Metabolism; Wellcome Trust Centre for Human Genetics; PI; **deputy leader WP1**
University of Oxford	Chris Groves	Technical staff
UK	Thorhildur Juliusdottir	PhD student
	Fredrik Karpe	PI OCDEM

Partner	Name	Position
	Vasiliki Lagou	Postdoc
	Andrew Morris	Wellcome Trust Senior Fellow; Bioinformatics and statistical genetics
	Will Rayner	Database manager
	Neil Robertson	Informatics
	Natalie van Zuydam	Postdoc
15	**Claudio Cobelli**	Prof. ; PI; **WP5 leader**
University of Padova	Barbara Di Camillo	Assist. Prof.
Italy	Francesca Finotello	PhD student
-	Francesco Sambo	Postdoctoral fellow
-	Gianna Toffolo	Prof.
-	Emanuele Trifoglio	PhD student
-	-	-
16	**Riccardo Bellazzi**	Prof. Bioengineering; PI; **deputy leader WP5**
	Nicola Barbarini	Postdoctoral fellow
University of Pavia	Mauro Bucalo	Software engineer
Italy	Christiana Larizza	Assist. Prof.
	Paolo Magni	Assoc. Prof.
	Alberto Malovini	Postdoctoral fellow
	Simone Marini	Postdoctoral fellow
	Francesca Mulas	Postdoctoral fellow
	Silvana Quaglini	Prof.
	Lucia Sacchi	Assist. Prof.
	Francesca Vitali	
17	**Ele Ferrannini**	Prof. Medicine; PI
	Beatrice Boldrini	Postdoctoral fellow
University of Pisa	Michaela Kozakova	Senior investigator Medical Pathophysiology
Italy	Andrea Mari	Senior researcher Biomedical engineering (ISIB-CNR, Padova)
	Carmela Morizzo	Biologist, Sonographer Cardiovascular ultrasound
	Lucrecia Mota	EGIR administrative office
	Andrea Natali	Assoc. Prof. Medicine
	Carlo Palombo	Assoc. Prof. Medicine; **deputy leader WP3**
	Elena Venturi	Researcher
	Mark Walker	Prof. Molecular diabetic medicine (Univ Newcastle-upon-Tyne)
18	**Carlo Patrono**	Prof.Pharmacology; PI
Catholic University of Rome	Francesca Pagliaccia	PhD student
Italy	Bianca Rocca	Assist. Prof. Pharmacology
19	**Pirjo Nuutila**	Prof. ; PI

Partner	Name	Position
University of Turku	Johanna Haukkala	PhD student
Finland	Juhani Knuuti	Prof. ; Director Turku PET Centre
	Anne Roivainen	Prof.
	Antti Saraste	Adj. Prof.
20	**Paul McKeague**	Prof. Genetic Epidemiology; PI
University of Edinburgh	Norma Brown	Research administrator, Public Health Services
Scotland	Marco Colombo	Bioinformaticist
21	**Birgit Steckel-Hamann**	Deputy coordinator; PI, Manager IMI, LRL
Eli Lilly	Krister Bokvist	Biostatistician
	Sudha Shankar	Diabetologist
	Melissa Thomas	Translational Science
22	**Li-ming Gan**	Prof.; Translational Science Director Cardiovascular Disease; PI, **WP3 leader**
AstraZeneca	Suvi Heinonen	PhD, Internal AZ postdoc, Bioscience
	Ann-Cathrine Jönsson-Rylander	PhD, Assoc. Prof., Team Leader Bioscience, **WP4 leader**
	Remi Momo	Postdoctoral fellow
	Volker Schnecke	Informatician Translational Science, **WP5 leader**
	Robert Unwin	Translational Science Director Diabetic Nephropathy
	Anna Walentinsson	Geneticist Translational Science
	Carl Whatling	Bioscientist
23	**Everson Nogoceke**	Pre-clinical and clinical aspects of metabolic and vascular disease; PI; **WP2 leader**
Roche	Gonzalo Durán Pacheco	Senior Research Statistician
	Ivan Formentini	Biomarker & Experimental Medicine Leader
	Thomas Schindler	Pre-clinical and clinical and clinical biomarkers
24	**Piero Tortoli**	Professor of Electronics
University of Florence	Luca Bassi	Postdoctoral fellow
	Enrico Boni	Postdoctoral fellow
	Alessandro Dallai	Postdoctoral fellow
	Francesco Guidi	Technician
	Matteo Lenge	PhD student
	Riccardo Matera	PhD student
	Alessandro Ramalli	PhD student
	Stefano Ricci	Assist. Prof.
	Jacopo Viti	PhD student
25	**Bernd Jablonka**	SAD internal IMI coordinator

Partner	Name	Position
Sanofi-aventis	Dan Crowther	Biomarker researcher
	Johan Gassenhuber	Biostatistician
	Sibylle Hess	Biomarker researcher
	Thomas Hübschle	Pharmacologist Diabetes
	Hans-Paul Juretschke	Imaging
	Hartmut Rütten	Head Translational Medicine
	Thorsten Sadowski	Pharmacologist Diabetes
	Paulus Wohlfart	Pharmacologist Diabetes
26	**Julia Brosnan**	Biochemist, (pre)clinical research CVD, Pfizer US; **WP2 leader**
Pfizer	Valerie Clerin	Cardio-renal biologist, WP2
	Eric Fauman	Computational biologist
	Craig Hyde	Statistician
	Anders Malarstig	Human genetics, Pfizer Europé; **WP1 leader**
	Nick Pullen	Renal Disease Research Director
	Mera Tilley	
	Theresa Tuthill	Imaging specialist
	Ciara Vangjeli	Cardiovascular genetic epidemiologist, Pfizer Europe
	Daniel Ziemek	Computational biologist

SUPPLEMENTAL FIGURES

Supplemental Figure 1: Schematic picture of the study plan. In the GWAS setting, the stage 1 included T1D patients from the FinnDiane, EURODIAB, SDR, and Cambridge studies. Stage 1 GWAS meta-analysis results were used for evaluation of the previously reported loci, analysis of genetic risk scores, LD score regression, and for the pathway analyses. Stage 2 included patients from the UK-ROI, GoKinD US, French-Danish effort, DCCT/EDIC, and Joslin studies. Stage 3 replication consisted of additional T1D FinnDiane patients not part of the FinnDiane GWAS. Whole exome sequencing (WES) included patients from the FinnDiane, SDR, and Steno studies. Finally, the bivariate association analyses were performed in all GWAS stage 1 studies and in WES studies.



Supplemental Figure 2: Manhattan and QQ-plots for the seven studied phenotype definitions. Manhattan and QQ-plots of the seven studied case-control phenotype definitions: A) Combined DKD (cases with micro- or macroalbuminuria or ESRD vs. controls with normal AER); B) Late DKD (cases with macroalbuminuria or ESRD vs. normal AER); C) ESRD vs. no DKD (cases with ESRD vs. controls with normal AER); D) ESRD vs. non-ESRD (cases with ESRD vs. everyone else); E) Early DKD (cases with microalbuminuria vs. controls with normal AER); F) CKD (cases with CKD (eGFR ≤ 60 ml/min) vs. controls without CKD (eGFR > 60 ml/min); G) CKD+DKD (cases with severe CKD (eGFR ≤ 45 ml/min) and microalbuminuria or worse vs. controls with normal AER and no CKD (eGFR > 60 ml/min).

A) Combined DKD



B) Late DKD



C) ESRD vs. no DKD





D) ESRD vs. non-ESRD





E) Early DKD





F) CKD





G) CKD + DKD





Supplemental Figure 3: LocusZoom and Forest plots of the top loci. A) rs72809865 for DKD. B) rs61277444 for ESRD versus normal AER. C) rs7562121 for ESRD versus non-ESRD. D) rs1989248 for CKD+DKD.



Supplemental Figure 4: P-value distribution of association at the previously reported loci for DKD or CKD in the general population.



Supplemental Figure 5: Association at previously reported loci plotted by the previously reported A) p-values and by B) Z-scores.



Supplemental Figure 6: Genome-wide comparison of the association results for the seven DKD traits, evaluated with LD score regression, shows high correlation between the DKD traits. Even though the overlapping samples between the DKD traits do not bias the estimates, the overlapping phenotype definitions may do so.



Supplemental Figure 7: KEGG pentose and glucoronate interconversions pathway with the red boxes indicating the genes flagged with MAGENTA enrichment analysis on the DKD phenotype. The Glucuronate sub-pathway (KEGG module M00014) is highlighted with pink background. P-value for enrichment of the glucoronate sub-pathway was tested *post hoc,* $p=1.9\times10^{-5}$, false discovery rate (FDR)$<1\times10^{-6}$. Figure modified from http://www.genome.jp/kegg/pathway/map/map00040.html



Supplemental Figure 8: WES QQ-plots of the p-value distribution of associations with 'Late DKD' and 'ESRD vs. no DKD' using the score test. A and B: DKD. C and D: ESRD. A and C: all SNPs. B and D: SNPs by MAF.



Supplemental Figure 9: WES QQ-plots for 'Late DKD' for different masks using SKAT-O.



Supplemental Figure 10: WES QQ-plots for 'ESRD vs. no DKD' for different masks using SKAT-O.



Supplemental Figure 11: Top 20 associations for 'Late DKD' for the three gene based tests; VT, SKAT-O and SKAT with the PTV+broad and PTV+missense masks.



Supplemental Figure 12: Top 20 associations for 'ESRD vs. no DKD' for the three gene based tests; VT, SKAT-O and SKAT with the PTV+broad and PTV+missense masks.



Supplemental Figure 13: Statistical power to detect association at the WES with exome-wide statistical significance (p<9×10-8) for 'Late DKD' setting (panels A and C) and for the 'ESRD vs. no DKD' comparison (panels B and D). The top panels show the statistical power for the effect allele frequency range from 0 to 1. The bottom panels show the statistical power for the effect allele frequency range from 0 to 10%.



REFERENCES

1. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, Waden J, Ronnback M, Rosengard-Barlund M, Bjorkesten CG, Taskinen MR, Groop PH, FinnDiane Study Group: Metabolic syndrome in type 1 diabetes: Association with diabetic nephropathy and glycemic control (the FinnDiane study). [Electronic version]. *Diabetes Care* 28: 2019-2024, 2005

2. Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T, McKay GJ, Williams WW, Sadlier DM, Makinen VP, Swan EJ, Palmer C, Boright AP, Ahlqvist E, Deshmukh HA, Keller BJ, Huang H, Ahola AJ, Fagerholm E, Gordin D, Harjutsalo V, He B, Heikkila O, Hietala K, Kyto J, Lahermo P, Lehto M, Lithovius R, Osterholm AM, Parkkonen M, Pitkaniemi J, Rosengard-Barlund M, Saraheimo M, Sarti C, Soderlund J, Soro-Paavonen A, Syreeni A, Thorn LM, Tikkanen H, Tolonen N, Tryggvason K, Tuomilehto J, Waden J, Gill GV, Prior S, Guiducci C, Mirel DB, Taylor A, Hosseini SM, DCCT/EDIC Research Group, Parving HH, Rossing P, Tarnow L, Ladenvall C, Alhenc-Gelas F, Lefebvre P, Rigalleau V, Roussel R, Tregouet DA, Maestroni A, Maestroni S, Falhammar H, Gu T, Mollsten A, Cimponeriu D, Ioana M, Mota M, Mota E, Serafinceanu C, Stavarachi M, Hanson RL, Nelson RG, Kretzler M, Colhoun HM, Panduru NM, Gu HF, Brismar K, Zerbini G, Hadjadj S, Marre M, Groop L, Lajer M, Bull SB, Waggott D, Paterson AD, Savage DA, Bain SC, Martin F, Hirschhorn JN, Godson C, Florez JC, Groop PH, Maxwell AP: New susceptibility loci associated with kidney disease in type 1 diabetes. [Electronic version]. *PLoS Genet* 8: e1002921, 2012

3. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH: Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold. [Electronic version]. *Kidney Int* 60: 219-227, 2001

4. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD: Classifying diabetes according to the new WHO clinical stages. [Electronic version]. *Eur J Epidemiol* 17: 983-989, 2001

5. Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J, Marcovecchio L, Neil A, Dalton RN, Dunger DB: Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: Prospective observational study. [Electronic version]. *BMJ* 336: 697-701, 2008

6. Marcovecchio ML, Dalton RN, Schwarze CP, Prevost AT, Neil HA, Acerini CL, Barrett T, Cooper JD, Edge J, Shield J, Widmer B, Todd JA, Dunger DB: Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. [Electronic version]. *Diabetologia* 52: 1173-1181, 2009

7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. modification of diet in renal disease study group. [Electronic version]. *Ann Intern Med* 130: 461-470, 1999

8. Levey AS, & Stevens LA: Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: More accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. [Electronic version]. *Am J Kidney Dis* 55: 622-627, 2010

9. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis corrects for stratification in genome-wide association studies. [Electronic version]. *Nat Genet* 38: 904-909, 2006

10. Howie BN, Donnelly P, Marchini J: A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. [Electronic version]. *PLoS Genet* 5: e1000529, 2009

11. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA: An integrated map of genetic variation from 1,092 human genomes. [Electronic version]. *Nature* 491: 56-65, 2012

12. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM: A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of drosophila melanogaster strain w1118; iso-2; iso-3. [Electronic version]. *Fly (Austin)* 6: 80-92, 2012

13. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F: Deriving the consequences of genomic variants with the ensembl API and SNP effect predictor. [Electronic version]. *Bioinformatics* 26: 2069-2070, 2010

14. Ruark E, Münz M, Renwick A, Clarke M, Ramsay E, Hanks S, Mahamdallie S, Elliott A, Seal S, Strydom A, Gerton L, Rahman N: The ICR1000 UK exome series: A resource of gene variation in an outbred population [version 1; referees: 2 approved]. *F1000Research* 42015

15. Lim ET, Wurtz P, Havulinna AS, Palta P, Tukiainen T, Rehnstrom K, Esko T, Magi R, Inouye M, Lappalainen T, Chan Y, Salem RM, Lek M, Flannick J, Sim X, Manning A, Ladenvall C, Bumpstead S, Hamalainen E, Aalto K, Maksimow M, Salmi M, Blankenberg S, Ardissino D, Shah S, Horne B, McPherson R, Hovingh GK, Reilly MP, Watkins H, Goel A, Farrall M, Girelli D, Reiner AP, Stitziel NO, Kathiresan S, Gabriel S, Barrett JC, Lehtimaki T, Laakso M, Groop L, Kaprio J, Perola M, McCarthy MI, Boehnke M, Altshuler DM, Lindgren CM, Hirschhorn JN, Metspalu A, Freimer NB, Zeller T, Jalkanen S, Koskinen S, Raitakari O, Durbin R, MacArthur DG, Salomaa V, Ripatti S, Daly MJ, Palotie A, Sequencing Initiative Suomi (SISu) Project: Distribution and medical impact of loss-of-function variants in the finnish founder population. [Electronic version]. *PLoS Genet* 10: e1004494, 2014

16. Yang J, Lee SH, Goddard ME, Visscher PM: GCTA: A tool for genome-wide complex trait analysis. [Electronic version]. *Am J Hum Genet* 88: 76-82, 2011

17. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. [Electronic version]. *Nature* 447: 661-678, 2007

18. Kang HM, Sul JH, Service SK, Zaitlen NA, Kong SY, Freimer NB, Sabatti C, Eskin E: Variance component model to account for sample structure in genome-wide association studies. [Electronic version]. *Nat Genet* 42: 348-354, 2010

19. Magi R, & Morris AP: GWAMA: Software for genome-wide association meta-analysis. [Electronic version]. *BMC Bioinformatics* 11: 288-2105-11-288, 2010

20. Willer CJ, Li Y, Abecasis GR: METAL: Fast and efficient meta-analysis of genomewide association scans. [Electronic version]. *Bioinformatics* 26: 2190-2191, 2010

21. Purcell S, Cherny SS, Sham PC: Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits. [Electronic version]. *Bioinformatics* 19: 149-150, 2003

22. Skol AD, Scott LJ, Abecasis GR, Boehnke M: Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. [Electronic version]. *Nat Genet* 38: 209-213, 2006

23. DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B: Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. [Electronic version]. *N Engl J Med* 365: 2366-2376, 2011

24. DCCT/EDIC research group: Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the diabetes control and complications trial and epidemiology of diabetes interventions and complications study. [Electronic version]. *Lancet Diabetes Endocrinol* 2: 793-800, 2014

25. Germain M, Pezzolesi MG, Sandholm N, McKnight AJ, Susztak K, Lajer M, Forsblom C, Marre M, Parving HH, Rossing P, Toppila I, Skupien J, Roussel R, Ko YA, Ledo N, Folkersen L, Civelek M, Maxwell AP, Tregouet DA, Groop PH, Tarnow L, Hadjadj S: SORBS1 gene, a new candidate for diabetic nephropathy: Results from a multi-stage genome-wide association study in patients with type 1 diabetes. [Electronic version]. *Diabetologia* 58: 543-548, 2015

26. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, Strawbridge RJ, Pers TH, Fischer K, Justice AE, Workalemahu T, Wu JM, Buchkovich ML, Heard-Costa NL, Roman TS, Drong AW, Song C, Gustafsson S, Day FR, Esko T, Fall T, Kutalik Z, Luan J, Randall JC, Scherag A, Vedantam S, Wood AR, Chen J, Fehrmann R, Karjalainen J, Kahali B, Liu CT, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bragg-Gresham JL, Buyske S, Demirkan A, Ehret GB, Feitosa MF, Goel A, Jackson AU, Johnson T, Kleber ME, Kristiansson K, Mangino M, Mateo Leach I, Medina-Gomez C, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Stancakova A, Ju Sung Y, Tanaka T, Teumer A, Van Vliet-Ostaptchouk JV, Yengo L, Zhang W, Albrecht E, Arnlov J, Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Bluher M, Bohringer S, Bonnet F, Bottcher Y, Bruinenberg M, Carba DB, Caspersen IH, Clarke R, Daw EW, Deelen J, Deelman E, Delgado G, Doney AS, Eklund N, Erdos MR, Estrada K, Eury E, Friedrich N, Garcia ME, Giedraitis V, Gigante B, Go AS, Golay A, Grallert H, Grammer TB, Grassler J, Grewal J, Groves CJ, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heikkila K, Herzig KH, Helmer Q, Hillege HL, Holmen O, Hunt SC, Isaacs A, Ittermann T, James AL, Johansson I, Juliusdottir T, Kalafati IP, Kinnunen L, Koenig W, Kooner IK, Kratzer W, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Lobbens S, Lorentzon M, Mach F, Magnusson PK, Mahajan A, McArdle WL, Menni C, Merger S, Mihailov E, Milani L, Mills R, Moayyeri A, Monda KL, Mooijaart SP, Muhleisen TW, Mulas A, Muller G, Muller-Nurasyid M, Nagaraja R, Nalls MA, Narisu N, Glorioso N, Nolte IM, Olden M, Rayner NW, Renstrom F, Ried JS, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Sennblad B, Seufferlein T, Sitlani CM, Vernon Smith A, Stirrups K, Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tayo BO, Thorand B, Thorleifsson G, Tomaschitz A, Troffa C, van Oort FV, Verweij N, Vonk JM, Waite LL, Wennauer R, Wilsgaard T, Wojczynski MK, Wong A, Zhang Q, Hua Zhao J, Brennan EP, Choi M, Eriksson P, Folkersen L, Franco-Cereceda A, Gharavi AG, Hedman AK, Hivert MF, Huang J, Kanoni S, Karpe F, Keildson S, Kiryluk K, Liang L, Lifton RP, Ma B, McKnight AJ, McPherson R, Metspalu A, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Olsson C, Perry JR, Reinmaa E, Salem RM, Sandholm N, Schadt EE, Scott RA, Stolk L, Vallejo EE, Westra HJ, Zondervan KT, ADIPOGen Consortium, CARDIOGRAMplusC4D Consortium, CKDGen Consortium, GEFOS Consortium, GENIE Consortium, GLGC, ICBP, International Endogene Consortium, LifeLines Cohort Study, MAGIC Investigators, MuTHER Consortium, PAGE Consortium, ReproGen Consortium, Amouyel P, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Brown MJ, Burnier M, Campbell H, Chakravarti A, Chines PS, Claudi-Boehm S, Collins FS, Crawford DC, Danesh J, de Faire U, de Geus EJ, Dorr M, Erbel R, Eriksson JG, Farrall M, Ferrannini E, Ferrieres J, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gieger C, Gudnason V, Haiman CA, Harris TB, Hattersley AT, Heliovaara M, Hicks AA, Hingorani AD, Hoffmann W, Hofman A, Homuth G, Humphries SE, Hypponen E, Illig T, Jarvelin MR, Johansen B, Jousilahti P, Jula AM, Kaprio J, Kee F, Keinanen-Kiukaanniemi SM, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuulasmaa K, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimaki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Musk AW, Mohlenkamp S, Morris AD, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Palmer LJ, Penninx BW, Peters A, Pramstaller PP, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Shuldiner AR, Staessen JA, Steinthorsdottir V, Stolk RP, Strauch K, Tonjes A, Tremblay A, Tremoli E, Vohl MC, Volker U, Vollenweider P, Wilson JF, Witteman JC, Adair LS, Bochud M, Boehm BO, Bornstein SR, Bouchard C, Cauchi S, Caulfield MJ, Chambers JC, Chasman DI, Cooper RS, Dedoussis G, Ferrucci L, Froguel P, Grabe HJ, Hamsten A, Hui J, Hveem K, Jockel KH, Kivimaki M, Kuh D, Laakso M, Liu Y, Marz W, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sinisalo J, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Veronesi G, Walker M, Wareham NJ,

Watkins H, Wichmann HE, Abecasis GR, Assimes TL, Berndt SI, Boehnke M, Borecki IB, Deloukas P, Franke L, Frayling TM, Groop LC, Hunter DJ, Kaplan RC, O'Connell JR, Qi L, Schlessinger D, Strachan DP, Stefansson K, van Duijn CM, Willer CJ, Visscher PM, Yang J, Hirschhorn JN, Zillikens MC, McCarthy MI, Speliotes EK, North KE, Fox CS, Barroso I, Franks PW, Ingelsson E, Heid IM, Loos RJ, Cupples LA, Morris AP, Lindgren CM, Mohlke KL: New genetic loci link adipose and insulin biology to body fat distribution. [Electronic version]. *Nature* 518: 187-196, 2015

27. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Magi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Hua Zhao J, Zhao W, Chen J, Fehrmann R, Hedman AK, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Mateo Leach I, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stancakova A, Strawbridge RJ, Ju Sung Y, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Arnlov J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Bluher M, Bohringer S, Bonnycastle LL, Bottcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Ida Chen YD, Clarke R, Daw EW, de Craen AJ, Delgado G, Dimitriou M, Doney AS, Eklund N, Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME, Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall AH, Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Grassler J, Gronberg H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, Hottenga JJ, James AL, Jeff JM, Johansson A, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W, Laitinen J, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Sin Lo K, Lobbens S, Lorbeer R, Lu Y, Mach F, Magnusson PK, Mahajan A, McArdle WL, McLachlan S, Menni C, Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken MA, Mulas A, Muller G, Muller-Nurasyid M, Musk AW, Nagaraja R, Nothen MM, Nolte IM, Pilz S, Rayner NW, Renstrom F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Scott WR, Seufferlein T, Shi J, Vernon Smith A, Smolonska J, Stanton AV, Steinthorsdottir V, Stirrups K, Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tan ST, Tayo BO, Thorand B, Thorleifsson G, Tyrer JP, Uh HW, Vandenput L, Verhulst FC, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Warren HR, Waterworth D, Weedon MN, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, LifeLines Cohort Study, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda A, Gadin JR, Gharavi AG, Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton RP, Ma B, McCarroll SA, McKnight AJ, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Okada Y, Perry JR, Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T, Van't Hooft FM, Vinkhuyzen AA, Westra HJ, Zheng W, Zondervan KT, ADIPOGen Consortium, AGEN-BMI Working Group, CARDIOGRAMplusC4D Consortium, CKDGen Consortium, GLGC, ICBP, MAGIC Investigators, MuTHER Consortium, MIGen Consortium, PAGE Consortium, ReproGen Consortium, GENIE Consortium, International Endogene Consortium, Heath AC, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Bovet P, Campbell H, Caulfield MJ, Cesana G, Chakravarti A, Chasman DI, Chines PS, Collins FS, Crawford DC, Cupples LA, Cusi D, Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB, Ferrannini E, Ferrieres J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman PV, Gieger C, Gottesman O, Gudnason V, Gyllensten U, Hall AS, Harris TB, Hattersley AT, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Homuth G, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Illig T, Jacobs KB, Jarvelin MR, Jockel KH, Johansen B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJ, Keinanen-Kiukaanniemi SM, Kiemeney LA, Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimaki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Madden PA, Pasterkamp G, Peden JF, Peters A, Postma DS, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Rioux JD, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz PE, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tonjes A, Tregouet DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC, Volker U, Waeber G, Willemsen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ,

Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hui J, Hunter DJ, Hveem K, Kaplan RC, Kivimaki M, Kuh D, Laakso M, Liu Y, Martin NG, Marz W, Melbye M, Metspalu A, Moebus S, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen P, Borecki IB, Deloukas P, Fox CS, Heid IM, O'Connell JR, Strachan DP, Stefansson K, van Duijn CM, Abecasis GR, Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso I, North KE, Ingelsson E, Hirschhorn JN, Loos RJ, Speliotes EK: Genetic studies of body mass index yield new insights for obesity biology. [Electronic version]. *Nature* 518: 197-206, 2015

28. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A, Styrkarsdottir U, Gretarsdottir S, Thorlacius S, Jonsdottir I, Jonsdottir T, Olafsdottir EJ, Olafsdottir GH, Jonsson T, Jonsson F, Borch-Johnsen K, Hansen T, Andersen G, Jorgensen T, Lauritzen T, Aben KK, Verbeek AL, Roeleveld N, Kampman E, Yanek LR, Becker LC, Tryggvadottir L, Rafnar T, Becker DM, Gulcher J, Kiemeney LA, Pedersen O, Kong A, Thorsteinsdottir U, Stefansson K: Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. [Electronic version]. *Nat Genet* 41: 18-24, 2009

29. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko Y, Heath S, Sober S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU, Peden JF, Tanaka T, Wild SH, Rudan I, Igl W, Milaneschi Y, Parker AN, Fava C, Chambers JC, Fox ER, Kumari M, Go MJ, van der Harst P, Kao WH, Sjogren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, Liu Y, Shi G, Kuusisto J, Tayo B, Seielstad M, Sim X, Nguyen KD, Lehtimaki T, Matullo G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper MN, Platou CG, Org E, Hardy R, Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T, Uiterwaal CS, Adeyemo A, Palmas W, Campbell H, Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND, CARDIoGRAM consortium, CKDGen Consortium, KidneyGen Consortium, EchoGen consortium, CHARGE-HF consortium, Aspelund T, Garcia M, Chang YP, O'Connell JR, Steinle NI, Grobbee DE, Arking DE, Kardia SL, Morrison AC, Hernandez D, Najjar S, McArdle WL, Hadley D, Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor DA, Beilby JP, Lawrence RW, Clarke R, Hopewell JC, Ongen H, Dreisbach AW, Li Y, Young JH, Bis JC, Kahonen M, Viikari J, Adair LS, Lee NR, Chen MH, Olden M, Pattaro C, Bolton JA, Kottgen A, Bergmann S, Mooser V, Chaturvedi N, Frayling TM, Islam M, Jafar TH, Erdmann J, Kulkarni SR, Bornstein SR, Grassler J, Groop L, Voight BF, Kettunen J, Howard P, Taylor A, Guarrera S, Ricceri F, Emilsson V, Plump A, Barroso I, Khaw KT, Weder AB, Hunt SC, Sun YV, Bergman RN, Collins FS, Bonnycastle LL, Scott LJ, Stringham HM, Peltonen L, Perola M, Vartiainen E, Brand SM, Staessen JA, Wang TJ, Burton PR, Soler Artigas M, Dong Y, Snieder H, Wang X, Zhu H, Lohman KK, Rudock ME, Heckbert SR, Smith NL, Wiggins KL, Doumatey A, Shriner D, Veldre G, Viigimaa M, Kinra S, Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A, Thelle DS, Corsi AM, Singleton A, Forrester T, Hilton G, McKenzie CA, Salako T, Iwai N, Kita Y, Ogihara T, Ohkubo T, Okamura T, Ueshima H, Umemura S, Eyheramendy S, Meitinger T, Wichmann HE, Cho YS, Kim HL, Lee JY, Scott J, Sehmi JS, Zhang W, Hedblad B, Nilsson P, Smith GD, Wong A, Narisu N, Stancakova A, Raffel LJ, Yao J, Kathiresan S, O'Donnell CJ, Schwartz SM, Ikram MA, Longstreth WT,Jr, Mosley TH, Seshadri S, Shrine NR, Wain LV, Morken MA, Swift AJ, Laitinen J, Prokopenko I, Zitting P, Cooper JA, Humphries SE, Danesh J, Rasheed A, Goel A, Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli CS, Mani KR, Yajnik CS, Hofman A, Mattace-Raso FU, Oostra BA, Demirkan A, Isaacs A, Rivadeneira F, Lakatta EG, Orru M, Scuteri A, Ala-Korpela M, Kangas AJ, Lyytikainen LP, Soininen P, Tukiainen T, Wurtz P, Ong RT, Dorr M, Kroemer HK, Volker U, Volzke H, Galan P, Hercberg S, Lathrop M, Zelenika D, Deloukas P, Mangino M, Spector TD, Zhai G, Meschia JF, Nalls MA, Sharma P, Terzic J, Kumar MV, Denniff M, Zukowska-Szczechowska E, Wagenknecht LE, Fowkes FG, Charchar FJ, Schwarz PE, Hayward C, Guo X, Rotimi C, Bots ML, Brand E, Samani NJ, Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M, Hveem K, Palmer LJ, van der Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O, Ganesh SK, Wong TY, Tai ES, Cooper RS, Laakso M, Rao DC, Harris TB, Morris RW, Dominiczak AF, Kivimaki M, Marmot MG, Miki T, Saleheen D, Chandak GR, Coresh J, Navis G, Salomaa V, Han BG, Zhu X, Kooner JS, Melander O, Ridker PM, Bandinelli S, Gyllensten UB, Wright AF, Wilson JF, Ferrucci L, Farrall M, Tuomilehto J, Pramstaller PP, Elosua R, Soranzo N,

Sijbrands EJ, Altshuler D, Loos RJ, Shuldiner AR, Gieger C, Meneton P, Uitterlinden AG, Wareham NJ, Gudnason V, Rotter JI, Rettig R, Uda M, Strachan DP, Witteman JC, Hartikainen AL, Beckmann JS, Boerwinkle E, Vasan RS, Boehnke M, Larson MG, Jarvelin MR, Psaty BM, Abecasis GR, Chakravarti A, Elliott P, van Duijn CM, Newton-Cheh C, Levy D, Caulfield MJ, Johnson T: Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. [Electronic version]. *Nature* 478: 103-109, 2011

30. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR: Newly identified loci that influence lipid concentrations and risk of coronary artery disease. [Electronic version]. *Nat Genet* 40: 161-169, 2008

31. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS: Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. [Electronic version]. *Nat Genet* 41: 703-707, 2009

32. DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium, South Asian Type 2 Diabetes (SAT2D) Consortium, Mexican American Type 2 Diabetes (MAT2D) Consortium, Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in muylti-Ethnic Samples (T2D-GENES) Consortium, Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, Horikoshi M, Johnson AD, Ng MC, Prokopenko I, Saleheen D, Wang X, Zeggini E, Abecasis GR, Adair LS, Almgren P, Atalay M, Aung T, Baldassarre D, Balkau B, Bao Y, Barnett AH, Barroso I, Basit A, Been LF, Beilby J, Bell GI, Benediktsson R, Bergman RN, Boehm BO, Boerwinkle E, Bonnycastle LL, Burtt N, Cai Q, Campbell H, Carey J, Cauchi S, Caulfield M, Chan JC, Chang LC, Chang TJ, Chang YC, Charpentier G, Chen CH, Chen H, Chen YT, Chia KS, Chidambaram M, Chines PS, Cho NH, Cho YM, Chuang LM, Collins FS, Cornelis MC, Couper DJ, Crenshaw AT, van Dam RM, Danesh J, Das D, de Faire U, Dedoussis G, Deloukas P, Dimas AS, Dina C, Doney AS, Donnelly PJ, Dorkhan M, van Duijn C, Dupuis J, Edkins S, Elliott P, Emilsson V, Erbel R, Eriksson JG, Escobedo J, Esko T, Eury E, Florez JC, Fontanillas P, Forouhi NG, Forsen T, Fox C, Fraser RM, Frayling TM, Froguel P, Frossard P, Gao Y, Gertow K, Gieger C, Gigante B, Grallert H, Grant GB, Grrop LC, Groves CJ, Grundberg E, Guiducci C, Hamsten A, Han BG, Hara K, Hassanali N, Hattersley AT, Hayward C, Hedman AK, Herder C, Hofman A, Holmen OL, Hovingh K, Hreidarsson AB, Hu C, Hu FB, Hui J, Humphries SE, Hunt SE, Hunter DJ, Hveem K, Hydrie ZI, Ikegami H, Illig T, Ingelsson E, Islam M, Isomaa B, Jackson AU, Jafar T, James A, Jia W, Jockel KH, Jonsson A, Jowett JB, Kadowaki T, Kang HM, Kanoni S, Kao WH, Kathiresan S, Kato N, Katulanda P, Keinanen-Kiukaanniemi KM, Kelly AM, Khan H, Khaw KT, Khor CC, Kim HL, Kim S, Kim YJ, Kinnunen L, Klopp N, Kong A, Korpi-Hyovalti E, Kowlessur S, Kraft P, Kravic J, Kristensen MM, Krithika S, Kumar A, Kumate J, Kuusisto J, Kwak SH, Laakso M, Lagou V, Lakka TA, Langenberg C, Langford C, Lawrence R, Leander K, Lee JM, Lee NR, Li M, Li X, Li Y, Liang J, Liju S, Lim WY, Lind L, Lindgren CM, Lindholm E, Liu CT, Liu JJ, Lobbens S, Long J, Loos RJ, Lu W, Luan J, Lyssenko V, Ma RC, Maeda S, Magi R, Mannisto S, Matthews DR, Meigs JB, Melander O, Metspalu A, Meyer J, Mirza G, Mihailov E, Moebus S, Mohan V, Mohlke KL, Morris AD, Muhleisen TW, Muller-Nurasyid M, Musk B, Nakamura J, Nakashima E, Navarro P, Ng PK, Nica AC, Nilsson PM, Njolstad I, Nothen MM, Ohnaka K, Ong TH, Owen KR, Palmer CN, Pankow JS, Park KS, Parkin M, Pechlivanis S, Pedersen NL, Peltonen L, Perry JR, Peters A, Pinidiyapathirage JM, Platou CG, Potter S, Price JF, Qi L, Radha V, Rallidis L, Rasheed A, Rathman W, Rauramaa R, Raychaudhuri S, Rayner NW, Rees SD, Rehnberg E, Ripatti S, Robertson N, Roden M, Rossin EJ, Rudan I, Rybin D, Saaristo TE, Salomaa V, Saltevo J, Samuel M, Sanghera DK, Saramies J, Scott J, Scott LJ, Scott RA, Segre AV, Sehmi J, Sennblad B, Shah N, Shah S, Shera AS, Shu XO, Shuldiner AR, Sigurdsson G, Sijbrands E, Silveira A, Sim X, Sivapalaratnam S, Small KS, So WY, Stancakova A, Stefansson K, Steinbach G, Steinthorsdottir V, Stirrups K, Strawbridge RJ, Stringham HM, Sun Q, Suo C, Syvanen AC, Takayanagi R, Takeuchi F, Tay WT, Teslovich TM, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tikkanen E, Trakalo J, Tremoli E, Trip MD, Tsai FJ, Tuomi T, Tuomilehto J, Uitterlinden AG, Valladares-Salgado A, Vedantam S, Veglia F, Voight BF, Wang C, Wareham NJ, Wennauer R, Wickremasinghe AR, Wilsgaard T, Wilson

JF, Wiltshire S, Winckler W, Wong TY, Wood AR, Wu JY, Wu Y, Yamamoto K, Yamauchi T, Yang M, Yengo L, Yokota M, Young R, Zabaneh D, Zhang F, Zhang R, Zheng W, Zimmet PZ, Altshuler D, Bowden DW, Cho YS, Cox NJ, Cruz M, Hanis CL, Kooner J, Lee JY, Seielstad M, Teo YY, Boehnke M, Parra EJ, Chambers JC, Tai ES, McCarthy MI, Morris AP: Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. [Electronic version]. *Nat Genet* 46: 234-244, 2014

33. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, Magi R, Strawbridge RJ, Rehnberg E, Gustafsson S, Kanoni S, Rasmussen-Torvik LJ, Yengo L, Lecoeur C, Shungin D, Sanna S, Sidore C, Johnson PC, Jukema JW, Johnson T, Mahajan A, Verweij N, Thorleifsson G, Hottenga JJ, Shah S, Smith AV, Sennblad B, Gieger C, Salo P, Perola M, Timpson NJ, Evans DM, Pourcain BS, Wu Y, Andrews JS, Hui J, Bielak LF, Zhao W, Horikoshi M, Navarro P, Isaacs A, O'Connell JR, Stirrups K, Vitart V, Hayward C, Esko T, Mihailov E, Fraser RM, Fall T, Voight BF, Raychaudhuri S, Chen H, Lindgren CM, Morris AP, Rayner NW, Robertson N, Rybin D, Liu CT, Beckmann JS, Willems SM, Chines PS, Jackson AU, Kang HM, Stringham HM, Song K, Tanaka T, Peden JF, Goel A, Hicks AA, An P, Muller-Nurasyid M, Franco-Cereceda A, Folkersen L, Marullo L, Jansen H, Oldehinkel AJ, Bruinenberg M, Pankow JS, North KE, Forouhi NG, Loos RJ, Edkins S, Varga TV, Hallmans G, Oksa H, Antonella M, Nagaraja R, Trompet S, Ford I, Bakker SJ, Kong A, Kumari M, Gigante B, Herder C, Munroe PB, Caulfield M, Antti J, Mangino M, Small K, Miljkovic I, Liu Y, Atalay M, Kiess W, James AL, Rivadeneira F, Uitterlinden AG, Palmer CN, Doney AS, Willemsen G, Smit JH, Campbell S, Polasek O, Bonnycastle LL, Hercberg S, Dimitriou M, Bolton JL, Fowkes GR, Kovacs P, Lindstrom J, Zemunik T, Bandinelli S, Wild SH, Basart HV, Rathmann W, Grallert H, DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium, Maerz W, Kleber ME, Boehm BO, Peters A, Pramstaller PP, Province MA, Borecki IB, Hastie ND, Rudan I, Campbell H, Watkins H, Farrall M, Stumvoll M, Ferrucci L, Waterworth DM, Bergman RN, Collins FS, Tuomilehto J, Watanabe RM, de Geus EJ, Penninx BW, Hofman A, Oostra BA, Psaty BM, Vollenweider P, Wilson JF, Wright AF, Hovingh GK, Metspalu A, Uusitupa M, Magnusson PK, Kyvik KO, Kaprio J, Price JF, Dedoussis GV, Deloukas P, Meneton P, Lind L, Boehnke M, Shuldiner AR, van Duijn CM, Morris AD, Toenjes A, Peyser PA, Beilby JP, Korner A, Kuusisto J, Laakso M, Bornstein SR, Schwarz PE, Lakka TA, Rauramaa R, Adair LS, Smith GD, Spector TD, Illig T, de Faire U, Hamsten A, Gudnason V, Kivimaki M, Hingorani A, Keinanen-Kiukaanniemi SM, Saaristo TE, Boomsma DI, Stefansson K, van der Harst P, Dupuis J, Pedersen NL, Sattar N, Harris TB, Cucca F, Ripatti S, Salomaa V, Mohlke KL, Balkau B, Froguel P, Pouta A, Jarvelin MR, Wareham NJ, Bouatia-Naji N, McCarthy MI, Franks PW, Meigs JB, Teslovich TM, Florez JC, Langenberg C, Ingelsson E, Prokopenko I, Barroso I: Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. [Electronic version]. *Nat Genet* 44: 991-1005, 2012

34. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, Rybin D, Liu CT, Bielak LF, Prokopenko I, Amin N, Barnes D, Cadby G, Hottenga JJ, Ingelsson E, Jackson AU, Johnson T, Kanoni S, Ladenvall C, Lagou V, Lahti J, Lecoeur C, Liu Y, Martinez-Larrad MT, Montasser ME, Navarro P, Perry JR, Rasmussen-Torvik LJ, Salo P, Sattar N, Shungin D, Strawbridge RJ, Tanaka T, van Duijn CM, An P, de Andrade M, Andrews JS, Aspelund T, Atalay M, Aulchenko Y, Balkau B, Bandinelli S, Beckmann JS, Beilby JP, Bellis C, Bergman RN, Blangero J, Boban M, Boehnke M, Boerwinkle E, Bonnycastle LL, Boomsma DI, Borecki IB, Bottcher Y, Bouchard C, Brunner E, Budimir D, Campbell H, Carlson O, Chines PS, Clarke R, Collins FS, Corbaton-Anchuelo A, Couper D, de Faire U, Dedoussis GV, Deloukas P, Dimitriou M, Egan JM, Eiriksdottir G, Erdos MR, Eriksson JG, Eury E, Ferrucci L, Ford I, Forouhi NG, Fox CS, Franzosi MG, Franks PW, Frayling TM, Froguel P, Galan P, de Geus E, Gigante B, Glazer NL, Goel A, Groop L, Gudnason V, Hallmans G, Hamsten A, Hansson O, Harris TB, Hayward C, Heath S, Hercberg S, Hicks AA, Hingorani A, Hofman A, Hui J, Hung J, Jarvelin MR, Jhun MA, Johnson PC, Jukema JW, Jula A, Kao WH, Kaprio J, Kardia SL, Keinanen-Kiukaanniemi S, Kivimaki M, Kolcic I, Kovacs P, Kumari M, Kuusisto J, Kyvik KO, Laakso M, Lakka T, Lannfelt L, Lathrop GM, Launer LJ, Leander K, Li G, Lind L, Lindstrom J, Lobbens S, Loos RJ, Luan J, Lyssenko V, Magi R, Magnusson PK, Marmot M, Meneton P, Mohlke KL, Mooser V, Morken MA, Miljkovic I, Narisu N, O'Connell J, Ong KK, Oostra BA, Palmer LJ, Palotie A, Pankow JS, Peden JF, Pedersen NL, Pehlic M, Peltonen L, Penninx B, Pericic M, Perola M, Perusse L, Peyser PA, Polasek O, Pramstaller PP, Province MA, Raikkonen K, Rauramaa R, Rehnberg E, Rice K, Rotter JI, Rudan I, Ruokonen A, Saaristo T, Sabater-Lleal M, Salomaa V, Savage DB, Saxena R, Schwarz P, Seedorf U, Sennblad B, Serrano-Rios M, Shuldiner AR, Sijbrands EJ, Siscovick DS, Smit JH, Small KS, Smith NL, Smith AV, Stancakova A, Stirrups K, Stumvoll M, Sun YV, Swift AJ, Tonjes A, Tuomilehto J, Trompet S, Uitterlinden AG, Uusitupa M, Vikstrom M, Vitart V, Vohl MC, Voight BF,

Vollenweider P, Waeber G, Waterworth DM, Watkins H, Wheeler E, Widen E, Wild SH, Willems SM, Willemsen G, Wilson JF, Witteman JC, Wright AF, Yaghootkar H, Zelenika D, Zemunik T, Zgaga L, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Multiple Tissue Human Expression Resource (MUTHER) Consortium, Wareham NJ, McCarthy MI, Barroso I, Watanabe RM, Florez JC, Dupuis J, Meigs JB, Langenberg C: A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. [Electronic version]. *Nat Genet* 44: 659-669, 2012

35. Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N, Dupuis J, Jackson AU, Kao WH, Li M, Glazer NL, Manning AK, Luan J, Stringham HM, Prokopenko I, Johnson T, Grarup N, Boesgaard TW, Lecoeur C, Shrader P, O'Connell J, Ingelsson E, Couper DJ, Rice K, Song K, Andreasen CH, Dina C, Kottgen A, Le Bacquer O, Pattou F, Taneera J, Steinthorsdottir V, Rybin D, Ardlie K, Sampson M, Qi L, van Hoek M, Weedon MN, Aulchenko YS, Voight BF, Grallert H, Balkau B, Bergman RN, Bielinski SJ, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Bottcher Y, Brunner E, Buchanan TA, Bumpstead SJ, Cavalcanti-Proenca C, Charpentier G, Chen YD, Chines PS, Collins FS, Cornelis M, J Crawford G, Delplanque J, Doney A, Egan JM, Erdos MR, Firmann M, Forouhi NG, Fox CS, Goodarzi MO, Graessler J, Hingorani A, Isomaa B, Jorgensen T, Kivimaki M, Kovacs P, Krohn K, Kumari M, Lauritzen T, Levy-Marchal C, Mayor V, McAteer JB, Meyre D, Mitchell BD, Mohlke KL, Morken MA, Narisu N, Palmer CN, Pakyz R, Pascoe L, Payne F, Pearson D, Rathmann W, Sandbaek A, Sayer AA, Scott LJ, Sharp SJ, Sijbrands E, Singleton A, Siscovick DS, Smith NL, Sparso T, Swift AJ, Syddall H, Thorleifsson G, Tonjes A, Tuomi T, Tuomilehto J, Valle TT, Waeber G, Walley A, Waterworth DM, Zeggini E, Zhao JH, GIANT consortium, MAGIC investigators, Illig T, Wichmann HE, Wilson JF, van Duijn C, Hu FB, Morris AD, Frayling TM, Hattersley AT, Thorsteinsdottir U, Stefansson K, Nilsson P, Syvanen AC, Shuldiner AR, Walker M, Bornstein SR, Schwarz P, Williams GH, Nathan DM, Kuusisto J, Laakso M, Cooper C, Marmot M, Ferrucci L, Mooser V, Stumvoll M, Loos RJ, Altshuler D, Psaty BM, Rotter JI, Boerwinkle E, Hansen T, Pedersen O, Florez JC, McCarthy MI, Boehnke M, Barroso I, Sladek R, Froguel P, Meigs JB, Groop L, Wareham NJ, Watanabe RM: Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. [Electronic version]. *Nat Genet* 42: 142-148, 2010

36. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I, Stolerman E, Sandhu MS, Heeney MM, Devaney JM, Reilly MP, Ricketts SL, Stewart AF, Voight BF, Willenborg C, Wright B, Altshuler D, Arking D, Balkau B, Barnes D, Boerwinkle E, Bohm B, Bonnefond A, Bonnycastle LL, Boomsma DI, Bornstein SR, Bottcher Y, Bumpstead S, Burnett-Miller MS, Campbell H, Cao A, Chambers J, Clark R, Collins FS, Coresh J, de Geus EJ, Dei M, Deloukas P, Doring A, Egan JM, Elosua R, Ferrucci L, Forouhi N, Fox CS, Franklin C, Franzosi MG, Gallina S, Goel A, Graessler J, Grallert H, Greinacher A, Hadley D, Hall A, Hamsten A, Hayward C, Heath S, Herder C, Homuth G, Hottenga JJ, Hunter-Merrill R, Illig T, Jackson AU, Jula A, Kleber M, Knouff CW, Kong A, Kooner J, Kottgen A, Kovacs P, Krohn K, Kuhnel B, Kuusisto J, Laakso M, Lathrop M, Lecoeur C, Li M, Li M, Loos RJ, Luan J, Lyssenko V, Magi R, Magnusson PK, Malarstig A, Mangino M, Martinez-Larrad MT, Marz W, McArdle WL, McPherson R, Meisinger C, Meitinger T, Melander O, Mohlke KL, Mooser VE, Morken MA, Narisu N, Nathan DM, Nauck M, O'Donnell C, Oexle K, Olla N, Pankow JS, Payne F, Peden JF, Pedersen NL, Peltonen L, Perola M, Polasek O, Porcu E, Rader DJ, Rathmann W, Ripatti S, Rocheleau G, Roden M, Rudan I, Salomaa V, Saxena R, Schlessinger D, Schunkert H, Schwarz P, Seedorf U, Selvin E, Serrano-Rios M, Shrader P, Silveira A, Siscovick D, Song K, Spector TD, Stefansson K, Steinthorsdottir V, Strachan DP, Strawbridge R, Stumvoll M, Surakka I, Swift AJ, Tanaka T, Teumer A, Thorleifsson G, Thorsteinsdottir U, Tonjes A, Usala G, Vitart V, Volzke H, Wallaschofski H, Waterworth DM, Watkins H, Wichmann HE, Wild SH, Willemsen G, Williams GH, Wilson JF, Winkelmann J, Wright AF, WTCCC, Zabena C, Zhao JH, Epstein SE, Erdmann J, Hakonarson HH, Kathiresan S, Khaw KT, Roberts R, Samani NJ, Fleming MD, Sladek R, Abecasis G, Boehnke M, Froguel P, Groop L, McCarthy MI, Kao WH, Florez JC, Uda M, Wareham NJ, Barroso I, Meigs JB: Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels via glycemic and nonglycemic pathways. [Electronic version]. *Diabetes* 59: 3229-3239, 2010

37. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D, Petrie JR, Travers ME, Bouatia-Naji N, Dimas AS, Nica A, Wheeler E, Chen H, Voight BF, Taneera J, Kanoni S, Peden JF, Turrini F, Gustafsson S, Zabena C, Almgren P, Barker DJ, Barnes D, Dennison EM, Eriksson JG, Eriksson P, Eury E, Folkersen L, Fox CS, Frayling TM,

Goel A, Gu HF, Horikoshi M, Isomaa B, Jackson AU, Jameson KA, Kajantie E, Kerr-Conte J, Kuulasmaa T, Kuusisto J, Loos RJ, Luan J, Makrilakis K, Manning AK, Martinez-Larrad MT, Narisu N, Nastase Mannila M, Ohrvik J, Osmond C, Pascoe L, Payne F, Sayer AA, Sennblad B, Silveira A, Stancakova A, Stirrups K, Swift AJ, Syvanen AC, Tuomi T, van 't Hooft FM, Walker M, Weedon MN, Xie W, Zethelius B, DIAGRAM Consortium, GIANT Consortium, MuTHER Consortium, CARDIoGRAM Consortium, C4D Consortium, Ongen H, Malarstig A, Hopewell JC, Saleheen D, Chambers J, Parish S, Danesh J, Kooner J, Ostenson CG, Lind L, Cooper CC, Serrano-Rios M, Ferrannini E, Forsen TJ, Clarke R, Franzosi MG, Seedorf U, Watkins H, Froguel P, Johnson P, Deloukas P, Collins FS, Laakso M, Dermitzakis ET, Boehnke M, McCarthy MI, Wareham NJ, Groop L, Pattou F, Gloyn AL, Dedoussis GV, Lyssenko V, Meigs JB, Barroso I, Watanabe RM, Ingelsson E, Langenberg C, Hamsten A, Florez JC: Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. [Electronic version]. *Diabetes* 60: 2624-2634, 2011

38. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Magi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JR, Egan JM, Lajunen T, Grarup N, Sparso T, Doney A, Voight BF, Stringham HM, Li M, Kanoni S, Shrader P, Cavalcanti-Proenca C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O'Connell J, Luan J, Elliott A, McCarroll SA, Payne F, Roccasecca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B, Barter P, Beilby JP, Ben-Shlomo Y, Benediktsson R, Bennett AJ, Bergmann S, Bochud M, Boerwinkle E, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Bottcher Y, Brunner E, Bumpstead SJ, Charpentier G, Chen YD, Chines P, Clarke R, Coin LJ, Cooper MN, Cornelis M, Crawford G, Crisponi L, Day IN, de Geus EJ, Delplanque J, Dina C, Erdos MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler J, Groves CJ, Grundy S, Gwilliam R, Gyllensten U, Hadjadj S, Hallmans G, Hammond N, Han X, Hartikainen AL, Hassanali N, Hayward C, Heath SC, Hercberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J, Hung J, Isomaa B, Johnson PR, Jorgensen T, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B, Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer O, Lecoeur C, Li Y, Lyssenko V, Mahley R, Mangino M, Manning AK, Martinez-Larrad MT, McAteer JB, McCulloch LJ, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Morken MA, Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orru M, Pakyz R, Palmer CN, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AF, Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner NW, Rice K, Ripatti S, Rivadeneira F, Roden M, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Scott LJ, Seedorf U, Sharp SJ, Shields B, Sigurethsson G, Sijbrands EJ, Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H, Syvanen AC, Tanaka T, Thorand B, Tichet J, Tonjes A, Tuomi T, Uitterlinden AG, van Dijk KW, van Hoek M, Varma D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Walters GB, Ward KL, Watkins H, Weedon MN, Wild SH, Willemsen G, Witteman JC, Yarnell JW, Zeggini E, Zelenika D, Zethelius B, Zhai G, Zhao JH, Zillikens MC, DIAGRAM Consortium, GIANT Consortium, Global BPgen Consortium, Borecki IB, Loos RJ, Meneton P, Magnusson PK, Nathan DM, Williams GH, Hattersley AT, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Rios M, Morris AD, Lind L, Palmer LJ, Hu FB, Franks PW, Ebrahim S, Marmot M, Kao WH, Pankow JS, Sampson MJ, Kuusisto J, Laakso M, Hansen T, Pedersen O, Pramstaller PP, Wichmann HE, Illig T, Rudan I, Wright AF, Stumvoll M, Campbell H, Wilson JF, Anders Hamsten on behalf of Procardis Consortium, MAGIC investigators, Bergman RN, Buchanan TA, Collins FS, Mohlke KL, Tuomilehto J, Valle TT, Altshuler D, Rotter JI, Siscovick DS, Penninx BW, Boomsma DI, Deloukas P, Spector TD, Frayling TM, Ferrucci L, Kong A, Thorsteinsdottir U, Stefansson K, van Duijn CM, Aulchenko YS, Cao A, Scuteri A, Schlessinger D, Uda M, Ruokonen A, Jarvelin MR, Waterworth DM, Vollenweider P, Peltonen L, Mooser V, Abecasis GR, Wareham NJ, Sladek R, Froguel P, Watanabe RM, Meigs JB, Groop L, Boehnke M, McCarthy MI, Florez JC, Barroso I: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. [Electronic version]. *Nat Genet* 42: 105-116, 2010

39. Scott RA, Fall T, Pasko D, Barker A, Sharp SJ, Arriola L, Balkau B, Barricarte A, Barroso I, Boeing H, Clavel-Chapelon F, Crowe FL, Dekker JM, Fagherazzi G, Ferrannini E, Forouhi NG, Franks PW, Gavrila D, Giedraitis V, Grioni S, Groop LC, Kaaks R, Key TJ, Kuhn T, Lotta LA, Nilsson PM, Overvad K, Palli D, Panico S, Quiros JR, Rolandsson O, Roswall N, Sacerdote C, Sala N, Sanchez MJ, Schulze MB, Siddiq A, Slimani N, Sluijs I, Spijkerman AM, Tjonneland

A, Tumino R, van der ADL, Yaghootkar H, RISC Study Group, EPIC-InterAct Consortium, McCarthy MI, Semple RK, Riboli E, Walker M, Ingelsson E, Frayling TM, Savage DB, Langenberg C, Wareham NJ: Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. [Electronic version]. *Diabetes* 63: 4378-4387, 2014

40. Tobacco and Genetics Consortium: Genome-wide meta-analyses identify multiple loci associated with smoking behavior. [Electronic version]. *Nat Genet* 42: 441-447, 2010

41. Segre AV, DIAGRAM Consortium, MAGIC investigators, Groop L, Mootha VK, Daly MJ, Altshuler D: Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. [Electronic version]. *PLoS Genet* 6: e1001058, 2010

42. Lin DY, & Tang ZZ: A general framework for detecting disease associations with rare variants in sequencing studies. [Electronic version]. *Am J Hum Genet* 89: 354-367, 2011

43. Moutsianas L, Agarwala V, Fuchsberger C, Flannick J, Rivas MA, Gaulton KJ, Albers PK, GoT2D Consortium, McVean G, Boehnke M, Altshuler D, McCarthy MI: The power of gene-based rare variant methods to detect disease-associated variation and test hypotheses about complex disease. [Electronic version]. *PLoS Genet* 11: e1005165, 2015

44. Price AL, Kryukov GV, de Bakker PI, Purcell SM, Staples J, Wei LJ, Sunyaev SR: Pooled association tests for rare variants in exon-resequencing studies. [Electronic version]. *Am J Hum Genet* 86: 832-838, 2010

45. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X: Rare-variant association testing for sequencing data with the sequence kernel association test. [Electronic version]. *Am J Hum Genet* 89: 82-93, 2011

46. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, NHLBI GO Exome Sequencing Project-ESP Lung Project Team, Christiani DC, Wurfel MM, Lin X: Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. [Electronic version]. *Am J Hum Genet* 91: 224-237, 2012

47. Mahajan A, Sim X, Ng HJ, Manning A, Rivas MA, Highland HM, Locke AE, Grarup N, Im HK, Cingolani P, Flannick J, Fontanillas P, Fuchsberger C, Gaulton KJ, Teslovich TM, Rayner NW, Robertson NR, Beer NL, Rundle JK, Bork-Jensen J, Ladenvall C, Blancher C, Buck D, Buck G, Burtt NP, Gabriel S, Gjesing AP, Groves CJ, Hollensted M, Huyghe JR, Jackson AU, Jun G, Justesen JM, Mangino M, Murphy J, Neville M, Onofrio R, Small KS, Stringham HM, Syvanen AC, Trakalo J, Abecasis G, Bell GI, Blangero J, Cox NJ, Duggirala R, Hanis CL, Seielstad M, Wilson JG, Christensen C, Brandslund I, Rauramaa R, Surdulescu GL, Doney AS, Lannfelt L, Linneberg A, Isomaa B, Tuomi T, Jorgensen ME, Jorgensen T, Kuusisto J, Uusitupa M, Salomaa V, Spector TD, Morris AD, Palmer CN, Collins FS, Mohlke KL, Bergman RN, Ingelsson E, Lind L, Tuomilehto J, Hansen T, Watanabe RM, Prokopenko I, Dupuis J, Karpe F, Groop L, Laakso M, Pedersen O, Florez JC, Morris AP, Altshuler D, Meigs JB, Boehnke M, McCarthy MI, Lindgren CM, Gloyn AL, T2D-GENES consortium and GoT2D consortium: Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. [Electronic version]. *PLoS Genet* 11: e1004876, 2015

48. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, O'Dushlaine C, Chambert K, Bergen SE, Kahler A, Duncan L, Stahl E, Genovese G, Fernandez E, Collins MO, Komiyama NH, Choudhary JS, Magnusson PK, Banks E, Shakir K, Garimella K, Fennell T, DePristo M, Grant SG, Haggarty SJ, Gabriel S, Scolnick EM, Lander ES, Hultman CM, Sullivan PF, McCarroll SA, Sklar P: A polygenic burden of rare disruptive mutations in schizophrenia. [Electronic version]. *Nature* 506: 185-190, 2014

49. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. [Electronic version]. *Proc Natl Acad Sci U S A* 102: 15545-15550, 2005

50. Di Camillo B, Sambo F, Toffolo G, Cobelli C: ABACUS: An entropy-based cumulative bivariate statistic robust to rare variants and different direction of genotype effect. [Electronic version]. *Bioinformatics* 30: 384-391, 2014

51. Huang da W, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. [Electronic version]. *Nucleic Acids Res* 37: 1-13, 2009

52. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. [Electronic version]. *Nat Protoc* 4: 44-57, 2009

53. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH: Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: Inception cohort study. [Electronic version]. *BMJ* 328: 1105, 2004

54. Harjutsalo V, Maric C, Forsblom C, Thorn L, Waden J, Groop PH, FinnDiane Study Group: Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. [Electronic version]. *Diabetologia* 54: 1992-1999, 2011

55. Shankar A, Klein R, Klein BE, Moss SE: Association between glycosylated hemoglobin level and 16-year incidence of chronic kidney disease in type 1 diabetes. [Electronic version]. *Exp Clin Endocrinol Diabetes* 115: 203-206, 2007

56. Mooyaart A, Valk EJJ, van Es L, Bruijn J, de Heer E, Freedman B, Dekkers O, Baelde H: Genetic associations in diabetic nephropathy: A meta-analysis. [Electronic version]. *Diabetologia* 54: 544-553, 2011

57. Sambo F, Malovini A, Sandholm N, Stavarachi M, Forsblom C, Makinen VP, Harjutsalo V, Lithovius R, Gordin D, Parkkonen M, Saraheimo M, Thorn LM, Tolonen N, Waden J, He B, Osterholm AM, Tuomilehto J, Lajer M, Salem RM, McKnight AJ, The GENIE Consortium, Tarnow L, Panduru NM, Barbarini N, Di Camillo B, Toffolo GM, Tryggvason K, Bellazzi R, Cobelli C, The FinnDiane Study Group, Groop PH: Novel genetic susceptibility loci for diabetic end-stage renal disease identified through robust naive bayes classification. *Diabetologia* 57: 1611-1622, 2014

58. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, Hau VS, Kaminoh Y, Harmon J, Pearson E, Buehler J, Chen Y, Yu B, Tinkham NH, Zabriskie NA, Zeng J, Luo L, Sun JK, Prakash M, Hamam RN, Tonna S, Constantine R, Ronquillo CC, Sadda S, Avery RL, Brand JM, London N, Anduze AL, King GL, Bernstein PS, Watkins S, Genetics of Diabetes and Diabetic Complication Study Group, Jorde LB, Li DY, Aiello LP, Pollak MR, Zhang K: Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. [Electronic version]. *Proc Natl Acad Sci U S A* 105: 6998-7003, 2008

59. Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, Koya D, Babazono T, Tanaka Y, Matsuda M, Kawai K, Iiizumi T, Imanishi M, Shinosaki T, Yanagimoto T, Ikeda M, Omachi S, Kashiwagi A, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Nakajima M, Nakamura Y, Maeda S: Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. [Electronic version]. *Diabetes* 54: 1171-1178, 2005

60. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DPK, Placha G, Canani LH, Bochenski J, Waggott D, Merchant ML, Krolewski B, Mirea L, Wanic K, Katavetin P, Kure M, Wolkow P, Dunn JS, Smiles A, Walker WH, Boright AP, Bull SB, 'DCCT/EDIC Research Group', Doria A, Rogus JJ, Rich SS, Warram JH, Krolewski AS: Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. [Electronic version]. *Diabetes* 58: 1403-1410, 2009

61. Craig DW, Millis MP, DiStefano JK: Genome-wide SNP genotyping study using pooled DNA to identify candidate markers mediating susceptibility to end-stage renal disease attributed to type 1 diabetes. [Electronic version]. *Diabet Med* 26: 1090-1098, 2009

62. Sandholm N, Forsblom C, Makinen VP, McKnight AJ, Osterholm AM, He B, Harjutsalo V, Lithovius R, Gordin D, Parkkonen M, Saraheimo M, Thorn LM, Tolonen N, Waden J, Tuomilehto J, Lajer M, Ahlqvist E, Mollsten A, Marcovecchio ML, Cooper J, Dunger D, Paterson AD, Zerbini G, Groop L, SUMMIT Consortium, Tarnow L, Maxwell AP, Tryggvason K, Groop PH, FinnDiane Study Group: Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes. [Electronic version]. *Diabetologia* 57: 1143-1153, 2014

63. Köttgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, Glazer NL, Parsa A, Gao X, Yang Q, Smith AV, O'Connell JR, Li M, Schmidt H, Tanaka T, Isaacs A, Ketkar S, Hwang SJ, Johnson AD, Dehghan A, Teumer A, Pare G, Atkinson EJ, Zeller T, Lohman K, Cornelis MC, Probst-Hensch NM, Kronenberg F, Tonjes A, Hayward C, Aspelund T, Eiriksdottir G, Launer LJ, Harris TB, Rampersaud E, Mitchell BD, Arking DE, Boerwinkle E, Struchalin M, Cavalieri M, Singleton A, Giallauria F, Metter J, de Boer IH, Haritunians T, Lumley T, Siscovick D, Psaty BM, Zillikens MC, Oostra BA, Feitosa M, Province M, de Andrade M, Turner ST, Schillert A, Ziegler A, Wild PS, Schnabel RB, Wilde S, Munzel TF, Leak TS, Illig T, Klopp N, Meisinger C, Wichmann HE, Koenig W, Zgaga L, Zemunik T, Kolcic I, Minelli C, Hu FB, Johansson A, Igl W, Zaboli G, Wild SH, Wright AF, Campbell H, Ellinghaus D, Schreiber S, Aulchenko YS, Felix JF, Rivadeneira F, Uitterlinden AG, Hofman A, Imboden M, Nitsch D, Brandstatter A, Kollerits B, Kedenko L, Magi R, Stumvoll M, Kovacs P, Boban M, Campbell S, Endlich K, Volzke H, Kroemer HK, Nauck M, Volker U, Polasek O, Vitart V, Badola S, Parker AN, Ridker PM, Kardia SL, Blankenberg S, Liu Y, Curhan GC, Franke A, Rochat T, Paulweber B, Prokopenko I, Wang W, Gudnason V, Shuldiner AR, Coresh J, Schmidt R, Ferrucci L, Shlipak MG, van Duijn CM, Borecki I, Kramer BK, Rudan I, Gyllensten U, Wilson JF, Witteman JC, Pramstaller PP, Rettig R, Hastie N, Chasman DI, Kao WH, Heid IM, Fox CS: New loci associated with kidney function and chronic kidney disease. [Electronic version]. *Nat Genet* 42: 376-384, 2010

64. McDonough CW, Palmer ND, Hicks PJ, Roh BH, An SS, Cooke JN, Hester JM, Wing MR, Bostrom MA, Rudock ME, Lewis JP, Talbert ME, Blevins RA, Lu L, Ng MC, Sale MM, Divers J, Langefeld CD, Freedman BI, Bowden DW: A genome-wide association study for diabetic nephropathy genes in african americans. [Electronic version]. *Kidney Int* 79: 563-572, 2011

65. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration: Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. [Electronic version]. *Clin Chem* 53: 766-772, 2007